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Von Willebrand factor (VWF) is a multifunctional plasma protein that plays a pre-
dominant role in the events that lead to normal arrest of bleeding. VWF is produced 
by endothelial cells and megakaryocytes and originates from the VWF precursor 
(pro-VWF), processing of which results in the formation of two large polypeptides, 
mature VWF and the VWF propeptide (also named VWAgII). Both polypeptides 
have distinct biological functions. Mature VWF both mediates the adhesion of blood 
platelets at sites of vascular injury and functions as a stabilizing carrier protein of 
factor VIII, an essential cofactor of the coagulation system. Its physiological signifi-
cance is underscored by the well known observations that qualitative or quantitative 
defects, or von Willebrand’s disease, may predispose to a severe bleeding diathe-
sis, both because of defective platelet plug formation and abnormal blood clotting 
at sites of vascular injury. In addition to its well defined role in platelet adhesion 
and regulation of the coagulation system, VWF may help to anchor endothelial 
cells to the extracellular matrix. The propeptide of VWF is required for proper post-
translational multimerisation and subsequent storage of VWF. In the last few years, 
increasing evidence has been obtained that the VWF propeptide might also be in-
volved in a variety of biological processes after it is secreted. It both may modulate 
platelet function and may act as an inflammatory mediator. 
The biosynthesis and the properties of VWF have been reported in com-
prehensive reviews [1,2]. Here we will briefly discuss the major molecular 
events associated with its biosynthesis, storage and secretion by endothelial 
cells. Subsequently, we will focus on the function of VWF as a chaperone pro-
tein for factor VIII. In addition, we concentrate on the unusual pleiotropic nature 
of the VWF propeptide.
BIOSYNTHESIS OF VON WILLEBRAND FACTOR
In the early 1970s, immunohistochemical studies revealed that antibodies to the 
factor VIII-VWF complex recognized immunoreactive material associated with the 
endothelium of a variety of human tissues [3,4]. Soon it became clear that endo-
thelial cells from large and smaller veins, capillaries, aorta and arteries indeed 
synthesize and secrete VWF [5,6]. More recent studies have demonstrated that the 
VWF gene is differentially expressed in endothelial cells present in different tissues 
[7]. Besides endothelial cells, also platelets contain VWF produced by the platelet 
precursor, the megakaryocyte [8,9]. 
VWF is a typical example of a secretory protein. The molecular events associ-
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The molecular events associated with the biosynthesis of VWF occur, in terms 
of time and space, in highly ordered manner (Fig.1). Molecular cloning of the full 
length human VWF cDNA revealed that the mRNA is translated as a pre-pro-
polypeptide, composed of a signal peptide of 22 amino acids, an unusually large 
pro-peptide of 741 amino acids, and mature a VWF molecule of 2050 amino acid 
residues. These features indicate that the pre-pro-protein undergoes two proteolytic 
processing steps before it enters the circulation: cleavage of the signal peptide by 
a signal peptidase and subsequent cleavage of the propeptide after the arginine 
residue at position 7631 by an endoprotease. A remarkable feature of the VWF 
precursor protein is its highly repetitive structure. The pro-protein is almost entirely 
(over 90%) composed of four types of repeated domains (A-D) exhibiting internal 
ated with the biosynthesis and secretion of VWF are, to a large extent similar to the 
processing steps and routing of many other proteins destined to be externalized. In 
one respect the biosynthesis of VWF distinguishes itself from the synthesis of most 
other proteins produced by endothelial cells, in that, at least part of the newly syn-
thesized protein is stored in characteristic organelles, called Weibel-Palade bodies 
(see below). 
Figure 1. Schematic representation of the processing steps involved in the 
biosynthesis of VWF. The hatched area represents the propeptide moiety of VWF and 
the dark area mature VWF. The compartments where the processing steps take place 
are indicated on the left. H=non-covalent interaction; S=disulfide bonds. The molecular 
mass of the different VWF species is given on the right. Adapted with permission from 
[79].
1 Amino acid numbering starts at the initiation codon of the signal peptide
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homologies, that are each present in two to five copies (Fig.2). 
VWF probably has a complex evolutionary history marked by repeated gene seg-
ment duplications and exon shuffling. To a certain extent these domains exert 
autonomous functions. Roughly speaking a number of distinct binding functions of 
VWF co-localize with a particular domain. Comparison of the protein sequences 
revealed that these domains share similarity with distinct, apparently unrelated 
structural motifs in a number of other proteins with binding functions, including 
integrins, components of the complement system, thrombospondin and collagens 
(reviewed in [2]). Also characteristic for the pro-VWF structure is the occurrence of 
Arg-Gly-Asp (RGD) sequences. One RGD sequence is located near the carboxy-
terminal region of the propeptide and one is located near the carboxy-terminal end 
of the C1 domain. There is ample evidence that the latter RGD sequence is essen-
tial for the binding of VWF to platelets [10]. Whether the propeptide RGD sequence 
plays a similar function has not been established. The RGD motif is not present in 
the bovine propeptide moiety of pro-VWF, suggesting an insignificant role of this 
Figure 2. Structure and functional sites of VWF and the VWF propeptide. The upper part represents 
pre-pro-VWF with its typical domain structure. Pre-pro-VWF (2813 amino acids) is composed of a signal 
peptide (SP) of 22 amino acids, the VWF propeptide of 741 residues and, at the carboxyl-terminal end, 
mature VWF of 2050 amino acid residues. The furin cleavage site as well as all known ligand binding 
sites of mature VWF are schematically depicted in the upper part. The lower part of this figure depicts 
the primary structure of the VWF propeptide, including PDI and RGD sequences, and its interactive 
sites. The four Gln (Q) sites of the propeptide of VWF that react with factor XIIIa are indicated by arrows. 
The numbering of the amino acid residues starts at the signal peptide (SP).
12
Chapter 1
sequence in controlling functional modalities of the propeptide [11]. 
After cleavage of the signal peptide and translocation in the ER, the primary 
translation product undergoes N-linked glycosylation and dimerisation (Fig.1) [1]. 
Dimerisation occurs through disulfide bonds within the carboxy-terminal amino ac-
ids of the pro-VWF subunits [12,13]. The pro-VWF dimers are then transported to 
the Golgi apparatus and post-Golgi compartments, where the high mannose oligo-
saccharides are processed to the complex form and also sulphation and O-linked 
glycosylation take place [1,14]. Simultaneously to these post-translational process-
es, the processed pro-VWF dimers polymerize during the travel through the Golgi 
compartments. Consecutively, pro-VWF is transported to the trans-Golgi network 
where further multimerisation and proteolytic cleavage occur, yielding mature VWF 
multimers and propeptide dimers. After cleavage, VWF and the VWF propeptide 
remain non-covalently associated, at least within the cell [15].
Detailed analysis of the secondary structure of VWF revealed that inter-sub-
unit disulfide bonds are localized in an amino-terminal region (residues 1046-1458) 
and carboxy-terminal region (amino acid residues 2671-2813), beyond the domain 
C2 [13]. Although polymerisation of VWF dimers by formation of intermolecular di-
sulfide bonds located within the D3 domains is apparently not affected by carboxy-
terminal disulfide bond formation (and vice versa), polypeptide regions upstream of 
the domain D3 do control polymerisation. For instance, if the domain D’ is deleted 
or harbors certain point mutations, no multimers are formed [16,17] Similarly, dele-
tion of the propeptide, or missense mutations within the propeptide region, results 
in defective polymerisation [18-21]. These observations can be interpreted in terms 
of a “zipper model” which proposes that both propeptide and the domain D’ serve 
to properly align the dimers for inter-dimer crosslinking. Pertinent to this point is the 
ability of the (cleaved) propeptide to form dimers through non-covalent interactions 
[22,23]. 
Accumulated data suggest that the propeptide not only plays a role in position-
ing the protomers but may also catalyse crosslinking of the D3 domains. Indeed, 
when mature VWF, devoid of the propeptide, is co-expressed with the free propep-
tide, each in a separate vector, polymerisation does occur [19]. Moreover, alteration 
of the primary structure of those peptide regions within the D domains of the pro-
peptide that are highly homologous to the active site of proteins harboring protein 
disulfide isomerase (PDI) activity, abolishes polymerisation [23]. PDI is the enzyme 
that catalyses thiol-disulfide interchange reactions in protein substrates leading to 
disulfide formation and folding of the protein [24]. These observations suggest that 
the ability of the propeptide to promote interchain disulfide bonding can be ascribed 
to intrinsic PDI activity of the propeptide. In this respect, the VWF propeptide acts 
as a intramolecular chaperone protein [25].
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The polymerisation process is accompanied by cleavage of the dimer form 
of the precursor into mature VWF and the free propeptide [26]. The propeptide 
cleavage occurs at a dibasic site, one of the most common processing motifs in 
mammalian pro-proteins and prohormones [27]. Two members of the eukaryotic 
subtilisin-like protease family, furin (also called PACE) and PACE4, were shown 
to process pro-VWF to its mature form [28,29]. These proteases share the same 
cleavage site but have different substrate specifcities [30]. Most likely, furin is the 
enzyme responsible for pro-VWF cleavage within the endothelium [31,32].
STORAGE OF VWF BY ENDOTHELIAL CELLS IN WEIBEL-
PALADE BODIES
VWF distinguishes itself from many other endothelial proteins in that it can be se-
creted from the cell by more than one pathway, the constitutive and the regulated 
pathway (Fig.3). The constitutive secretory nature of the endothelium is reflected by 
the observation that soon after synthesis, VWF accumulates extracellularly in the 
absence of a stimulus [33]. On the other hand, if endothelial cells are exposed to 
agonists that give rise to an increase of cytosolic free Ca2+ ([Ca2+]i), such as throm-
bin, histamine or the calcium ionophore A23187, or to cAMP-raising agents, such 
as epinephrine or forskolin, VWF is rapidly secreted by the cell [34-36]. The rate of 
Figure 3. Partitioning of VWF, propeptide 
and pro-VWF between the constitutive 
and regulated secretory pathway by 
vascular endothelial cells. The pro-VWF 
molecule is processed in the trans-Golgi 
network and results in heterogenous forms of 
VWF, ranging from dimers to large polymers. 
The largest proportion of the VWF species, 
consisting of partially processed and inmature 
VWF, is secreted through the constitutive 
pathway. The remainder, the largest, fully 
processed and functional VWF, is sorted into 
Weibel-Palade bodies and secreted via the 
regulated pathway. This model proposes that 




this type of secretion is much higher than the biosynthetic rate of VWF. The stimu-
lus-induced secretion of VWF originates from storage vesicles, previously identified 
as Weibel-Palade bodies [37]. These vesicles are endothelial cell-specific elon-
gated organelles, enclosed by a limiting membrane, which are about 0.1 µm wide 
and up to 4 µm long [38]. Besides VWF, Weibel-Palade bodies have been shown 
to contain a subset of other proteins, including P-selectin and endothelin (Table 1). 
Similar to VWF, these proteins can be secreted upon demand by endothelial cells 
upon stimulation by Ca2+- or cAMP agonists. Apparently, Weibel-Palade bodies are 
not only restricted for VWF storage.
Electron microscopical studies revealed that Weibel-Palade bodies most likely 
originate from the trans-Golgi network [39]. Immunostaining of ultrathin frozen sec-
tions of cultured endothelial cells revealed that, together with apparently mature 
Weibel-Palade bodies, densely packed VWF, surrounded by a limiting membrane, 
is occasionally found in close apposition with the trans-Golgi network [40]. This ob-
servation supports the view that VWF-containing storage vesicles emerge through 
budding from the Golgi complex, an event generally associated with the secretion 
of proteins in eukaryotes [41]. It has been proposed that targeting of VWF to Wei-
bel-Palade bodies occurs as a consequence of selective aggregation, by means of 
multimerisation of this protein in the trans-Golgi network [40,42]. However, evidence 
has been obtained that VWF-multimerisation is not the sole targeting signal. It has 
been proposed that the propeptide could also play a role in this process [23,43]. 
Apparently, the sorting mechanism is more complex than previously understood.
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VON WILLEBRAND SECRETION AND CATABOLISM
Regulated secretion of VWF involves the translocation of Weibel-Palade bodies 
from the cytoplasm towards the plasma membrane and fusion of these vesicles 
with the plasma membrane. These events are regulated by second messengers in 
response to [Ca2+]i - or cAMP raising agents. There is ample evidence that G pro-
teins are involved in the [Ca2+]i-mediated VWF secretion by endothelial cells (Fig.4) 
[44-46]. 
Figure 4. Machinery of stimulus-induced exocytosis of Weibel-Palade bodies by endothelial cells. 
Upon stimulation of endothelial cells by agonists such as thrombin, the phosphatidylinositol pathway 
is activated, resulting in a rise of cytoplasmic Ca2+. Thrombin signalling is mediated by a G protein-
coupled protease-activated receptor (PAR). Calcium in complex with calmodulin (CaM) binds the small 
GTP-binding protein Ral in its GDP-form, a small amount of which is associated with the Weibel-Palade 
bodies. GDP on Ral is then exchanged with for GTP by mediation of an Ral guanine nucleotide exchange 
factor (RalGEF). Ral in its GTP-bound conformation interacts downstream with effector molecules such 
as RLIP76, a GTPase activating protein for Cdc42 and Rac. The hydrolysis of GTP on Cdc42 or Rac 
may result in cytoskeleton rearrangement, which may precede exocytosis of Weibel-Palade bodies. The 
contents of Weibel-Palade bodies are released into the circulation (e.g. VWF, black circles) or exposed 
at the plasma membrane (e.g. P-selectin). Regulated, receptor-mediated secretion of VWF can also 
be accomplished by agonists, such as epinephrine or DDAVP (1-deamino-8-D-arginine vasopressin), 
agents known for their ability to activate G protein-coupled receptors and cAMP-dependent signalling, 
independently of a rise of cytosolic Ca2+. The molecular mechanism of cAMP-mediated VWF secretion 
have not been identified. V2R: vasopressin type 2 receptor, ß2-AR: ß2-adrenergic receptor. (Courtesy 
of dr. Hubert de Leeuw [80]).
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However their role in cAMP-dependent exocytosis remains to be established. 
Qualitative differences in Weibel-Palade body secretion are observed in response 
to [Ca2+] i - and cAMP agonists [46]. [Ca
2+]i induces release of both peripheral and 
central granules, whereas cAMP involves only vesicles located in the periphery 
of the cell. It is worth noting that the role of 1-deamino-8-D-arginine vasopressin 
(DDAVP), which is widely used to raise plasma VWF and factor VIII levels in pa-
tients with von Willebrand’s disease and haemophilia A, has recently been delin-
eated [47]. It has been shown that DDAVP can directly induce VWF secretion from 
human microvascular endothelial cells by activation of the vasopressin V2 receptor 
(V2R). This process is mediated by a rise in cAMP.
PHYSIOLOGICAL SIGNIFICANCE OF VWF PROCESSING AND 
SECRETION.
As outlined above, expression of the VWF gene is associated with a number of 
post-translational modifications, including a discrete endoproteolytic cleavage step. 
The latter step results in the generation of mature VWF and the propeptide moiety 
of pro-VWF. Subsequently these polypeptides are released to the outside of the 
cell, either directly or after appropriate stimulation of the cell. After release, VWF 
and its propeptide have divergent fates. VWF serves a role in controlling platelet 
adhesion and aggregation and acts as a chaperone protein for factor VIII; the pro-
peptide may act as an antagonist of platelet function and may serve a role as an 
inflammatory mediator. Little is known about the physiological significance of the 
diversity of processing, secretion and the ability of endothelial cells to store VWF. 
It seems reasonable to assume that a subset of biologically active VWF polymers 
become readily available in the vicinity of the injured vessel upon activation of en-
dothelial cells and subsequent exocytosis of Weibel-Palade bodies (for instance 
induced by thrombin formed locally as a result of vascular damage). In particular 
these VWF species play a prominent role in controlling platelet adhesion and ag-
gregation (and possibly controlling factor VIII function, see below). Because of its 
limited degree of polymerisation, VWF released through the constitutive pathway 
would be less efficient in this respect. In vitro studies have shown that a significant 
portion of de novo synthesised VWF is secreted through the constitutive pathway 
as partially processed, incompletely polymerised and functionally incompetent pro-
tein [48]. Only fully processed, substantially polymerised and functionally mature 
VWF is stored in the Weibel-Palade bodies, together with its propeptide (Fig.3). 
To what extent the plasma VWF pool stems from the constitutive route in vivo, 
is unknown. Only trace amounts of pro-VWF are detectable in plasma [49]. This 
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suggests that under normal physiological conditions the constitutive pathway does 
not substantially contribute to the release of VWF. On the other hand, it is possible 
that after release pro-VWF is rapidly cleared from the circulation or, alternatively, 
converted into mature VWF and propeptide outside the cell. Indeed, animal experi-
mental studies have shown that upon infusion of (unprocessed) pro-VWF the VWF 
propeptide is rapidly cleaved from its precursor [50]. It remains unclear, therefore, to 
what extent release through the constitutive pathway plays a role in the replenish-
ment of the plasma VWF pool. In any case, only mature VWF and its propeptide are 
detectable in plasma in significant amounts (50 and 5 nM respectively), not their 
precursor, pro-VWF [49].
FUNCTIONS OF VWF
After its release from the endothelium (and platelets) VWF serves two essential 
biological functions: it mediates the adhesion and aggregation of platelets at sites 
of vascular injury and modulates the survival and function of factor VIII. In addition, 
proper haemodynamic conditions (high shear rate) and highly polymerised VWF 
molecules are required to ascertain efficient platelet adhesion and aggregation. 
The molecular basis and physical chemical backgrounds of events associated with 
VWF-mediated platelet functions are well documented (reviewed in [2] and [10]). 
The factor VIII chaperone function of VWF is less well understood and this unique 
property will be discussed here.
Factor VIII binding
VWF circulates in plasma with factor VIII as a non-covalent complex. This interac-
tion extends the survival of factor VIII in the circulation. Any change in plasma VWF 
level is coupled with a concordant change in the plasma concentration of factor VIII. 
For instance, low VWF levels, as in von Willebrand’s disease, are associated with 
low plasma factor VIII levels as well. Similarly, qualitative VWF defects, as in von 
Willebrand’s disease type 2N (see below), may abolish proper factor VIII-VWF in-
teractions and, as a consequence, plasma factor VIII levels are decreased. In clini-
cal conditions associated with elevated VWF levels, such as malignancies, sepsis 
or liver disease, factor VIII levels seem to increase in a coordinate fashion [51,52]. 
Similarly, also physiological stimuli such as exercise or pregnancy enhance VWF 
levels with a concomitant rise in factor VIII levels. These examples clearly illustrate 
that VWF is essential for the stabilisation of factor VIII in the circulation. The oppo-
site is not the case; plasma VWF levels are not influenced by factor VIII levels.
The molecular basis of the factor VIII-VWF complex formation is fairly well 
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understood, at least the polypeptide domains and interactive sites of the VWF and 
factor VIII molecule that mutually interact have been identified (reviewed in [53]). 
The amino-terminal D’ domain of VWF comprises the primary factor VIII binding 
site [54]. Only in its dimeric form this Cys-rich domain is able to bind factor VIII, in-
dicating a complex mode of protein-protein interaction. In patients with a markedly 
decreased affinity of their VWF with (otherwise normal) factor VIII, (socalled von 
Willebrand’s disease type 2N) several missense mutations in VWF have been iden-
tified that selectively abolish factor VIII binding [55,56]. The majority of mutations 
were localized to the D’ domain. In most (though not all) cases reported these muta-
tions do not affect the plasma VWF levels or the reactivity of VWF with platelets or 
the subendothelial connective tissue. Only the affinity for factor VIII is decreased. 
Recent studies indicate that multiple amino acid residues within the D’ domain are 
critical in stabilising the conformational structure of this domain and, as a conse-
quence, factor VIII binding [17,57]. The complementary interactive sites for VWF on 
the factor VIII molecule have also been identified (reviewed in [53]).
VWF not only binds to factor VIII and thereby controls its biological survival, 
it also protects factor VIII from premature proteolytic cleavages and inactivation. 
Possibly biological survival and proteolytic degradation are interconnected, though 
a causal relationship has not been identified. VWF and factor VIII are probably syn-
thesized by different cell types [53] and during or after release into the circulation 
these proteins form a tight, non-covalent complex. Each VWF monomer is able to 
bind one factor VIII molecule. However, in vivo not all VWF monomers are bound to 
factor VIII. Rather a relatively small portion (1-2%) of the available VWF monomers 
is occupied by factor VIII [58]. These complexes are relatively stable. Only upon 
triggering of the coagulation system one of the VWF-binding sites on the factor VIII 
molecule is cleaved off, notably by thrombin, resulting in dissociation of the complex 
and subsequent conversion of factor VIII into its active configuration (factor VIIIa) 
[59]. 
VWF modulates the function of factor VIII at various levels. It inhibits the inter-
action of factor VIII to different proteases of the coagulation system, including fac-
tor IX, factor X, protein C as well as negatively charged phospholipid membranes, 
thereby preventing premature activation of the coagulation system. These interac-
tions most likely play a significant role in controlling haemostatic responses to vas-
cular injury. There is indeed ample evidence that VWF can protect factor VIII against 
proteolytic degradation, at least in vitro (reviewed in [53]). It seems reasonable to 
assume, therefore, that the decreased half-life of factor VIII in the absence of VWF 
is due to premature cleavages of factor VIII and subsequent enhanced clearance 
of the proteolytically modified factor VIII molecule. However, experimental data in 
support of this view is lacking so far. 
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Recent reports have shown that VWF could also control the biological half-life 
of factor VIII by controlling its interaction with LRP (low density lipoprotein recep-
tor-related protein) [60]. LRP is a multifunctional scavenger receptor involved in the 
clearance of a spectrum of ligands, including proteases, protease-inhibitor com-
plexes, lipases and apolipoproteins from the circulation (reviewed in [61,62]). LRP 
also binds factor VIII and thereby mediates its cellular internalisation and degrada-
tion [63,64]. These processes are inhibited by VWF. These observations suggest 
that VWF may also control factor VIII clearance by a mechanism independent of 
premature proteolytic breakdown of factor VIII. Indeed, in VWF deficient mice the 
half-life of factor VIII is prolonged by pre-infusion of the animals with RAP, a LRP 
antagonist [60]. Future studies should reveal the biological significance of the latter 
clearance mechanism.  
 
Functions of VWF-propeptide
As discussed above, the VWF-propeptide plays an important role in controlling in-
tracellular targeting and polymerisation of VWF. During the maturation of VWF, the 
propeptide is subsequently cleaved from pro-VWF but is co-stored in the Weibel-
Palade bodies and co-secreted with mature VWF in response to stimulation of en-
dothelial cells rather than being secreted or degraded as a waste product. Indeed, 
plasma levels of propeptide (and VWF) are markedly increased under clinical con-
ditions known to be associated with perturbation of the endothelium, such as sep-
ticaemia or thrombotic thrombocytopenic purpura (TTP) [65]. It has been thought 
that, after its release, the propeptide is biologically inert. This is most likely not the 
case. Accumulating evidence suggests that the propeptide, apart from its presumed 
PDI activity (see above), possesses a number of functions that could serve a role 
in controlling inflammatory and cell adhesion processes. Recent studies indicated 
that the propeptide harbours a number of sites that interact with constituents of the 
connective tissue of the subendothelium as well as integrins (Table 2). 
Evidence has been obtained that the VWF propeptide specifically binds to 
collagen type I and is able to inhibit collagen-induced platelet aggregation [66,67]. 
The latter effect is probably due to inhibition of the interaction between collagen 
and the collagen receptor. Detailed analysis of the ability of different monoclonal 
anti-propeptide antibodies to interfere with the binding of VWF propeptide to col-
lagen revealed that the propeptide contains at least two collagen-binding sites [68] 
(See Figure 2 above). One of these peptide domains is located in the first Cys-rich 
region of the propeptide molecule (Glu303-Lys397). The second collagen-binding site 
is located in a Cys-rich region near the carboxy-terminal region of the VWF propep-
tide, extending from residues Phe592 to Lys704. In particular, the sequence WREPSF-
CALS (Trp642-Ser651) is involved in collagen binding [69]. Although the VWF propep-
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tide preferentially binds to native type I collagen fibrils, the Phe592-Lys704 fragment 
and the decapeptide bind to several other collagens, both in the native as well as in 
a heat-denatured state. Also mature VWF harbours collagen binding sites (Fig.2). 
Peptides regions involved in the latter are structurally distinct from the propeptide 
binding sites [69,70].
The VWF propeptide has also been shown to be present on the surface of 
platelets [71]. As antibodies to the propeptide may induce platelet activation and 
aggregation, it has been suggested that membrane-bound propeptide could serve 
a role in controlling platelet function [72]. The biological significance of the propep-
tide as a modulator of platelet function remains to be established, however.
A few reports demonstrated that the VWF propeptide is a substrate for coagu-
lation factor XIIIa. This transglutaminase is able to catalyse the cross-linking of the 
propeptide to laminin, a constituent of the extracellular matrix [73,74]. The Gln resi-
dues in the propeptide specifically reacting with factor XIIIa as amine acceptor have 
been identified (Fig.2) [74]. Only 4 out of the 40 Gln residues of the propeptide act 
in this manner, highlighting the specificity of the factor XIIIa-propeptide interaction. 
As laminin has a variety of cellular functions, including its role as cell attachment or 
cell migration mediator, it is tempting to speculate that the propeptide could play a 
role in modulating these processes.
Of particular interest is the observation that the propeptide is able to promote 
specific adhesion and spreading of certain cell types, in a integrin-dependant 
manner [75-77] These processes are mediated by the α4ß1 (VLA4) and the α9ß1 
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(VLA9) integrins [76,77]. These integrins bind to the same propeptide site, involving 
residues 417-432. Interestingly, these integrins also bind factor XIIIa, the enzyme 
that catalyses the cross-linking of the propeptide to laminin. Both integrins are 
highly expressed on leukocytes; VLA-4 is primarily expressed by lymphocytes, 
monocytes and eosinophils, whereas VLA-9 is mostly found on neutrophils [78]. As 
both integrins play a prominent role in transendothelial migration of these cells, the 
propeptide could modulate these processes.
Taken together, in addition to its important intracellular function, evidence is 
accumulating that the propeptide serves a number of extracellular functions, at 
least in vitro. Future studies should reveal the physiological and pathophysiological 
significance of these observations.
SCOPE OF THIS THESIS
As outlined above, endothelial cells are able to secrete VWF either constitutively 
or through the regulated pathway. As illustrated in Figure 5, storage of VWF in 
Weibel-Palade bodies is one of the essential steps for its rapid regulated secretion 
in circulation, and its subsequent function in correct haemostasis. Interestingly, 
Weibel-Palade bodies are not only restricted to VWF-storage, but are also capable 
to store and secrete proteins with divergent extracellular functions, among which 
the VWF-propeptide, P-selectin and IL-8. However, mechanisms such as sorting 
of proteins to Weibel-Palade bodies, Weibel-Palade body trafficking in the cell and 
secretion of their content in circulation are far of being understood. Each chapter in 
this thesis addresses an issue involved in the life cycle of Weibel-Palade bodies or 
the extracellular function of one of their constituents. Figure 5 illustrates the differ-
ent steps that were studied in this thesis: 
1. targeting of proteins into Weibel-Palade bodies 
2. intracellular trafficking of Weibel-Palade bodies 
3. exocytosis 
4. extracellular function of the VWF-propeptide, a Weibel-Palade body 
     constituent.
The mechanism of protein targeting and in particular the targeting of IL-8 into 
Weibel-Palade bodies, and the role of VWF in this mechanism is studied in Chapter 
2. Chapter 3 focuses on the trafficking of Weibel-Palade bodies inside the cell and 
their secretory behaviour upon stimulation of the cell. Weibel-Palade body exocyto-
sis was also investigated in Chapter 4, focussing on the role of a small GTP binding 
protein Ral in this process. 
The second part of this thesis concentrates on one of the Weibel-Palade body 
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constituent, the VWF-propeptide. In contrast to its well-defined role in controlling 
intracellular targeting and polymerisation of VWF, less evidence has been provided 
regarding its biological functions after its release from the cell. Chapter 5, a litera-
ture review about the VWF-propeptide, describes in more detail the functions of 
the propeptide in vascular disorders so far known, including its role as a marker 
for endothelium perturbation. The latter property of VWF-propeptide served to 
examine the degree endothelial cell stimulation in patients suffering of thrombotic 
thrombocytopenic purpura (chapter 6). Chapter 7 focuses on another property of 
the propeptide, namely its possible role as an inflammatory mediator. 
The implications of our findings for the unravelling of the life cycle of Weibel-
Palade bodies are discussed in Chapter 8 and directions for future research are 
indicated.
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ABSTRACT 
Vascular endothelial cells are able to store the chemotactic cytokine interleukin-8 
(IL-8) in specialized storage vesicles, Weibel-Palade bodies, together with von Wil-
lebrand factor (VWF) and P-selectin. We investigated whether VWF plays a role in 
the sorting of IL-8 into these organelles. We examined the effect of VWF expression 
on IL-8 targeting in an endothelial cell line (EC-RF24). This cell line has retained 
the typical phenotypic characteristics of primary endothelial cells but has lost the 
capacity to produce VWF in appreciable amounts. EC-RF24 cells were retrovirally 
transduced with a vector encoding a VWF-green fluorescent protein chimera (VWF-
GFP). This approach enables direct visualization of the cellular distribution and 
secretory behavior of the VWF-GFP hybrid. Expression of VWF-GFP resulted in the 
generation of Weibel-Palade body-like organelles as shown by the co-localization 
of VWF-GFP and P-selectin. VWF-GFP expressing EC-RF24 cells also showed 
significant co-localization of VWF-GFP with IL-8 in these storage vesicles. Live cell 
imaging revealed that the number of VWF-GFP containg granules decreased upon 
cell stimulation. These observations indicate that VWF plays an active role in se-
questering IL-8 into Weibel-Palade bodies.
INTRODUCTION
Von Willebrand factor (VWF) is a multifunctional plasma protein that is required for 
normal haemostasis. Its physiological significance is demonstrated by the observa-
tion that VWF deficiency, or von Willebrand’s disease, may predispose to a severe 
bleeding tendency. VWF is synthesized by endothelial cells and megakaryocytes 
and plays a major role in platelet adhesion and haemostatic plug formation at sites 
of vascular injury. In endothelial cells VWF is secreted through two different path-
ways. The major portion of de novo synthesized VWF is secreted constitutively. 
The remainder is stored in specialized vesicles, the so-called Weibel-Palade bod-
ies, and is secreted only upon stimulation of the cell by Ca2+- and/or cAMP-raising 
agents. Only fully processed, haemostatically active VWF is stored in Weibel-Pal-
ade bodies. 
In addition to VWF, these secretory granules also contain a number of other 
proteins with different biological functions, including P-selectin [1], CD63 [2], endo-
thelin [3], IL-8 [4;5], tissue-type plasminogen activator [6;7] and α1,3-fucosyltrans-
ferase VI [8]. The mechanism responsible for sorting of these proteins into these 
secretory vesicles is poorly understood. Accumulated evidence suggests that VWF 
not only plays a role in directing the formation of Weibel-Palade bodies [9-11], but 
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may also have a helper function in the sorting of distinct proteins to Weibel-Pal-
ade bodies [11;12]. For instance, when an epithelial cell line, which synthesizes 
P-selectin but does not retain this receptor in storage vesicles, was transfected 
with VWF-cDNA, Weibel-Palade body-like organelles, containing both VWF and 
P-selectin, were formed [11]. Similarly, in VWF-deficient mice, P-selectin is not 
properly stored in endothelial cells [12]. These observations suggest that VWF may 
trigger sequestering of structurally unrelated proteins into Weibel-Palade bodies. To 
further substantiate this hypothesis we have studied the role of VWF in controlling 
the sorting of IL-8 into Weibel-Palade bodies. For this purpose we used a human 
endothelial cell line (EC-RF24, [13]) with markedly reduced VWF synthesis and 
decreased Weibel-Palade bodies. Preliminary experiments showed that this cell 
line is not capable of storing IL-8 in significant amounts. We used this cell line as a 
model system to address the hypothesis outlined above. Here, we demonstrate that 
when VWF synthesis is restored in these cells by means of retroviral transduction, 
IL-8 together with VWF and P-selectin is targeted into granules that, in terms of 
morphology and secretory behavior, are similar to Weibel-Palade bodies. 
MATERIALS AND METHODS
Cell culture
Freshly isolated human umbilical vein endothelial cells (HUVEC) [14] and the im-
mortalized HUVEC cell line EC-RF24 [13] were cultured in medium containing an 
equal mixture of RPMI 1640 and Medium 199 (Gibco BRL, Paisley, U.K.) supple-
mented with 20% human serum, 2 mM glutamine (Merck, Darmstadt, Germany), 
100 units/ml penicillin, 100 µg/ml streptomycin and 5 µg/ml amphotericin B (Gibco) 
[14]. HUVEC were used for all experiments after their fourth passage. For real-time 
experiments, EC-RF24 transfected cells were grown in 35 mm-diameter gelatin-
coated glass coverslips and were used at confluency (4 x 104 cells per cm2).
Immunofluorescence staining and microscopy
For immunofluorescence studies, cells were grown on 1 cm-diameter gelatin-coat-
ed glass coverslips. To enhance IL-8 synthesis, confluent cells were pre-stimulated 
for 24 h at 37°C with 10 ng/ml IL-1β (Strathmann Biotech GMBH, Hannover, Ger-
many) containing culture medium. Subsequently, cells were fixed in 3.7% formal-
dehyde and permeabilized with a PBS buffer containing 0.02% saponine (Sigma) 
and 1% bovine serum albumin. The cells were then incubated with unconjugated 
primary antibodies, washed three times, and incubated with conjugated secondary 
antibodies, as indicated in the figure legends. Cells were embedded in Vectashield 
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mounting medium (Vecta Laboratories, Burlington, CA, USA) and viewed by confo-
cal microscopy using a Zeiss LSM510 (Carl Zeiss, Heidelberg, Germany). Confocal 
images were recorded using standard settings for GFP and Texas-Red detection. 
When appropriate, images were recorded in the Multi-track mode (sequential scan-
ning) to exclude interchannel crosstalk.
Antibodies
VWF was detected by immunofluorescence with a monoclonal antibody (CLB-RAg 
35, CLB, Amsterdam, The Netherlands) directed against the A1 domain of VWF 
[15]. A rabbit anti-human cathepsin D polyclonal antiserum, a generous gift from 
Dr. J.M.F.G. Aerts, Department of Biochemistry, Academic Medical Center, Amster-
dam, The Netherlands, was used as a lysosomal marker. The monoclonal antibody 
to P-selectin (RUU 1.18) was kindly provided by Dr H. K. Nieuwenhuis, University 
Medical Center Utrecht, Utrecht, The Netherlands [16]. As secondary antibody, we 
used either Texas-red-, FITC-conjugated goat-anti-mouse IgG or horse-anti-rabbit 
IgG (CLB). For IL-8 detection, a biotinylated polyclonal sheep anti-human IL-8 anti-
serum was used (CLB), followed by poly-HRP-labeled, FITC-labeled or Alexa594-
labeled streptavidin (Molecular Probes, Eugene, Oregon, U.S.A).
Construction of the LZRS IRES VWF-GFP vector
VWF-GFP was constructed by replacing the VWF A2 domain by the sequence en-
coding the green fluorescent protein (GFP). The GFP fragment was amplified from 
the pEGFP-N3 vector by PCR using primers containing the XmaI and BsPI restric-
tion sites flanking the A2 domain and the ends of the GFP coding sequence. The 
primers used were as follows: GFP-sense: 5’-AATCCCGGGGGTGAGCAAGGGC-
GAGGAG-3’; GFP-antisense: 5’-AATTCCGGACTTGTACAGCTCGTCCAT-3’. A 
recombinant retroviral vector for delivery of the VWF-GFP gene was constructed 
using the dicistronic retroviral LZRS vector as described previously [17]. The frag-
ment was inserted downstream of the 5’ long terminal repeat (LTR) using EcoRI 
restriction site.
Retroviral gene transduction
Helper-free recombinant retrovirus was produced after transfection of the LZRS-
VWF-GFP DNA into Phoenix-A cells (a 293T-based amphotropic retroviral packag-
ing cell line) [18] by calcium phosphate transfection (Gibco). The cells were cultured 
in medium containing IMDM, 10% heat-inactivated fetal calf serum, 100 units/ml 
penicillin, 100 µg /ml streptomycin (all from Gibco) and 2 µg/ml puromycin (Sigma). 
For the production of virus, cells were maintained for at least 6 h in medium lacking 
puromycin. EC-RF24 cells, grown on 35 mm-diameter fibronectin-coated wells until 
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a confluency of 20-40%, were transduced with the harvested virus supernatant as 
previously described [19]. The transduction efficiency was tested by determining 
the percentage of GFP positive cells using flow cytometry analysis with a FACSs-
can (Becton Dickinson, San Jose, CA, USA).
 
Multimer analysis
EC-RF24-VWF-GFP were grown in fibronectin coated 80 cm2 flasks. At conflu-
ence, cells were incubated for 60 min in 6 ml serum-free medium containing 1U/ml 
thrombin (Sigma). Cell supernatants were collected and cleared of cell debris by 
centrifugation. The medium containing VWF was concentrated by incubation with 
0.5 volume of buffer containing 50 mM imidazol pH 6.5, 100 mM NaCl, 10 mM ben-
zamidine and 1% (v/v) S-Sepharose Fast Flow (Pharmacia; Uppsala, Sweden) for 
20 h. S-Sepharose was collected and suspended in sample buffer (9.7 M urea, 4 ml 
10% SDS, 1 ml 0.5% bromophenol blue and 5 ml stacking gel buffer, pH 6.7 con-
taining 70 mM Tris, 4 mM Na2EDTA and 0.4% SDS) and boiled for 5 min. Samples 
(5-10 ng VWF) were layered on a 1.4% SeaKem HGT (P) agarose gel (BioWhit-
taker Molecular Applications; Rockland, ME USA), run for 2 h at 100 V and 45 mA 
and blotted on a polyvinylidene difluoride filter (Immobilon-P transfer membranes; 
Millipore Corporations, Bedford). Finally, blots were incubated with anti-GFP (PoAb 
A11122, Molecular Probes, Eugene, Oregon, U.S.A) and HRP-labeled horse-anti-
rabbit antibodies or HRP-labeled anti-VWF (DAKO, Denmark A/S, Glostrup, Den-
mark) polyclonal antibodies. Multimers were visualized by ECL (Roche Diagnostics 
Nederland B.V., Almere, The Netherlands).
Quantitative analysis of Weibel-Palade bodies in living cells
EC-RF24-VWF-GFP were grown on 10 mm-diameter gelatin-coated glass cover-
slips. At confluency, cells were mounted in an incubation chamber (LaCon, Stein-
berg, Baden-Württemberg, Germany) in HEPES medium consisting of 20 mM 
Hepes, 132 mM NaCl, 6 mM KCl, 1 mM MgSO4, 1 mM CaCl2 and 1.2 mM K2HPO4, 
that was supplemented with 1 mg/ml glucose and 1% human serum albumin. Con-
focal images were recorded with a Zeiss LSM510 using standard settings for GFP. 
During analysis, the sample chamber was maintained at 37oC using a thermostat-
ted chamber holder. Selected cells were first imaged for 10 min in their initial me-
dium. Subsequently, the medium was replaced by medium with or without 50 ng/ml 
PMA (Sigma Chemical Co., St Louis, Mo., U.S.A.). Images of VWF-GFP containing 
granules in living EC-RF24-VWF-GFP were generated by making series of opti-
cal sections (Z-stacks, 400 nm interval/thickness) of single cells at different time 
points. Three-dimensional analysis (x-y-z axis) was performed using depth-coding 
software (application for Zeiss LSM510, version 2.3) that allowed the monitoring 
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of all Weibel-Palade bodies present in each cell. The total number of vesicles per 
cell was counted before and 60 minutes after stimulation with PMA. The difference 
between the number of Weibel-Palade bodies counted at 0 and 60 minutes was 
analysed by the paired Student’s t-test. The difference between the number of Wei-
bel-Palade bodies in PMA-stimulated cells versus control cells was analysed using 
the umpaired Student’s t-test.
RESULTS
Co-localization of VWF and IL-8 in HUVEC.
It has been previously shown that IL-8 accumulates in Weibel-Palade bodies 
after prolonged stimulation of endothelial cells and co-localizes with VWF [4;5]. 
This feature was further explored to study our hypothesis that sorting of IL-8 to 
these secretory vesicles is directed by VWF. Staining of unstimulated HUVEC with 
Texas-red-conjugated anti-VWF demonstrated VWF in the rod-shaped vesicles 
corresponding to Weibel-Palade bodies (Fig.1a,c). These cells did not stain with 
FITC-conjugated anti-IL-8. However, upon de novo synthesis induced by IL-1β, 
cells did stain with anti-IL8 antibody (Fig.1e,f). IL-8 was observed both in structures 
Figure 1. VWF and IL-8 localization in cultured HUVEC. Untreated endothelial cells 
(a-c) or cells treated for 24 h with 10 ng/ml IL-1β (d-f), were immunostained for VWF 
(a,d), IL-8 (b,e) or both (c,f). VWF (red) was stained with the monoclonal anti-VWF CLB-
Rag 35 and Texas-red-conjugated goat anti-mouse IgG. IL-8, in green, was stained with 
biotinylated polyclonal anti-IL-8 antibodies and FITC-conjugated streptavidin. Overlapping 
distribution of VWF and IL-8 is shown in yellow (c,f). Scale bars, 10 µm.
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typical of the Golgi apparatus and rod-shaped vesicles (Fig.1e). The latter were 
similar to those containing VWF (Fig.1d,f). Some vesicles stained for VWF only. We 
did not find granules that stained only for IL-8 (Fig.1f). Similarly, HUVEC stimulated 
with endotoxin, instead of IL-1β, revealed granular co-localization of IL-8 and VWF 
(data not shown). 
VWF and IL-8 expression by EC-RF24 cells
To determine whether co-localization of IL-8 and VWF is mediated by VWF expres-
sion, we studied the subcellular localization and secretion of IL-8 by immortalized, 
VWF-deficient endothelial cells (EC-RF24). These cells originated from wild-type 
HUVEC and have retained several phenotypic characteristics of HUVEC [13]. 
However, their VWF expression level has decreased dramatically upon culture pas-
sages [13]. We took advantage of this phenotype to investigate whether this cell 
line could be used as a model to study VWF-mediated sorting of IL-8. EC-RF24 
cells were cultured for 24 h in medium with or without IL-1β and were subsequently 
stained for VWF and IL-8 with the appropriate antibodies. Compared to HUVEC 
(Fig.1a), untreated EC-RF24 demonstrated significant reduced vesicular staining 
for VWF (Fig.2a,c). IL-8 was sporadically detected in these cells (Fig.2b,c). When 
EC-RF24 cells were pre-treated with IL-1β, VWF staining was virtually absent 
Figure 2. Expression of VWF and IL-8 by EC-RF24 cells. EC-RF24 cells untreated 
(a-c) or treated for 24 h with 10 ng/ml IL-1β (d-f). Cells were examined for expression of 
VWF and IL-8 by double immunofluorescence. VWF staining (in red, a,d) was performed 
with a monoclonal anti-VWF antibody followed by incubation with Texas-red-conjugated 
goat anti-mouse. IL-8 (in green, b,e) was detected using a biotinylated polyclonal anti-
IL-8 antibody, followed and FITC-conjugated streptavidin. Merges of the VWF and IL-8 
images, c,f. Scale bars, 10 µm.
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Figure 3. Vesicular localization of VWF-GFP and IL-8 in transduced EC-RF24. Vesicle formation by 
VWF-GFP-infected EC-RF24 cells was characterized by immunofluorescence. In all panels, VWF-GFP 
was visualized with the GFP marker (green). Localization of VWF was determined using a monoclonal 
antibody (CLB-RAg35) directed against the A1 domain of VWF, followed by Texas red labelled goat anti 
mouse IgG (b,c). Localization of cathepsin D was determined with anti-human cathepsin D polyclonal 
antiserum, followed by Texas-red-conjugated horse-anti-rabbit IgG (e,f). Sequential incubation of 
monoclonal anti-P-selectin antibody RUU 1.18, and Texas Red-labeled goat-anti-mouse IgG was 
performed for P-selectin detection (h-i). To determine the IL-8 localization in IL-1β untreated (j-l) or 
treated (m-o) cells, a biotinylated polyclonal sheep anti-human IL-8 antiserum was used, followed 
by Alexa594-labeled streptavidin incubation (k,l,n,o). The antibody against VWF co-localized entirely 
with GFP (c). VWF-GFP did not co-localize with the lysosomal marker cathepsin D (f). However, co-
localization of VWF-GFP containing vesicles with P-selectin (i) and with IL-8 (o) (only upon IL-1β 
stimulation) is shown in yellow. Scale bars, 10 µm.
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(Fig.2d) whereas IL-8 expression was only found in structures characteristic of the 
Golgi apparatus (Fig.2e). As expected, no co-localization of VWF and IL-8 was ob-
served (Fig.2f). These observations suggest that in endothelial cells with reduced 
VWF-synthesizing capacity, IL-8 targeting into Weibel-Palade bodies is defective. 
Co-localization of IL-8 and VWF in VWF-GFP infected EC-RF24 cells.
To further substantiate this hypothesis, VWF synthesis was restored in EC-RF24 
cells by retroviral transduction. These cells were used for co-localization studies of 
de novo synthesized VWF and IL-8. To discriminate between sporadic, endogenous 
VWF expression and transgenic VWF, EC-RF24 cells were transfected with a VWF-
GFP hybrid vector (see Material and Methods). Fluorescence microscopical analy-
sis demonstrated the formation of granular, green fluorescent vesicles in infected 
EC-RF24 cells (Fig.3a,d,g,j,m). Staining of transfected cells with a monoclonal 
antibody (CLB-RAg35) directed against the A1 domain of VWF (Fig.3b) showed 
entire co-localization between GFP and VWF (Fig.3a-c). This observation suggests 
that the GFP tag is an integral part of the VWF molecule. This is supported by the 
observation that VWF-GFP secreted by EC-RF24-VWF-GFP showed identical mul-
timeric patterns after staining with either anti-VWF or anti-GFP antibodies (Fig.4). 
The vesicles were distinct from lysosomes as the GFP-associated vesicles did 
not co-localize with granules that stained with a Texas red-conjugated antibody to 
cathepsin D, a lysosomal marker (Fig.3e,f). On the other hand, VWF-GFP did co-
localize with P-selectin, a typical marker of Weibel-Palade bodies (Fig.3g-i). Like 
uninfected EC-RF24 cells, VWF-GFP-infected cells did not stain for IL-8 (Fig.3j-l). 
On the other hand, pre-treatment of the VWF-GFP-infected cells for 24 h with IL-1β 
resulted in significant co-localization of de novo synthesized IL-8 and VWF-GFP 
(Fig.3m-o). These observations suggest that in endothelial cells VWF functions as 
Figure 4. Multimer analysis of 
VWF-GFP. VWF-GFP-infected EC-
RF24 were stimulated for 60 min with 
1U/ml thrombin. Released VWF was 
concentrated by S-Sepharose, run on 
a 1.4% agarose gel, and blotted. VWF 
multimers produced by EC-RF24-
VWF-GFP react identically to either 
anti-VWF or anti-GFP antibodies. 
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a helper protein in the sorting of IL-8 and P-selectin to Weibel-Palade bodies.
Visual inspection of live cells stimulated with PMA during 60 min showed that 
the number of granules decreased under these conditions, suggesting that regu-
lated exocytosis had occurred. Also some non-stimulated control cells displayed 
loss of granules during 60 min incubation period under the microscope. However, 
the decrease of granule number was less apparent than the decrease observed 
in the presence of PMA. To document regulated exocytosis in a more quantitative 
manner, the number of vesicles was counted at the single cell level in 30-40 cells 
before and 60 min after stimulation. This analysis revealed that the decrease of 
granule number in PMA treated cells was significantly larger than the decrease in 
vesicle number of control cells (Table 1), indicating that indeed the VWF-GFP con-
taining vesicles may undergo regulated secretion. Attempts to quantify the amount 
of either VWF-GFP or IL-8 released by agonist stimulation of the transfected cells 
have been hampered by the low number of GFP-transfected cells.
DISCUSSION
In this report two novel approaches were employed to study the role of VWF in 
controlling the sorting of IL-8 in endothelial cells. First, we used an endothelial cell 
line (EC-RF24) that closely mimics the phenotypic features of primary endothelial 
cells but lacks the capacity to produce VWF and Weibel-Palade bodies in substan-
tial amounts. Therefore, this cell line provides a proper model to study the effect of 
transgenic VWF expression on the biogenesis of Weibel-Palade bodies and target-
ing of endogenous proteins in endothelial cells. Accumulated evidence indicates 
that different cell types may use different sorting mechanisms (reviewed in [20;21]). 
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Sorting pathways of cell lines of non-endothelial origin, previously used to study 
VWF-associated regulated secretion, such as the mouse pituitary cell line AtT-20 
[22;23] or CV-1 cells (monkey kidney cells) [10] do not necessarily reflect endothe-
lial cell sorting mechanisms. Second, a VWF-GFP hybrid was expressed in these 
cells to enable direct visualization of vesicle formation and to allow discrimination 
between residual, endogenous VWF and transgenic, tagged VWF. In terms of cel-
lular localization and multimeric distribution the GFP tag appeared to be an integral 
part of the VWF-GFP hybrid (Fig. 3a-c, Fig.4). Although this was not the primary 
aim of the present study, this procedure also allows to study the dynamics of Wei-
bel-Palade bodies in living endothelial cells.
This experimental approach revealed that VWF plays an active role in target-
ing IL-8 into Weibel-Palade bodies. This conclusion is based on the following ob-
servations and considerations. (i). Unlike in wild-type endothelial cells, in EC-RF24 
cells IL-8 is primarily observed in structures typical of the Golgi apparatus (Fig.2e,f); 
IL-8 was not found in Weibel-Palade body like vesicles. This suggests that when 
VWF expression is reduced, IL-8 storage is reduced or absent. (ii). In VWF-GFP-
infected EC-RF24 cells, IL-8 is co-targeted with VWF-GFP into Weibel-Palade 
body-like granules (Fig.3o). VWF-GFP and the lysosomal marker cathepsin D did 
not co-localize in these cells (Fig.3f), arguing against the possibility that VWF-GFP 
(and IL-8) was targeted to lysosomes. (iii) P-selectin co-localized with VWF-GFP in 
VWF-GFP containing vesicles (Fig.3i). (iv) VWF-GFP containing vesicles are ca-
pable of regulated exocytosis (Table 1). As most of the VWF-GFP-positive granules 
colocalize with IL-8 (Fig.3o), this observation suggest that in infected EC-RF24 
cells also IL-8 can be secreted through the regulated pathway. Taken together, 
these observations indicate that in VWF-GFP-infected EC-RF24 cells VWF-GFP 
and, thus, IL-8 are co-targeted into Weibel-Palade bodies. Apparently, VWF is able 
to facilitate sorting of structurally unrelated, though selected subset of proteins into 
the regulated secretory pathway in endothelial cells. Similarly, VWF may also direct 
the sorting in endothelial cells of CD63, endothelin and α1,3-fucosyltransferase, 
also residents of Weibel-Palade bodies.
Little is known about the mechanism by which these proteins are targeted into 
Weibel-Palade bodies. It is possible that these proteins interact or co-aggregate 
with VWF multimers in TGN, a process that may further facilitate their retention and 
condensation within the Weibel-Palade bodies [24;25]. Indeed, VWF may bind a 
variety of proteins and biological compounds [26]. We speculate that other Weibel-
Palade body constituents may specifically interact with VWF preceding maturation 
of secretory vesicles. Pertinent to this point is our preliminary observation that IL-8 
may bind to VWF (results not shown).
A recent study demonstrated that the role of VWF and P-selectin can be 
VWF targets IL-8 to Weibel-Palade bodies
41
intricately linked [12]. VWF-deficient mice present a significant reduction in leu-
kocyte recruitment in experimental inflammation. In these mice, P-selectin is not 
properly expressed at the plasma membrane after stimulation of endothelial cells 
by inflammatory mediators such as IL-1β or tumor necrosis factor α. The present 
study suggests that VWF deficiency could also lead to an aberrant release of IL-8 
which, together with reduced expression of P-selectin, might decrease neutrophil 
recruitment in early phases of inflammation and sites of endothelial cell perturba-
tion. Similarly, it is tempting to speculate that severe VWF deficiency also affects 
physiological and pathophysiological processes in which regulated mobilization of 
other residents of Weibel-Palade bodies is required.
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ABSTRACT
Weibel-Palade bodies (WPbs) are specialized secretory granules found in endo-
thelial cells. These vesicles store hormones, enzymes and receptors, and exhibit 
regulated exocytosis upon cellular stimulation. Here we have directly visualized 
intracellular trafficking and secretory behavior of WPbs in living cells employing a 
hybrid protein consisting of von Willebrand factor (VWF), a prominent WPb con-
stituent, and the green fluorescent protein (GFP). Immunofluorescent microscopy 
demonstrated that this chimera was targeted into WPbs as visualized by its co-lo-
calization with endogenous VWF and P-selectin, another WPb resident protein. In 
unstimulated cells, some WPbs seemed motionless, whereas others moved at low 
speed (<10 nm/sec) in a stochastic manner. A prominent feature was the formation 
of membrane-apposed patches upon stimulation of cells with [Ca2+]i- or cAMP-rais-
ing secretagogues, suggesting fusion of WPbs with the plasma membrane. Patches 
remained visible for more than 20 min. This sustained, membrane-associated re-
tention of VWF, or other WPb residents, might play a role in focal adhesion of blood 
constituents to the endothelium upon vascular injury.  In addition, stimulation with 
cAMP-raising resulted in clustering of a subset of WPbs in the perinuclear region 
of the cell. Apparently, these WPbs escaped secretion. This feature may provide a 
mechanism to control regulated exocytosis.
INTRODUCTION
Vascular endothelial cells are equipped with a machinery that, upon perturbation, 
allows prompt delivery of a number of bioactive substances, including hormones, 
receptors and adhesive molecules, to the surface of the cell. A distinct subset of 
proteins destined to be released upon stimulation of the endothelium stems from 
Weibel-Palade bodies (WPbs), typical and morphologically highly organized stor-
age vesicles that release their contents by regulated exocytosis. WPbs are endo-
thelial cell-specific elongated organelles, enclosed by a limiting membrane, which 
are about 0.1 µm wide and up to 4 µm long [1] and originate from the trans-Golgi 
network [2,3]. They serve as storage vesicles for a variety of proteins with different 
biological functions, such as the leukocyte adhesion receptor P-selectin [4,5], and 
the chemokine interleukin-8 (IL-8) [6,7]. Effective translocation of P-selectin from 
WPbs to the cell surface is critical for the binding and rolling of leukocytes on the 
endothelium at sites of inflammation [8,9]. Similarly, regulated exocytosis of IL-8 
provides an effective means for controlling local leukocyte extravasation [10]. One 
of the most prominent WPb residents is von Willebrand factor (VWF), an adhesive 
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multimeric glycoprotein that contributes to platelet adhesion and haemostatic plug 
formation at sites of vascular injury (reviewed in [11,12]. Regulated secretion of 
VWF provides an adequate means for endothelial cells to actively participate in 
controlling the arrest of bleeding upon vascular damage. Taken together, it seems 
likely that regulated exocytosis of WPbs serves several physiological functions in-
cluding inflammatory and haemostatic responses. 
Regulated exocytosis of VWF and other WPb residents involves the transloca-
tion of WPbs from the cytoplasm toward the cell surface and the fusion of these ves-
icles with the plasma membrane. Increased concentrations of cytosolic Ca2+ have 
been implicated in the mechanism of exocytosis of a number of agonists, including 
thrombin and histamine [13,14]. Release of WPbs can also be induced by secreta-
gogues, such as epinephrine or forskolin, agents known for their ability to activate 
cAMP-dependent signaling [15,16]. The cellular responses to increased cytosolic 
Ca2+ are most likely mediated by calmodulin and small GTP-binding proteins [17-
20]. The molecular mechanisms associated with cAMP-dependent exocytosis of 
WPbs remain to be identified. Besides the possibility that cAMP triggers a cascade 
of reactions, including activation of protein kinases, that eventually lead to cellular 
secretion, little is known about the molecular mechanisms distal to adenylate cy-
clase activation and cAMP generation. In one respect cAMP-mediated responses 
differ from regulated secretion elicited by a rise in cytosolic Ca2+ in that secretion 
induced by Ca2+-raising agents involves the release of both peripheral and central 
granules, whereas cAMP-mediated secretion primarily involves vesicles located in 
the periphery of the cell [19]. 
Though studies performed so far have clearly provided the basis for under-
standing the molecular machinery responsible for exocytotic trafficking of WPbs, 
little is known about the dynamics of this secretory process. To date, exocytosis of 
WPbs has been studied only morphologically by monitoring defined stages of this 
process in fixed cells. These conditions do not necessarily reflect the dynamics 
found in intact living cells. The aim of this study was to investigate the intracellular 
trafficking of WPbs in living, wild-type endothelial cells in real time. For this purpose, 
we introduced, by retroviral transduction, a green fluorescent protein (GFP)-tagged 
VWF into primary human umbilical vein endothelial cells (HUVEC), a well char-
acterized model of vascular endothelium. The VWF-GFP chimera was correctly 
processed and targeted to WPbs, together with endogenous VWF and P-selectin. 
This approach, exploiting the intrinsic fluorescence of VWF-GFP, allows direct vi-
sualization of the routing and fate of WPbs upon stimulation of the cell. Our data 
reveal novel features of the dynamics and secretory behavior of WPbs, including 
perinuclear redistribution and membrane-apposed accumulation of GFP-containing 
granules. This study also supports the role of WPb constituents in controlling adher-
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ence of circulating blood cells to activated endothelium.
MATERIALS AND METHODS
Cell culture
Freshly isolated HUVEC and VWF-GFP infected HUVEC were cultured in medium 
containing an equal amount of RPMI 1640 and Medium 199 (Gibco BRL, Paisley, 
U.K.), supplemented with 10% human serum, 10% fetal calf serum, 2 mM gluta-
mine (Merck, Darmstadt, Germany), 100 units/ml penicillin, 100 µg/ml streptomycin 
(Gibco), 5 units/ml heparin (Leo Pharmaceutical Products, Weesp, The Nether-
lands), and 2.5 ng/ml fibroblast growth factor-Basic (Sigma Chemical Co., St Louis, 
Mo., U.S.A.) [21]. 
Construction of the LZRS IRES VWF-GFP vector
VWF-GFP was constructed by replacing the VWF A2 domain by the sequence 
encoding the GFP (Fig.1A). The GFP fragment was amplified from the pEGFP-N3 
vector by PCR using primers containing the XmaI and BsPI restriction sites flanking 
the A2 domain and the ends of the GFP coding sequence. The primers used were 
as follows: GFP-sense: 5’-AATCCCGGGGGTGAGCAAGGGCGAGGAG-3’; GFP-
antisense: 5’-AATTCCGGACTTGTACAGCTCGTCCAT-3’. A recombinant retroviral 
vector for delivery of the VWF-GFP gene was constructed using the dicistronic 
retroviral LZRS vector as described previously [22]. The fragment was inserted 
downstream of the 5’ long terminal repeat (LTR) using EcoRI restriction site.
Retroviral gene transduction
Helper-free recombinant retrovirus was produced after transfection of the LZRS-
VWF-GFP DNA into Phoenix-A cells (a 293T-based amphotropic retroviral packag-
ing cell line) [23] by calcium phosphate transfection (Gibco). The cells were cultured 
in medium containing IMDM, 10% heat-inactivated fetal calf serum, 100 units/ml 
penicillin, 100 µg/ml streptomycin (all from Gibco) and 2 µg/ml puromycin (Sigma). 
For the production of virus, Phoenix-A cells were maintained for at least 6 h in 
medium lacking puromycin. HUVEC were grown on 35 mm-diameter fibronectin-
coated wells until they reached a cell density of 20-40%. Cells were subsequently 
transduced with the harvested virus supernatant of the Phoenix cells [24]. The 
transduction efficiency was tested by determining the percentage of GFP positive 
cells using flow cytometry analysis with a FACSscan (Becton Dickinson, San Jose, 
CA, USA). HUVEC were also transduced with the VWF-GFP vector together with 
the human telomerase reverse transcriptase (hTERT) gene. This was performed 
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by co-transduction of LZRS-VWF-GFP and LZRS-hTERT-NGFR virus (1:1 v/v) (a 
generous gift from Dr. H. Spits, Dutch Cancer Institute, Amsterdam, The Nether-
lands). The LZRS-hTERT-NGFR construct was made by replacing GFP present 
in LZRS-hTERT-GFP [23] by a truncated form of the neural growth factor receptor 
(NGFR). NGFR is expressed downstream hTERT and was used as a marker for 
hTERT transfection. 
Multimer analysis
HUVEC and VWF-GFP-infected HUVEC were grown in fibronectin coated 80 cm2 
flasks. At confluence, cells were incubated for 60 min in 6 ml serum-free medium 
containing 1U/ml thrombin (Sigma). Cell supernatants were collected and cleared 
of cell debris by centrifugation. The medium containing VWF was concentrated by 
incubation with 0.5 volume of buffer containing 50 mM imidazol pH 6.5, 100 mM 
NaCl, 10 mM benzamidine and 1% (v/v) S-Sepharose Fast Flow (Pharmacia; Up-
psala, Sweden) for 20 h. S-Sepharose was collected and suspended in sample buf-
fer (9.7 M urea, 4 ml 10% SDS-solution, 1 ml 0.5% bromophenol blue solution and 
5 ml stacking gel buffer, pH 6.7 containing 70 mM Tris, 4 mM Na2EDTA and 0.4% 
SDS) and boiled for 5 min. Samples (5-10 ng) were layered on a 1.4% SeaKem 
HGT (P) agarose gel (BioWhittaker Molecular Applications; Rockland, ME USA), 
run for 2 h at 100 V and 45 mA and blotted on a polyvinylidene difluoride filter 
(Immobilon-P transfer membranes; Millipore Corporations, Bedford). Finally, blots 
were incubated with anti-GFP (PoAb A11122, Molecular Probes, Eugene, Oregon, 
U.S.A) and HRP-labeled horse-anti-rabbit antibodies or HRP-labeled anti-VWF 
(DAKO, Denmark A/S, Glostrup, Denmark) polyclonal antibodies. Multimers were 
visualized by ECL (Roche Diagnostics Nederland B.V., Almere, The Netherlands).
Immunofluorescence
Cells were grown to confluence on 1 cm-diameter gelatin-coated glass coverslips, 
fixed in 3.7% (v/v) formaldehyde and permeabilized for 30 min with PBS buffer 
containing 0.02% saponin (Sigma) and 1% bovine serum albumin. The cells were 
then incubated with unconjugated primary antibodies in the permeabilizing buffer 
for 1 h at 37oC, washed three times, and incubated with conjugated secondary 
antibodies, as indicated in the figure legends. VWF was visualized with a mono-
clonal antibody directed against either the A1 domain (CLB-RAg 35) [25] or the 
A2 domain (CLB-RAg 50) [26] of VWF. A rabbit anti-human cathepsin D polyclonal 
antiserum (a generous gift from Dr. J.M.F.G. Aerts, Department of Biochemistry, 
Academic Medical Center, Amsterdam, The Netherlands) was used as a lysosomal 
marker. The monoclonal antibody to P-selectin (RUU 1.18) was kindly provided by 
Dr H. K. Nieuwenhuis, University Medical Center Utrecht, Utrecht, The Netherlands 
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[27]. As secondary antibody, we used Texas-Red -conjugated goat-anti-mouse IgG 
or horse-anti-rabbit IgG (Vector Laboratories, Burlington, CA, USA). Cells were 
embedded in Vectashield mounting medium (Vector Laboratories) and viewed on 
a Zeiss LSM510 confocal laser scanning microscope (Carl Zeiss, Heidelberg, Ger-
many).
Real-time imaging and microscopy
HUVEC-VWF-GFP were grown on 35 mm-diameter gelatin-coated glass cover-
slips. At confluence, cells were mounted in an incubation chamber (LaCon, Germa-
ny) in HEPES medium consisting of 20 mM Hepes, 132 mM NaCl, 6 mM KCl, 1 mM 
MgSO4, 1 mM CaCl2 and 1.2 mM K2HPO4, supplemented with 1 mg/ml glucose and 
2% human serum albumin. Confocal images were recorded with the Zeiss LSM510 
using standard settings for GFP and Texas-Red detection. When required, images 
were recorded in the multi-track mode (sequential scanning) to exclude interchan-
nel crosstalk. During real-time analysis, the sample chamber was maintained at 
37oC using a thermostatted chamber holder. Time-lapse images of WPbs in living 
HUVEC-VWF-GFP were generated by repetitive imaging at the same focal plane 
or by making series of optical sections (Z-stacks, 400 nm interval/thickness, 12-15 
slices/cell) every 2-5 min. Selected cells were first imaged for 10 min in their initial 
medium. Subsequently, 10 µl of the secretagogue of interest (final concentrations 
1 U/ml thrombin, 50 ng/ml PMA, 10 µM forskolin / 100 µM IBMX or 10 µM epineph-
rine / 100 µM IBMX; all from Sigma) was carefully added to the medium in order 
not to disturb the cells or change the focal plane. The recording was continued for 
another 60 or 90 min. Top view of the cells was performed using the xy axis. Three-
dimensional analysis was performed using depth-coding software that allowed the 
monitoring of WPbs translocation along the z-axis. This software enabled division 
of cells in three areas (the apical, the central and the basal area) by encoding each 
part with a color. Lateral analysis of WPbs was visualized by plotting the cells as 
yz diagrams. 
VWF secretion 
Regulated secretion of VWF-GFP was investigated either by determining the 
amount of secreted VWF-GFP antigen or by assessing the decrease of the number 
of WPbs in living cells after stimulation. HUVEC were grown in 35 mm-diameter 
fibronectin-coated wells and were used at confluence. Cells were washed three 
times with PBS and were stimulated for 60 min either with serum-free medium 
alone or with medium containing 50 ng/ml PMA. VWF antigen concentrations (nM) 
were measured by ELISA as described previously [28]. VWF-GFP levels (expressed 
as absorbance at 550 nm) were measured by ELISA using a monoclonal antibody 
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raised against GFP (MoAb 3E6 from Molecular probes) as coating antibody and 
an HRP-labeled anti-VWF polyclonal antibodies (DAKO) as conjugate. Results are 
expressed in relative values, i.e. as a percentage of release from unstimulated con-
trol cells from the same cell preparation. To measure the decrease of the number 
of WPbs, real time imaging was performed on living cells (see previous paragraph). 
Cells were stimulated with different secretagogues (1 U/ml thrombin, 50 ng/ml 
PMA, or 10 µM forskolin / 100 µM IBMX), Z-stacks were taken before and 60 min 
after stimulation and the number of WPbs was counted. The number obtained at 
t=0 was set at 100%.
RESULTS
VWF-GFP expression and distribution in HUVEC
In initial experiments, HUVEC were retrovirally transfected with either the VWF-
GFP hybrid protein (Fig. 1A) alone, or, to extend the life span [29], together with 
hTERT-NGFR. In terms of the expression and localization of VWF-GFP in cells and 
trafficking of WPbs, we observed no differences between these transfected cells. In 
this study results shown are both from VWF-GFP/hTERT-NGFR- and VWF-GFP-
transfected HUVEC. The respective cell line used is indicated. The transduction 
efficiency was approximately 20%, as determined by measuring GFP expression 
by flow cytometry (not shown). Similarly, analysis by confocal microscopy showed 
that about 20% of the cells were GFP-positive. Positive cells revealed a vesicular 
distribution of the green fluorescence (Fig. 1B). Three-dimensional analysis of the 
cells showed rod shaped vesicles that were distributed throughout the cytoplasm. 
Closer examination of the position of the GFP-containing organelles within the cell, 
visualized with a color scale (Fig. 1B), revealed that some vesicles were located 
at the bottom of the cell (red vesicles), whereas the majority was positioned in the 
middle (green vesicles) and some others were located at the top of the cell (blue 
vesicles). Thus, transfection of HUVEC with VWF-GFP results in the formation 
of GFP-labeled vesicles, typical of WPbs, which are heterogeneously distributed 
throughout the cell. 
We next confirmed whether VWF-GFP was indeed targeted to genuine WPbs. 
Staining of VWF-GFP-infected HUVEC with anti-VWF (CLB-RAg 35) revealed rod-
shaped granules that were always co-localized with the GFP signal, consistent with 
targeting of VWF-GFP to WPbs (Fig. 2a-c). Similarly, VWF-GFP was co-localized 
with P-selectin, a typical marker of WPbs (Fig. 2g-i). GFP-positive vesicles were 
distinct from lysosomes, as GFP-associated vesicles were not co-localized with 
granules that stained with a Texas red-conjugated antibody to cathepsin D, a ly-
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sosomal marker (Fig. 2j-l). These data demonstrate that VWF-GFP is targeted to 
WPbs together with endogenous, wild-type VWF. 
Since the monoclonal antibody CLB-RAg 35 used for VWF staining is directed 
against a domain (A1 domain) present in both VWF and VWF-GFP, WPbs may con-
tain either a mixture of endogenous VWF and VWF-GFP or only the VWF-GFP chi-
mera. To discriminate between endogenous VWF and VWF-GFP, cells were stained 
with an anti-VWF antibody (CLB-RAg 50) directed against the A2 domain of VWF. 
All GFP-positive vesicles stained with this antibody (Fig. 2d-f). This indicates that 
WPbs of VWF-GFP-infected HUVEC contain both endogenous, wild-type VWF and 
the VWF-GFP hybrid protein. 
VWF-GFP multimerization and secretion
Polymerization of VWF is one of the most characteristic events that occur during 
its post-translational maturation. Only VWF in its multimeric form is stored in WPbs 
[11]. To verify whether VWF-GFP is also able to multimerize, wild-type and VWF-
GFP-transfected HUVEC were stimulated with thrombin and the respective media 
were subjected to multimer analysis. 
Figure 1. HUVEC transduced with 
VWF-GFP. (A) Schematic representation 
of the primary structure of the pro-VWF-
GFP chimera used for the expression 
of VWF-GFP. The location of conserved 
structural domains of the propeptide and 
mature VWF moiety is indicated. The A2 
domain of VWF was replaced by GFP 
(green) allowing direct visualization of 
hybrid VWF-GFP. (B) Localization of VWF-
GFP-containing vesicles in transduced 
HUVEC. The VWF-GFP vector shown in 
A was retrovirally transduced in wild-type 
HUVEC. VWF-GFP was only observed 
in rod-shaped vesicles. The distribution 
of VWF-GFP-expressing vesicles in the 
cell was determined by three-dimensional 
analysis of the cells using depth-coding 
software (see Materials and Methods). 
This software enabled division of cells in 
three areas (the apical, the central and the 
basal area) by encoding each part with a 
color. Red-coded vesicles are located at 
the bottom of the cell (upper left panel), 
green in the middle region (upper right 
panel) and blue at the top of the cell (lower 
left panel). The merged image of all parts 
is shown in the lower right panel. Scale 
bars, 10 µm. 
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Figure 2. VWF-GFP is co-localized with endogenous VWF and P-selectin in WPbs. VWF-GFP-
infected HUVEC were fixed and examined by immunofluorescence microscopy. VWF-GFP-containing 
vesicles were directly visualized (a,d,g,j). Cells were stained either with a monoclonal antibody, CLB-
RAg 35, directed against the VWF-A1 domain (b,c) or an antibody, CLB-RAg 50, against the VWF-
A2 domain (e,f), followed by Texas-red-conjugated goat anti-mouse IgG. Monoclonal anti-P-selectin 
antibody RUU 1.18, and Texas Red-labeled goat-anti-mouse IgG were used for P-selectin detection 
(h,i). Co-localization of VWF-GFP containing vesicles with P-selectin (i) is shown in yellow. Localization 
of cathepsin D was determined with anti-human cathepsin D polyclonal antiserum, followed by Texas-
red-conjugated horse-anti-rabbit IgG (k,l). VWF-GFP was not co-localized with the lysosomal marker 
cathepsin D (l). Scale bars, 10 µm.
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VWF-GFP-transfected cells produced VWF multimers that were similar to wild-
type VWF multimers (Fig.3, lane 1 and 2). As expected, VWF multimers produced 
by wild-type HUVEC did not stain with an antibody against GFP (Fig. 3, lane 3). 
However, the distribution of multimers secreted by VWF-GFP HUVEC revealed by 
staining with anti-GFP was identical to the pattern observed after staining with poly-
clonal antibodies to VWF (Fig. 3, lane 4). Thus, the replacement of the A2 domain 
by GFP did not affect the ability of VWF to multimerize. Slight differences in mobility 
most likely reflect differences in size between the A2 domain (191 amino acids) 
present in wild-type VWF and the inserted GFP (239 amino acids).
We also quantified the secreted VWF-GFP. Stimulation with PMA for 60 min 
resulted in a 1.5 fold increase of VWF (p<0.05) and GFP antigen (p<0.01) secreted 
in the medium compared to the amounts secreted by unstimulated cells (Fig. 4).
Similarly, after incubation with thrombin, PMA or forskolin for 60 min, we observed 
a significant decrease of the number of WPbs compared with the number secreted 
by untreated cells (Table 1). Collectively, these data indicate that WPbs containing 
VWF-GFP retain their ability to secrete their cargo in a regulated manner. 
Dynamics of WPbs in resting VWF-GFP-transfected HUVEC
Having established that VWF-GFP properly accumulated in WPbs, was releasable 
and had retained its ability to multimerize, we first examined the dynamics of WPbs 
in living resting cells. To follow individual vesicles we selected cells with relatively 
few WPbs. These vesicles were monitored for 60 min at intervals of 2 min.
Figure 5 shows individual frames of the first 40 min (at intervals of 10 min) of 
a real time movie of resting VWF-GFP-transfected cells (Fig5video1.mov). We ob-
served vesicle traffic in an apparently random and uncoordinated fashion through-
Figure 3. Multimer analysis of VWF-
GFP. Wild-type HUVEC (lanes 1 and 3) 
as well as VWF-GFP-infected HUVEC 
(lanes 2 and 4) were stimulated for 60 
min with 1U/ml thrombin. Released VWF 
was concentrated by S-Sepharose, run 
on a 1.4% agarose gel, and blotted. 
Blots were incubated either with anti-
VWF (left panel) or with anti-GFP (right 
panel). VWF multimers produced by 
HUVEC-VWF-GFP (lane 2) are similar 
to wild-type multimer forms (lane 1). 
VWF-GFP multimers also react with the 
anti-GFP antibody (lane 5), in contrast 
to wild-type VWF (lane 3). 
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out the cell body. Some granules seemed motionless during the entire recording 
period as if they were tethered (Fig. 5, WPb 1,3), whereas others were continuously 
moving in a stochastic manner (Fig. 5, WPb 2,4-7). Some vesicles seemed to travel 
longer distances, notably toward the periphery (Fig. 5, WPb 4,7), whereas others 
returned to their starting point (Fig. 5, WPb 2,5). We also observed WPbs that ro-
tated along their longitudinal axis and sometimes appeared as round vesicles (Fig. 
5, WPb 6). Under these conditions WPbs moved with velocities of up to 10 nm/s. 
Compared to traffic of secretory granules in other cell types their movement is ex-
tremely slow (e.g.[30]).
Figure 4. Regulated secretion 
of VWF and GFP by VWF-GFP-
transfected cells. Confluent VWF-
GFP-infected HUVEC grown in 35 
mm-diameter wells were incubated 
for 60 min with medium containing 
50 ng/ml PMA or with medium alone. 
Released VWF-GFP was assessed by 
measuring VWF (nM) and GFP (A550) 
antigen. Results are expressed in 
relative values. VWF and GFP release 
from unstimulated cells was defined 
as 100%. Results are the mean ± 
SEM of 3 experiments.
Table 1. Decrease of WPb number from VWF-GFP-infected HUVEC induced by 
different secretagogues
Cells were incubated with 1 U/ml thrombin, 50 ng/ml PMA, 10 µM forskolin / 100 µM IBMX 
or medium alone (control), and monitored in real-time. The number of WPbs was counted 
in individual cells before and after 60 min of incubation. The relative decrease (in %) of 
vesicle number after 60 min is depicted in this table. a The number of WPbs was difficult to 
assess due to strong perinuclear clustering (cf. Fig. 9)
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Dynamics of WPbs in PMA-stimulated HUVEC-VWF-GFP
We next investigated WPb trafficking induced by different agonists such as throm-
bin, PMA, forskolin and epinephrine. Cells were monitored during 60 min of stimu-
lation at intervals of 1 min. Figure 6 shows a typical time-lapse sequence of VWF-
GFP-infected HUVEC stimulated with PMA (Fig6video2.mov). 
The apparent random movement of WPbs changed radically upon stimulation 
with PMA. In each real-time stimulation experiment performed (n=8) we observed 
the same succession of events. Cells contracted slightly which coincided with a 
slight movement of WPbs toward the center of the cell. Vesicles were not seen 
to clearly move to the periphery of the cell. However, approximately 15 min after 
stimulation of the cells, the rod-shaped WPbs transformed into very bright, station-
ary patches (Fig. 6A, WPb 1,2,3; Fig. 6B). Typically, individual patches remained 
Figure 5. Dynamics of WPbs in resting cells. Living VWF-GFP/hTERT-NGFR 
transduced HUVEC were monitored in real-time at intervals of 2 min during 54 min 
of incubation with medium. 5 individual frames (0, 10, 20, 30 and 40 min) of the real-
time movie (Fig5video1.mov) are shown. WPbs of interest are numbered on top or at 
the right side. WPbs showed a variety of motions. WPb 1 and 3 seemed motionless. 
Other WPbs seem to move in a random fashion. However, some covered long 
distances toward the periphery (WPb 4,7) whereas others returned to their original 




Figure 6. Dynamics of WPbs upon 
stimulation of HUVEC-VWF-GFP 
with PMA. Living VWF-GFP/hTERT-
NGFR transduced HUVEC were 
monitored in real-time at intervals of 1 
min during 54 min of incubation with 50 
ng/ml PMA (see also Fig6video2.mov). 
A. WPb trafficking of one single cell is 
shown at intervals of 10 min. During 
the first 10 min WPbs showed the 
same behavior as in resting cells 
(Fig. 4). However, after 10 min of 
incubation with PMA, WPbs started to 
transform into highly GFP-condensed 
patches. Patches were not formed 
simultaneously (WPb 1, 10 min; WPb 
2 and 3, 20 min). However, most of 
the patches were observed 20 min 
after stimulation with PMA. Patches 
lasted on average 20 min (WPb 1-3). 
Some patches formed a cloud before 
completely disappearing (WPb 1 and 
3, 40 min). 60 min after stimulation the 
cell was devoid of WPbs. Scale bar, 
5 µm. B. Total fluorescence intensity 
produced by WPb 2 during the whole 
recording period. The fluorescence was 
measured using the LSM510 function 
“Mean Region of Interest”. Note the 
sharp increase of the fluorescence 
signal that is produced upon formation 
of the patch. The gradual fading of the 
patch correlates with the long trailing 
edge of the fluorescence peak.
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visible for approximately 20 min. Finally, these patches completely disappeared and 
the cells became depleted of fluorescent material. Interestingly, disappearance of 
a patch often coincided with the appearance of a diffuse “cloud” (Fig. 6, WPb 2, 30 
min and WPb 3, 40 min) at the surface of the cell. This feature most likely reflects 
gradual dispersion of VWF-GFP into the extracellular environment. The formation of 
patches of a single cell was not synchronized. The first patches appeared on aver-
age 15 min after stimulation; others appeared only after 60 min. Similarly, patches 
disappeared at apparently different rates. Cells were totally depleted of WPbs be-
tween 60 and 120 min after stimulation. 
Figure 7 shows a three-dimensional analysis of the transformation of a single 
WPb into a patch (arrow). To facilitate this analysis, we selected a cell with few 
vesicles. The xy view of this cell (Fig. 7A) shows that during the first 20 min of 
stimulation with PMA, the WPb appeared as a thin, rod-shaped vesicle. Its depth-
coding staining signal suggested that the vesicle was located in the middle of the 
cell (green color). Indeed, a yz view of this WPb (Fig. 7B) confirmed its tubular 
morphology and central localization. About 20 min after stimulation, this vesicle 
transformed into a bright round patch located at the apical side (blue depth coding 
Fig. 7A, 20 min). Examination of the cell on the xy plane indicated that the patch 
indeed represented the same vesicle (Fig. 7B, arrow). However, it had rotated about 
45° and was positioned perpendicularly to the focal plane. The vesicle was apposed 
to the cell membrane at the apical part of the cell (Fig. 7B). The patch remained vis-
ible in the xy view for approximately 20 min (Fig. 7A, 50 min). YZ view of the vesicle 
showed that its size diminished in time (Fig. 7B, 22-40 min). Finally, 50 min after 
stimulation the vesicle had completely disappeared. It is worth noting that upon 
stimulation WPbs moved at a similar speed as in untreated cells (<10 nm/s). The 
entire process of patch formation, disappearance of vesicles and the appearance 
of VWF-GFP “clouds” (see Fig. 6) upon stimulation with PMA most likely reflects 
fusion of WPbs with the plasma membrane and secretion of VWF-GFP at the fu-
sion site into the extracellular milieu. These processes were observed at both sides 
of the cell. However, vesicles that were primarily located at the bottom of the cell 
tended to form patches at the basal side of the cell, whereas vesicles residing at 
the upper part of the cell tended to dock at the apical side. We also noted that WPbs 
localized around the nucleus were often positioned in the upper part of the cell (Fig. 
7B). We also observed that patches formed by the majority of WPbs located at the 
periphery of the cell became localized at the basal part of the cells. Furthermore, 
patches or “clouds” at the apical side of the cell tended to disappear faster than 
those at the basal side. 
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Figure 7. XY and YZ analysis of a GFP-
condensed patch formation. Time-lapsed 
images of a PMA-stimulated cell showing 
the transformation of a single WPb into a 
highly condensed patch. A. XY view of the 
cell. About 20 min after stimulation with PMA, 
the rod-shaped vesicle transformed into a 
round patch (arrow). The patch phase lasted 
for approximately 20 min before disappearing 
(arrow, 22-40 min). The depth of the WPb 
was coded using the color scale described in 
Fig.1. Scale bar, 5 µm. B. View of the GFP-
condensed patch on the yz plane. During the 
first 10 min of stimulation, the yz view of the 
WPb revealed a round conformation (arrow, 
0-10 min). After about 20 min, the vesicle was 
located perpendicularly and apposed to the 
luminal cell membrane. In time the size of the 
WPb diminished (arrow, 30-40 min), until it 
finally disappeared (50 min). Scale bar, 5 µm.
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Dynamics of WPbs in thrombin-stimulated HUVEC-VWF-GFP 
When VWF-GFP-infected HUVEC were stimulated with thrombin and examined in 
real time, we often observed an immediate contraction of the cells. This somewhat 
obscured the visualization of the dynamics of WPb secretion. This process started 
only a few min after the addition of the stimulus. Thrombin also induced more rapid 
formation of patches than PMA. Most patches were formed within the first 5 min of 
stimulation (Fig. 8, 4 min), and they disappeared faster (about 10 min) than PMA-
induced patches (Fig. 8, 16 min). In some cases, concomitant formation of clouds 
was observed (Fig. 8, WPb 2,3, 16 min). It is worth mentioning that fewer patches 
were formed with thrombin than with PMA. As during PMA- induced stimulation, 
patch formation and fading were observed at the apical as well as the basal part 
of the cells. Thus, tentative fusion of WPbs with the plasma membrane induced by 
thrombin was faster than upon stimulation with PMA. 
Figure 8. Rapid patch formation induced by thrombin. A VWF-GFP/
hTERT-NGFR-transduced cell was stimulated with 1 U/ml thrombin for 
60 min. Time-lapse images were taken at intervals of 2 min. The depicted 
time points (0, 4,16 and 46 min) show the appearance of patches very 
soon after stimulation (WPb 1-3, 4 min). After 10 min of stimulation, 
disappearance of the patches coincided with the appearance of clouds 
(WPb 2 and 3, 16 min). N, Nucleus. Scale bar, 10 µm.
62
Chapter 3
WPb dynamics induced by cAMP-agonists
Unlike PMA and thrombin, neither forskolin (not shown) nor epinephrine (Fig. 9) 
induced contraction of the cell. However, we observed that these secretagogues in-
duced a vectorial migration of WPbs toward the nucleus (Fig. 9). Perinuclear redis-
tribution was much more pronounced than that induced by either PMA or thrombin. 
After 30 min most of the vesicles clustered around the nucleus in a starlike structure 
(Figs. 9A, 30-60 min). YZ analysis of the cell demonstrated that the initial random 
distribution of WPbs changed completely upon stimulation with epinephrine. We 
clearly observed that upon stimulation, vesicles moved to the center of the cell, in 
particular to the luminal side (Fig. 9B). Furthermore, vesicles moved up to ten times 
faster (<100 nm/s) than in resting cells.
During migration, secretion was suggested to occur by means of the forma-
tion of patches that started to appear within approximately 20 min of stimulation. 
However, they disappeared faster than upon PMA stimulation. Indeed, patches 
lasted for about 5 min (Fig9video3.mov). Patches were seen both at the periphery 
of the cell and around the nucleus. Furthermore, patch formation was observed at 
the basal (Fig. 9, WPb 1) as well as the apical (WPb 2) part of the cell. Thus, cAMP 
agonists induced distinct migration of WPbs to a specific site directly above the 
nucleus and concomitant formation of a starlike clustering of vesicles. Tentative fu-
sion events started within the same time interval as observed upon stimulation with 
PMA, but the event itself was as fast as after stimulation with thrombin. 
DISCUSSION
Biogenesis and regulated exocytosis of WPbs have been extensively studied by 
biochemical and morphological analyses of endothelial cells. So far, the dynam-
ics of this unique endothelial-cell specific storage device could not be addressed. 
In this study the first evidence is presented for the complexity of the dynamics of 
WPbs. We constructed a VWF-GFP chimera that was properly targeted to WPbs 
and secreted upon stimulation. This allowed direct visualization of WPb trafficking 
in living endothelial cells. Our conclusion that VWF-GFP could serve as a genuine 
WPb marker was based on the following observations: (i) VWF-GFP and endoge-
nous VWF were packaged in the same WPbs (Fig. 2a-f), (ii) VWF-GFP co-localized 
with a typical WPb resident, P-selectin (Fig. 2g-i), (iii) VWF-GFP was able to mul-
timerize, a typical feature of WPb VWF. The extent of polymerization did not differ 
from that of wild-type VWF (Fig. 3), and (iv) the VWF-GFP containing WPbs were 
able to secrete VWF-GFP in a regulated manner (Fig.4, Table 1). Thus, this VWF-
GFP species expressed in primary HUVEC behaved, in terms of post-translational 
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modification and targeting into the regulated secretory pathway, as wild-type VWF 
and, as such, is a faithful tag of WPb traffic under various experimental conditions.
 By monitoring WPb dynamics in live cells we observed that in resting cells 
these vesicles are not static but consist of pools with different motilities (Fig. 5). 
Some vesicles barely move as if they were tethered, others seem to travel in a 
stochastic manner and frequently reverse their direction. Furthermore, all WPbs 
Figure 9. Perinuclear clustering of WPbs 
induced by epinephrine. A VWF-GFP/hTERT-
NGFR-transduced cell that was stimulated with 
10 µM epinephrine / 100 µM IBMX for 60 min 
(see also Fig9video3). Time-lapse images were 
taken at intervals of 5 min. (A) xy and (B) yz views 
of the cell during stimulation with epinephrine 
are depicted. Remarkable is the perinuclear 
recruitment of WPbs that is observed about 30 
min after stimulation (A and B, 30-60 min). They 
seem to be docked at a distinct site proximal to 
the nucleus, forming a starlike structure (A, 30-
60 min). The yz view revealed a clustering of the 
vesicles at the apical side of the cell. Formation of 
patches was also observed in the xy view of the 
cell after about 45 min of stimulation (A, arrows, 
45 min). Examination of the cell on the yz plane 
showed the perpendicular state of the WPbs (B, 
WPb 2, 45 min). Patches disappeared within 5 min 
of stimulation (A, WPb 2) or formed a cloud (A, 
WPb 1, 60 min). Scale bars, 10 µm.
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moved with remarkably low speed, not exceeding 10 nm/s. Previous studies on 
other cell types have shown that secretory vesicles may travel in different directions 
and move with different speed. Newly formed, microtubule-associated vesicles trav-
el at high speed (about 1 µm/s) from the Golgi to the plasma membrane [31-34]. 
Upon arrival at the plasma membrane, these vesicles are trapped and mature in 
the dense meshwork of the actin cortex which restricts their motility (about 50 nm/s) 
[34-36]. Based on these data and on the similar dynamics observed of WPbs, we 
speculate that tethered WPbs seen in our study (e.g. Fig. 5, WPb 1,3) are docked 
at the plasma membrane or trapped in the actin cortex of endothelial cells. On the 
other hand, WPbs that moved in all directions are reminiscent of microtubule-as-
sociated granules [31]. It is possible that the lower speed of WPbs is related to their 
relatively large size compared to that of other secretory granules [32,33]. Whether 
WPbs examined here are immature or mature granules cannot be concluded from 
this study. Future studies, using maturation markers and drugs that affect the orga-
nization of the cytoskeleton, should define their state of maturation and the role of 
specific cytoskeletal elements in mediating WPb traffic in more detail.
Stimulation with secretagogues dramatically changes the dynamics of WPbs. 
We observed two characteristic features of traffic: i) formation of patches observed 
upon stimulation with both Ca2+ and cAMP agonists ii) perinuclear clustering of 
WPbs only induced by cAMP secretagogues.
Formation of membrane-associated patches
Previously, in several studies with fixed endothelial cells, the formation of large 
extracellular patches of VWF was noticed upon stimulation of the cells [37-39]. In 
our study this typical feature is more clearly documented. This is most apparent in 
the real-time movie of PMA-stimulated cells (Fig6video2.mov). These observations 
suggest that patch formation reflects fusion of a single WPb with the plasma mem-
brane rather than the clustering of vesicles and subsequent bulk extrusion [38]. We 
were also able to monitor the gradual release and diffusion of VWF-GFP into the 
extracellular milieu (Fig. 6,7). This process is reminiscent of fusion events in other 
cell types monitored by real-time [33,35,40]. Striking was the rather long life span of 
WPb patches [33]. The rapid (sec) increase of the fluorescence signal due to fusion 
with the plasma membrane was followed by a slow (min) decay of the fluorescence 
(Fig. 6B) as VWF-GFP diffused into the extracellular space. The apparent slow re-
lease of VWF-GFP from the cell could be due to the compact, crystalloid structure 
of VWF, which may hamper its dissolution. The possible interaction of VWF with 
other WPb constituents or with proteins localized at the plasma membrane may 
also affect the rate of VWF dispersion. 
These long lasting patches could have a physiological significance. Patches 
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at the cell surface may not only reflect diffusion of VWF-GFP but may also provide 
focal sites with a high concentration of VWF. These sites could play a role in ad-
equately recruiting and binding plasma proteins, blood cells or matrix components 
to sites of vascular injury. Pertinent to this point is the observation of André and 
co-workers [41] who showed that platelets adhered rapidly, though transiently, to 
VWF secreted at the luminal face of endothelial cells upon triggering of the cell with 
Ca2+-agonists. The observation that adherence of platelets to the endothelium was 
transient (min) corresponds with the time course of the fading of patches. Although 
this has not been demonstrated, it is possible that VWF-containing patches also 
present IL-8, P-selectin or other WPb residents at high concentrations at the cell 
surface. Focal sites expressing these proteins at high levels could contribute to the 
rapid recruitment of leukocytes to endothelial cells after simulation. Indeed, the 
time frame of P-selectin-mediated rolling of leukocytes on the endothelium is in the 
same order of magnitude as patch fading [42]. It would be fascinating to determine 
in real-time studies whether indeed blood components interact with WPb constitu-
ents at these specific focal sites.
 The vectorial movement of WPbs induced by stimulation with either Ca2+- 
or cAMP raising agents was less prominent than expected on the basis of previ-
ous observations. Basolateral as well apical secretion of VWF after simulation of 
endothelial cells with different secretagogues has been observed [28,43,44]. In this 
study we observed that WPbs that are recruited toward the nucleus tended to se-
crete their content at the apical side of the cell whereas vesicles that reside at the 
periphery of the cell secreted at the basal side. The location of the microtubule-or-
ganizing center (MTOC, see below) at the apical side of the cell, might contribute to 
preferential luminal secretion associated with exocytosis of vesicles located in the 
vicinity of the nucleus. However, we did not observe any preferential accumulation 
of WPbs, or a distinct vectorial movement. Quantitative analysis of the dynamics of 
WPbs in real-time of multiple cells might provide more insight into a possible vecto-
rial behavior of vesicle trafficking.
Perinuclear clustering of WPbs
Another prominent feature of the dynamics of WPbs was the perinuclear clustering 
of WPbs. Only when cells were exposed to cAMP-raising agonists, such as for-
skolin or epinephrine, were WPbs docked at a distinct site proximal to the nucleus 
and spatially organized in a starlike structure (Fig. 9). WPbs migrated to that site 
at velocities approximately 10 times higher than in resting cells. Based on the ob-
served localization and the morphology of these clusters we assume that the site 
toward which WPbs migrate is associated with the MTOC, a cytoskeletal element 
typically located at one side of the nucleus. This observation suggests that micro-
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tubuli play a role in the cAMP-induced migration of WPbs. Although not studied 
here, the cAMP-dependent mechanism responsible for the perinuclear recruitment 
of WPbs is most likely caused by PKA-dependent modulation of the activity of mi-
crotubule-associated motor proteins [45-47]. Further studies should reveal whether 
MTOC and WPbs are indeed co-localized, and whether cytoskeletal motor proteins 
are involved in WPb dynamics under these conditions. In addition to perinuclear 
clustering, also patch formation was observed (Fig. 9, WPb 1,2). Notably, tethered 
WPbs escaped clustering and fused directly with the plasma membrane. Upon 
stimulation with thrombin or PMA, WPbs did not accumulate around the nucleus 
(Fig. 6,8). Apparently, WPbs are directly translocated to the plasma membrane un-
der these conditions. Both actin filaments and microtubules are most likely involved 
in the Ca2+-dependent trafficking of WPbs [19,48-51]. 
Taken together, though both cAMP- and Ca2+-raising agents induce patch 
formation, WPb dynamics triggered by these agonists are clearly different. cAMP-
dependent perinuclear recruitment of WPbs may provide a means to limit excessive 
release of pro-thrombotic and pro-inflammatory mediators stored in WPbs under 
physiological conditions that raise intracellular levels of cAMP, such as physical ex-
ercise or other stress situations [52]. On the other hand, Ca2+-mediated secretion, 
e.g. in response to vascular damage, most likely reflects mobilization of the entire 
WPb population to accomplish adequate release of bioactive molecules at sites of 
vascular injury.
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ABSTRACT
Weibel-Palade bodies are endothelial cell-specific organelles, which contain von 
Willebrand factor, P-selectin and several other proteins. Recently, we found that 
the small GTP-binding protein Ral is present in a subcellular fraction containing 
Weibel-Palade bodies. In the present study, we investigated whether Ral is involved 
in regulated exocytosis of Weibel-Palade bodies. Activation of endothelial cells by 
thrombin resulted in transient cycling of Ral from its inactive GDP- to its active GTP-
bound state which coincided with release of VWF. Ral activation and exocytosis of 
Weibel-Palade bodies were inhibited by incubation with trifluoperazine, an inhibitor 
of calmodulin, prior to thrombin stimulation. Functional involvement of Ral in exo-
cytosis was further investigated by expression of constitutively active and dominant 
negative Ral variants in primary endothelial cells. Introduction of active Ral G23V 
resulted in disappearance of Weibel-Palade bodies from endothelial cells. In con-
trast, expression of the dominant negative Ral S28N did not affect the amount of 
Weibel-Palade bodies in transfected cells. These results indicate that Ral is involved 
in regulated exocytosis of Weibel-Palade bodies by endothelial cells.
INTRODUCTION
Von Willebrand factor (VWF) is a multimeric glycoprotein involved in adhesion of 
platelets to a damaged vessel wall [1,2]. Synthesis of VWF is confined to endothe-
lial cells and megakaryocytes. During its biosynthesis in endothelial cells, part of 
VWF is segregated from the bulk flow of proteins and stored in rod-shaped organ-
elles, the Weibel-Palade bodies [3,4]. A number of other components have been 
identified in Weibel-Palade bodies which include P-selectin, CD63, endothelin and 
interleukin-8 [5-9]. Upon stimulation with agonists such as thrombin and histamine, 
Weibel-Palade bodies release their contents into the blood [10-12]. The mechanism 
of thrombin-induced exocytosis of Weibel-Palade bodies has only been partially 
elucidated [13-15]. Thrombin induces elevation of intracellular Ca2+-levels which 
appears crucial for release of VWF from Weibel-Palade bodies [15,16]. Inhibition 
studies have shown that intracellular Ca2+ exerts its effect on regulated secretion of 
VWF via calmodulin [13,15].
Little attention has been directed at involvement of small GTPases in regulated 
secretion in endothelial cells. Small GTPases cycle between an active GTP-bound 
and inactive GDP-bound form. Guanine nucleotide exchange factors (GEFs) en-
hance the conversion from the inactive GDP-bound to the active GTP-bound form 
whereas GTPase activating proteins (GAPs) promote GTP-hydrolysis of small GT-
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Pases. In many cells, small GTP-binding proteins have been implicated in regulated 
exocytosis as exemplified by the pivotal role of Rab3A in release of synaptic vesicles 
at the nerve terminal [17]. Therefore, it seems likely that small GTP-binding proteins 
are also involved in release of VWF through the regulated pathway in endothelial 
cells. Recently, we identified the small GTP-binding protein Ral in a subcellular 
fraction containing Weibel-Palade bodies suggesting a role for this GTPase in regu-
lated exocytosis of these organelles [18]. Ral is a geranylgeranylated GTPase that 
is ubiquitously expressed [19]. Activated GTP-bound Ral binds to RLIP76 (or Ral 
binding protein (RalBP)) an effector molecule that possesses GTPase activity for 
cdc42 and Rac suggesting a link between activation of Ral and rearrangement of 
the cytoskeleton [20]. Morphological studies have identified Ral on dense granules 
in platelets and on synaptic vesicles in nerve terminals suggesting a role for Ral in 
regulated exocytosis [21,22]. Interestingly, Ral has been proposed to interact with 
calmodulin in Ca2+-dependent manner [23]. Binding to calmodulin enhances GTP-
binding to Ral 2-3 fold [24]. These observations may suggest a regulatory role for 
Ral in calmodulin-mediated release of VWF from endothelial cells. 
In this study, we investigated the involvement of Ral in the secretion of Wei-
bel-Palade bodies by endothelial cells. We show that activation of Ral correlates 
with thrombin induced secretion of VWF from Weibel-Palade bodies. Expression of 
constitutively active Ral in endothelial cells results in exocytosis of Weibel-Palade 
bodies whereas expression of a dominant negative Ral variant did not show this 
effect. Together, these findings suggest that Ral is involved in regulated exocytosis 
of Weibel-Palade bodies from endothelial cells. 
METHODS
Materials
Culture media, trypsin, penicillin, streptomycin and fungizone were from Gibco BRL 
(Rockville, MD). Human serum was from healthy donors. Heparin (5000 IE/ml) was 
purchased from Leo Pharmaceutical Products (Weesp, The Netherlands). Bovine 
fibroblast growth factor and soybean trypsin inhibitor were from Sigma-Aldrich 
Chemie (Zwijndrecht, The Netherlands). Chemiluminescence blotting substrate 
was from Boehringer Mannheim (Mannheim, Germany). Monoclonal antibody 
CLB-RAg 35 directed against VWF has been described previously [25]. Monoclo-
nal antibody CLB-HEC 75 directed against CD31 has been characterized previ-
ously [26]. Peroxidase-conjugated polyclonal rabbit IgG against human VWF was 
obtained from Dakopatts a/s (Glostrup, Denmark). Monoclonal anti-Ral antibody 
was from Transduction Laboratories (Lexington, KY). Hybridoma cell line 9E10 was 
RalA modulates exocytosis of VWF by endothelial cells
75
from ATCC (USA). Protease inhibitors cocktail, CompleteTM mini, was from Boeh-
ringer Mannheim (Mannheim, Germany). Vectashield was from Vecta Laboratories 
(Burlington, CA, USA). All chemicals used were of analytical grade. 
Cell culture 
Endothelial cells were isolated from human umbilical veins and cultured as de-
scribed previously [18]. Stimulation of endothelial cells by thrombin, Ca2+-ionophore 
A23187 and phorbol myristic acetate (PMA) was performed as follows. Endothelial 
cells were washed three times with PBS and cultured for 2 h in M199 medium 
supplemented with 1% human serum albumin. At the onset of stimulation, the cul-
ture medium was replaced by medium containing thrombin, Ca2+-ionophore, PMA 
or no agonist. To study the effect of the calmodulin inhibitor trifluoperazine (TFP) on 
thrombin induced secretion, cells were precincubated for 30 min with 40 mM TFP 
prior to stimulation by thrombin. The amount of VWF secreted from both stimulated 
and non-stimulated cells was determined in triplicate for each individual time-point.
Ral activation assay
The GTP-bound form of Ral was isolated from total cell lysates by incubating the 
cell lysate with GST-RalBD coupled to glutathione Sepharose essentially as de-
scribed previously [27]. Vector pGEX4T3-GST-RalBD was kindly provided by dr. 
J.L. Bos (Utrecht University, The Netherlands). GST-RalBD was purified from IPTG-
induced bacteria as described previously [27]. HUVEC were cultured in 6 wells 
dishes and grown to confluency. Stimulation of endothelial cells was performed as 
described in the previous paragraph. At indicated time periods HUVEC were lysed 
in Ral buffer (15% (v/v) glycerol, 1% NP-40, 50 mM Tris (pH 7.4), 200 mM NaCl, 
2.5 mM MgCl2, 1 mM PMSF and 0.1 mM Trasylol). Cell lysates were incubated 
with 15 mg GST-RalBD precoupled to glutathione Sepharose for 60 min at 4 °C. 
Beads were washed and analyzed by 12.5 % SDS-PAGE and Western blotting with 
a monoclonal anti-Ral antibody. All Ral-BD experiments were performed at least 
three times and yielded similar findings. 
Transient expression of Ral and Rab3B variants in HUVEC
Total cDNA of HUVEC and plasmid pGEM-T-Myc-Rab30 were used to construct 
epitope tagged human Ral, Ral G23V, Ral S28N, Rab3B, Rab3B T36N and Rab3B 
Q81L [28]. 
HUVEC were transfected by electroporation using a Genepulser equiped with a RF 
module (Biorad, Veenendaal, The Netherlands). Confluent HUVEC were trypsin-
ized and 2 million cells were resuspended in 350 ml HEPES-buffered media. Five 
mg CsCl-purified plasmid was added to the cell suspension and incubated for 5 
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min at room temperature. Electroporation was performed in 2 mm cuvets at 240 V. 
Following transfection, cells were seeded on coverslips and cultured for 48 h. Cells 
were fixed with 3.7 % formaldehyde for 10 min and permeabilized with 0.02% sa-
ponin in PBS supplemented with 1% BSA. Cells were then stained with monoclonal 
anti-myc antibody 9E10 and polyclonal anti-VWF antibody in PBS/0.02% saponin/
1% BSA. Secondary antibodies used were FITC-labelled goat anti-mouse (CLB, 
Amsterdam, The Netherlands) and Texas Red-labelled horse anti-rabbit antibod-
ies (Vector Laboratories, Burlinghame, CA). FITC-conjugated CLB-HEC/75 (CLB, 
Amsterdam, The Netherlands) was used for staining of  CD31 in endothelial cells. 
Cells were embedded in Vectashield mounting medium and viewed by confocal 
microscopy using a Leica TCS NT (Leica Microsystems, Heidelberg, Germany). 
Results of two independent experiments are given. The number of Weibel-Palade 
bodies present in endothelial cells expressing Ral wild type, G23V or S28N was 
determined. For each construct 20-30 individual transfected cells were evaluated.
RESULTS
Thrombin-induced secretion of von Willebrand factor coincides with activa-
tion of Ral 
Stimulation of endothelial cells by agents such as thrombin results in exocytosis of 
Weibel-Palade bodies [10,11]. Recently, we have shown the presence of Ral in a 
subcellular fraction containing Weibel-Palade bodies [18]. To investigate whether 
secretion of Weibel-Palade bodies coincides with activation of Ral, HUVEC were 
stimulated with thrombin for various periods of time (Fig. 1). Exocytosis of Weibel-
Palade bodies was determined by measuring release of VWF in the medium. Se-
cretion of VWF initiated 30 sec after the addition of 1 U/ml of thrombin and gradually 
increased in time (Fig. 1A). The specificity of the Ral binding domain (Ral-BD) of the 
Ral effector molecule RLIP76 for GTP bound Ral has previously been used to mon-
itor activation of Ral in thrombin stimulated platelets [27]. Similarly, we used GST-
tagged Ral-BD to measure activation of Ral in thrombin stimulated endothelial cells 
(Fig. 1B). A transient activation of Ral was observed which reached a maximum 
after 2 min of stimulation with thrombin. After 10 min the amount of GTP-bound Ral 
had decreased significantly. No increase in activation of Ral could be detected in 
unstimulated cells and the total amount of Ral was similar in all samples analyzed 
(Fig. 1C). These results show that activation of Ral coincides with release of VWF 
in endothelial cells following stimulation by thrombin. Similar to thrombin, stimula-
tion of endothelial cells by Ca2+-ionophore A23187 and the phorbol ester PMA also 
resulted in activation of Ral (please see http://atvb.ahajournals.org).
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Role of calmodulin in activation of Ral and regulated secretion of VWF.
In endothelial cells, calmodulin has been implicated in thrombin-induced exocytosis 
of Weibel-Palade bodies [12,15]. Recently, a binding site for calmodulin on Ral has 
been detected and calmodulin has been shown to enhance the binding of GTP to 
Ral [23,24]. We investigated whether thrombin-induced activation of Ral is affected 
by antagonists of calmodulin. Endothelial cells were stimulated with thrombin in 
the presence and absence of calmodulin inhibitor TFP. Two min after the addition 
Figure 1. Thrombin-induced secretion of vWF coincides with Ral 
activation in endothelial cells. Endothelial cells were cultured in 6 
wells plates and grown till confluency. Two hours prior to stimulation, 
culture medium was replaced by M199/1 % (v/v) HSA. Subsequently, 
cells were stimulated with thrombin (1 U/ml) for the indicated periods 
of time. Medium was collected and cells were lysed in Ral binding 
buffer. The concentration of vWF in culture medium was determined 
by ELISA. Activation of Ral was measured as described in Materials 
and Methods. (A) Concentration of vWF in medium (white bar, control; 
black bar, stimulated with thrombin); (B) Activation of Ral in endothelial 




of thrombin, TFP inhibited secretion of VWF by 70%. A slightly lower inhibition was 
observed at 5 and 10 min following incubation with TFP (Fig. 2A). 
In the same series of experiments the effect of TFP on activation of Ral was de-
termined. In the absence of TFP, the amount of GTP-bound Ral increased 6-7 fold 
following incubation with thrombin for 2 minutes (Fig. 2B and 2C). Incubation with 
TFP resulted in a 3-fold increase in amount of intracellular GTP-bound Ral at the 
same time-point (Fig. 2C). At 5 and 10 min following stimulation with thrombin no 
significant effect of TFP on the activation of Ral was observed (Fig. 2C). Our find-
ings suggest that TFP partially inhibits activation of Ral and release of VWF in 
endothelial cells stimulated with thrombin.
Figure 2. Effect of the calmodulin 
inhibitor TFP on thrombin-induced 
secretion of Weibel-Palade bodies 
and activation of Ral. Endothelial 
cells were cultured in 6 wells plates 
and grown till confluency. Two hours 
prior to stimulation, culture medium 
was replaced by M199/1 % HSA. 
Then medium was replaced and TFP 
was added to a final concentration 
of 50 mM. In control cells no TFP 
was added. After 30 min, cells were 
stimulated with thrombin (IIa; 1 U/
ml) for indicated periods of time in 
the presence/absence of TFP and 
analysed as described in Materials 
and Methods. (A) Concentration 
of vWF in culture medium: non 
stimulated endothelial cells (white 
bar); cells stimulated with thrombin 
in absence (black bar) or presence 
(grey bar) of TFP. (B) Activation of Ral 
in non-stimulated endothelial cells 
(left panel) and cells stimulated with 
thrombin in absence (second panel) 
or presence (right panel) of TFP. (C) 
Densitometric analysis of activation of 
Ral in the presence (gray bars) and 
absence (black bars) of TFP. On the y-
axis fold stimulation of Ral activation 
compared to non-stimulated cells 
is given. On the x-axis time is 
depicted in minutes. Data from three 
independent experiments have been 
used to quantify activation of Ral in 
the presence and absence of TFP.  
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Overexpression of variant Ral and Rab3b in endothelial cells.
In the previous paragraphs we showed that Ral activation coincides with thrombin-
induced release of VWF. To study the functional role of Ral in exocytosis of Weibel-
Palade bodies, we expressed Ral wild type, constitutively active (GTP-bound) Ral 
G23V or dominant negative (GDP-bound) Ral S28N in primary human endothelial 
cells by electroporation. Expression of myc-tagged Ral G23V revealed that in the 
majority of transfected cells the number of Weibel-Palade bodies was greatly re-
duced (Fig. 3A-C). 
In some of the transfected cells, a residual number of Weibel-Palade bodies 
could be detected (Table 1). Quantification of a large number of transfected cells 
revealed that 48% of cells expressing Ral G23V contained a limited number (<5) 
Weibel-Palade bodies (Table 1). A similar phenotype was observed in cells express-
ing wild type Ral (Table 1). In 48% of cells expressing wild type Ral the number of 
Weibel-Palade bodies is strongly decreased compared to non-transfected cells. 
In cells transfected with dominant negative mutant Ral S28N normal amounts 
of Weibel-Palade bodies were observed. (Fig. 3D-F). Quantitative analysis revealed 
that in only 8% of cells transfected with Ral S28N reduced numbers of Weibel-Pal-
ade bodies were present. Similarly, 4% of non-transfected primary endothelial cells 
also contained reduced numbers of Weibel-Palade bodies. Overall, these results 
indicate that overexpression of Ral in the GTP-bound form reduces the number of 
Weibel-Palade bodies in endothelial cells. To provide evidence that cells express-
Figure 3. Wild type and constitutively 
active Ral induce exocytosis of Weibel-
Palade bodies in endothelial cells. Primary 
endothelial cells were transfected with 
Ral and Rab3B variants and cultured on 
coverslips for 48 hours. Cells were fixed with 
3.7% formaldehyde and immunofluorescence 
was performed as described in Materials and 
Methods. Exogenous Ral and Rab3B was 
visualized using monoclonal antibody 9E10 
directed to Myc-tag and a FITC-labelled 
secondary goat anti-mouse antibody (A, D, 
G, J). VWF was visualized using polyclonal 
antibody directed to vWF and a Texas Red-
labelled secondary horse anti-rabbit antibody 
(B, E, H, K). (A, B, C) Cells transfected with 
pCDNA3.1-Myc-Ral G23V; (D,E,F) Cells 
transfected with pCDNA3.1-Myc-Ral S28N; 
(G,H,I) Cells transfected with pCDNA3.1-




ing variant Ral are indeed endothelial cells, we performed co-localization studies 
with a monoclonal antibody directed against CD31, a transmembrane adhesion 
molecule which is abundantly expressed at intracellular junctions of endothelial 
cells [29]. CD31 was observed at the junctions of both non-transfected cells and 
cells expressing Ral G23V (data not shown). To further establish the specificity of 
the Ral G23V-mediated release of VWF from Weibel-Palade bodies, we expressed 
dominant negative (Rab3B T36N) and constitutively active Rab3B (Rab3B Q81L) 
in endothelial cells. Previously,  Rab3B has been implicated in regulated exocytosis 
in neuroendocrine cells [30]. However, introduction of Rab3B T36N or Rab3B Q81L 
in human endothelial cells did not result in a decrease in the number of Weibel-Pal-
ade bodies (Fig. 3G-L). These findings indicate that expression of Rab3B does not 
induce exocytosis of Weibel-Palade bodies. 
DISCUSSION
Stimulation of endothelial cells with agents such as thrombin results in release 
of high molecular weight multimers of VWF and translocation of P-selectin to the 
plasma membrane. Both these events are an immediate consequence of the 
thrombin-induced exocytosis of endothelial cell-specific storage organelles, the 
Weibel-Palade bodies. In this report, we provide evidence that the small GTP-
binding protein Ral is transiently activated following stimulation of endothelial cells 
by thrombin. A previous study has shown that activation of Ral occurs also upon 
stimulation of human platelets with thrombin [27]. In platelets, activation of Ral 
reached a maximum 1 minute following stimulation with thrombin whereas in endo-
thelial cells maximal levels were reached after 2 min (Fig. 1) [27]. Furthermore, the 
amount of activated Ral decreased rapidly (between 5 and 10 min) in endothelial 
cells whereas in platelets significant levels of activated Ral were still present at 10 
TABLE 1. Quantitative analysis of the number of Weibel-Palade bodies in 
transfected and non-transfected human endothelial cells. 
Primary endothelial cells were transfected with Ral wild type, Ral G23V, and Ral 
S28N as described in Materials and Methods. For each construct the number 
of Weibel-Palade bodies was determined in 20-30 transfected cells. Results are 
expressed in percentages and are compared to the number of Weibel-Palade 
bodies present in non-transfected cells.
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min following stimulation. Similar to what has been observed for platelets, elevation 
of intracellular calcium levels resulted in a rapid activation of Ral. In this study, we 
show that thrombin-induced activation of Ral is inhibited by the calmodulin antago-
nist TFP. This observation indicates that Ral functions downstream of calmodulin in 
endothelial cells. Also the release of VWF is decreased in the presence of TFP (Fig. 
2). These findings lend additional support to a close correlation between activation 
of Ral and regulated secretion of VWF.  
Functional involvement of Ral in regulated exocytosis of Weibel-Palade bodies 
by endothelial cells is suggested by the substantial decrease in number of Wei-
bel-Palade bodies in endothelial cells overexpressing wild type and ‘constitutively 
active’ Ral. In some transfected cells, a residual number of Weibel-Palade bodies 
can still be detected (Table 1). This may relate to variability in expression levels of 
Ral variants among individual primary endothelial cells. A large variability in the 
number of Weibel-Palade bodies is also observed in non-transfected primary hu-
man endothelial cells (Table 1). A reduced number of Weibel-Palade bodies in a 
particular cell does not always result from exocytosis but may also be caused by 
cell-to-cell variability within primary cultures. Therefore, we determined the num-
ber of Weibel-Palade bodies in a large number of transfected primary endothelial 
cells. Our results suggest that both constitutively active Ral (G23V) and wild type 
Ral can induce exocytosis of Weibel-Palade bodies. The number of Weibel-Palade 
bodies in endothelial cells transfected with dominant negative Ral (S28N) is similar 
to control, non-transfected cells. We also studied whether dominant negative Ral 
interfered with stimulus induced exocytosis of Weibel-Palade bodies. Stimulation by 
thrombin, Ca2+-ionophore A23187 and PMA did result in a decrease in the number 
of Weibel-Palade bodies in cells expressing Ral S28N similar to that observed in 
non-transfected cells (data not shown). These findings indicate that under our ex-
perimental conditions dominant negative Ral is unable to block stimulus-induced 
release of VWF from the Weibel-Palade bodies. Most likely the concentration of Ral 
S28N in transfected cells is too low to completely block cycling of endogenous Ral. 
Alternatively, Ral-independent signalling pathways may exist that are capable of 
inducing regulated exocytosis of Weibel-Palade bodies. 
It should be noted that our analysis does not allow for direct monitoring of 
exocytosis of Weibel-Palade bodies. The amount of Weibel-Palade bodies in trans-
fected cells is evaluated 48 hours following transfection. We cannot exclude that 
the observed effects of Ral on Weibel-Palade body content are not directly related 
to exocytosis. For instance, Ral may be involved in the formation of Weibel-Palade 
bodies from the trans Golgi network thereby reducing the number of these granules 
in cells transfected with active Ral-G23V. A possible role for Ral in granule biogen-
esis has recently been proposed. Several studies have suggested that a complex 
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of Ral with phospholipase D and Arf mediates vesicle budding from the Golgi ap-
paratus [31,32]. 
In a previous study, we have reported that Ral associates with Weibel-Palade 
bodies in endothelial cells [18]. In the present study, expression of Ral variants did 
not reveal colocalization of Ral with VWF in Weibel-Palade bodies. Several reasons 
may be forwarded for this apparent discrepancy. First, Ral may only transiently 
associate with Weibel-Palade bodies. Finally, only a limited part of the intracellu-
lar amount of Ral may participate in the exocytosis of Weibel-Palade bodies. The 
intense membrane stain observed for Ral may interfere with the detection of small 
amounts of exogenous Ral that associate with Weibel-Palade bodies. Cell fraction-
ation studies revealed that Ral is not exclusively present in subcellular fractions that 
contain Weibel-Palade bodies. A significant amount of Ral was detected in other 
subcellular fractions derived from endothelial cells (data not shown). 
Several studies have suggested a role for Ral in cytoskeleton dynamics [19]. 
Ral interacts in a GTP-dependent manner with filamin inducing filopodia [33]. Fur-
thermore, Ral interacts with RLIP76, a Ral effector protein with GTPase protein 
activity for cdc42 [20]. Inspection of Figure 5A-C reveals that cells expressing Ral 
G23V appear larger then surrounding endothelial cells. The observed morphologi-
cal changes may result from an altered organization of the cytoskeleton in endothe-
lial cells harbouring constitutively active Ral G23V. At present it is unclear whether 
the observed changes in organization of the cytoskeleton are related to the ab-
sence of Weibel-Palade bodies in cells expressing Ral G23V. Recently, it has been 
shown that thrombin induced release of VWF can be potentiated by specific inhibi-
tion of Rho, a small GTPase involved in cytoskeletal rearrangements like stress 
fiber formation [34]. This interesting observation suggests that the cytoskeleton 
may modulate agonist-induced release of Weibel-Palade bodies. It is possible that 
Ral-induced changes in the organization of the cytoskeleton may promote fusion of 
Weibel-Palade bodies with the plasma membrane.
Recently, Ral has also been implicated in endocytosis [35]. Interestingly, 
both constitutively active and dominant negative forms of Ral inhibited endocyto-
sis. These observations suggest that GTP hydrolysis of active Ral is required for 
endocytosis. Potentially, Ral may be involved in the rapid endocytosis of integral 
membrane proteins like P-selectin and CD63, that are also contained within the 
Weibel-Palade bodies, following fusion of these organelles with the plasma mem-
brane. Taken together, it appears that Ral may have multiple functional roles within 
endothelial cells. Future studies aim at defining individual steps in the biogenesis 
and release of Weibel-Palade bodies that are controlled by this small GTP binding 
protein.
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ABSTRACT
Von Willebrand factor (VWF) is a multifunctional plasma protein that plays a promi-
nent role in haemostasis. In endothelial cells processing of its precursor pro-VWF 
results in the formation of two large polypeptides, mature VWF and a propeptide. 
These proteins are co-secreted on an equimolar basis but are cleared from the 
circulation at different rates. VWF levels are frequently elevated in response to vas-
cular disorders. Similarly, propeptide levels are increased under these conditions, 
although primarily in fulminant vascular disease, such as thrombotic thrombocy-
topenic purpura and septicemia. In chronic vascular disease, e.g. diabetes or pe-
ripheral vascular disease, propeptide levels are much less elevated. The differential 
response of VWF and propeptide levels to vascular disease could provide a means 
to assess the extent and time course of endothelial cell activation. After secretion, 
the propeptide may play a role in modulating cellular adhesion processes. Thus, 
enhanced propeptide secretion seems not of merely diagnostic significance.
INTRODUCTION
Von Willebrand factor (VWF) is a multifunctional, polyvalent plasma protein that 
plays a prominent role in events that lead to normal arrest of bleeding. VWF is 
synthesised by endothelial cells and megakaryocytes and originates from the VWF 
precursor pro-VWF, processing of which results in the formation of two large poly-
peptides, i.e. mature VWF (hereafter named VWF) and the VWF propeptide (also 
named von Willebrand antigen II, see below). Both polypeptides have distinct bio-
logical functions. VWF mediates the adhesion and aggregation of platelets at sites 
of vascular injury and also functions as a stabilising chaperone protein of factor VIII, 
an essential cofactor of the coagulation system. The VWF propeptide is required 
for proper intra-cellular, post-translational multimerisation and targeting of VWF to 
storage vesicles. Montgomery and Zimmerman were the first to identify VWF pro-
peptide, called von Willebrand antigen II (VW AgII), a unique protein that, together 
with VWF, is deficient in plasma of patients with von Willebrand’s disease [1,2]. After 
the full-length VWF cDNA was cloned, it became clear that VW AgII was identical to 
the propeptide moiety of the VWF precursor and, consequently, deficient in severe 
von Willebrand’s disease [3-5].
To date most evidence supports that plasma VWF is predominantly derived 
from endothelial cells rather than from platelet storage pools [6]. Similarly, steady 
state plasma propeptide levels most likely stem from endothelial cells rather than 
from platelet stores [7]. As plasma VWF levels are increased in clinical conditions 
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associated with vascular abnormalities, such as coronary artery disease or periph-
eral vascular disease, it has been postulated that VWF could serve as a marker 
of endothelial cell perturbation or damage. Indeed, many studies have shown that 
plasma VWF levels are frequently elevated in disorders associated with endothelial 
cell dysfunction, including ischaemic heart disease, diabetes and inflammatory dis-
orders. Raised plasma VWF concentrations may also have prognostic implications 
in vascular disease [8-13]. 
The significance of VWF as a specific marker of endothelial cell perturbation 
has also been challenged, however [6,13,14]. A major point of concern is the knowl-
edge that the systemic VWF concentration does not necessarily reflect the VWF 
secretory capacity of endothelial cells due to extraction of VWF by subendothelial 
connective tissue. Secretion of VWF by endothelial cells occurs in a bi-directional 
fashion [15,16] and substantial amounts of released VWF may be trapped by the 
extra-cellular matrix [17,18]. In addition, secreted VWF may also bind to the endo-
thelium itself [19,20], a process that may also mask VWF secretion. Furthermore, 
because of the relative long half-life of VWF in the circulation (about 12h), fluctua-
tions in VWF levels will, in general, be less apparent. Also the latter might limit the 
use of VWF as an index of endothelial cell function.
Recently, it was shown that measurement of VWF propeptide levels could 
provide a means to assess endothelial cell activation in vivo in a more specific and 
quantitative manner [5,14,21-23]. VWF propeptide is co- secreted from endothelial 
cells on an equimolar basis with VWF. However, unlike VWF, the propeptide is not 
trapped by subendothelial connective tissue after it is secreted [17]. Therefore, sys-
temic propeptide levels probably more accurately reflect endothelial secretion pro-
cesses than do VWF levels. Also from an analytical point of view measurement of 
propeptide levels for monitoring endothelial cell perturbation could be an attractive 
alternative. The three dimensional structure of the propeptide is by far less complex 
than the delicate quaternary structure of mature VWF. Consequently, in terms of 
accuracy and precision, propeptide analysis is probably less prone to analytical 
variations than VWF measurements. 
Although the VWF propeptide could be an attractive candidate marker for en-
dothelial cell perturbation in vivo, measurement of propeptide levels in combination 
with VWF levels could be of additional diagnostic value. This view stems from the 
observation that VWF and propeptide are cleared from the circulation at different 
rates [21]. It has been postulated that this feature could provide a means to assess 
the extent and time course of endothelial cell secretion rates and could allow for a 
more subtle and differentiated analysis of endothelial cell activation than reported 
before [14,21]. This review is intended to discuss the potential use of propeptide 
measurements as an index of endothelial cell function and to offer a perspective 
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on the significance of the VWF propeptide as a marker of endothelial cell perturba-
tion. 
CELLULAR BASIS OF VWF AND VWF-PROPEPTIDE RELEASE
Mature VWF and its propeptide are the end products of a complex biosynthetic 
pathway. (For comprehensive reviews on the cell biology and biochemical proper-
ties of VWF, see refs. [24,25]. Polymerisation of VWF is one of the most character-
istic post-translational events that occurs during its travel to the outside of the cell 
(Fig. 1). This phenomenon is responsible for the typical polyvalent, multi-interac-
Figure 1. Assembly, processing and storage of VWF. The top panel shows an electron micrograph 
image of endothelial cells stained with a polyclonal antibody directed against VWF. Labeling of a rod-
shaped vesicle (Weibel-Palade body) is observed (bar, 0.1 µm). The middle panel depicts a schematic 
representation of the primary structure of pro-VWF. The location of conserved structural domains and 
of the propetide and mature VWF moiety are indicated. The lower panel schematically depicts the 
multimeric structure of VWF. Pro-VWF monomers dimerise through cysteine residues located at the 
carboxy-terminus. Multimers are formed via cysteines in the D’ and D3 domain. The propeptide plays 
an essential role in the assembly of multimers in that it promotes inter-chain disulphide formation and 
subsequent polymerisation [24,25]. The subtilisin-like endoprotease furin most likely catalyses the 
cleavage (arrows) of the propeptide portion of the molecule [73-75]. The propeptide is probably secreted 
as a dimer [19]. (Courtesy of dr. Hubert de Leeuw, ref.76).
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tive nature of VWF. The propeptide moiety of pro-VWF serves a major role in this 
process. It both controls inter-subunit interaction through homo-dimerisation of the 
amino-terminal regions of two pro-VWF molecules and catalyses the formation of 
disulphide bonds between them [26,27]. After endoproteolytic cleavage of pro-VWF 
in the trans-Golgi network [28], mature VWF and its propeptide partition between 
two different secretion pathways. The majority of VWF and propeptide molecules 
that are generated upon proteolytic maturation is directly secreted by endothelial 
cells, together with some unprocessed pro-VWF (Fig. 2, [29]). A relatively small 
portion is co-stored in unique cytoplasmic vesicles, the Weibel-Palade bodies. The 
latter pool, representing mature and functionally the most potent VWF multimers, 
is only secreted upon proper stimulation of the cell. For instance, when cultured 
endothelial cells are treated with phorbol myristate acetate (PMA), a phorbol ester 
known for its ability to stimulate the protein kinase C-dependent signal transduction 
pathways, VWF and propeptide are released rapidly and in essentially equimolar 
amounts (Refs.14,21; Fig. 3). Similarly, more physiological secretagogues that give 
rise to an increase of cytosolic free Ca2+, such as thrombin or histamine, or expo-
sure of endothelial cells to cAMP-raising agents, such as epinephrine, adenosine or 
prostacyclin, rapidly induce exocytosis of VWF from Weibel-Palade bodies [30-35]. 
Although this has not been studied in detail, it is to be expected that also the VWF 
propeptide is released under these conditions through the regulated pathway. 
Figure 2. Partitioning of VWF, propeptide 
and pro-VWF between the constitutive and 
regulated secretory pathway by vascular 
endothelial cells. Pro-VWF is processed in the 
trans-Golgi network and results in heterogeneous 
forms of VWF, ranging from dimers to large 
polymers (see also Fig. 1). The majority of the 
VWF species, consisting of partially processed, 
immature VWF is secreted through the constitutive 
pathway. The remainder, the largest, fully 
processed and functionally mature VWF, is sorted 
into Weibel-Palade bodies and secreted upon 
demand. This model proposes that the majority of 
VWF and its propeptide are secreted through the 
constitutive pathway [29].
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Besides VWF and its propeptide, Weibel-Palade bodies have been shown 
to contain a subset of other proteins, including P-selectin, interleukin-8 (IL-8) and 
endothelin (Table 1). Similar to VWF and the propeptide, these proteins are trans-
ported to the outside of the cell upon stimulation and may control local or systemic 
biological effects, including inflammatory and vaso-active responses. If one consid-
ers endothelial cell perturbation and subsequent exocytosis of Weibel-Palade bod-
ies as an etiological component of vascular disease, this feature should be taken 
into account as well.
Figure 3. Regulated secretion of VWF 
and its propeptide by endothelial cells. 
Human umbilical vein endothelial cells 
were stimulated with the phorbol ester 
PMA (50 ng/ml) and at indicated time 
points VWF and propeptide levels were 
measured. Open symbols, release of VWF 
and propeptide by quiescent endothelial 
cells; closed symbols, secretion of VWF 
and propeptide induced by PMA. Note 




VWF PROPEPTIDE SECRETION IN VIVO 
As a plasma constituent, the VWF propeptide is a rather abundant protein 
[7,14,21,22,36-38]. In healthy individuals the propeptide concentration ranges from 
about 2 to 10 nM (Fig. 4). Assuming a molecular mass of 100 kDa, this corresponds 
to an average concentration of about 0.6 µg per ml. As expected, in subtypes of von 
Willebrand’s disease characterised by a major gene defect (e.g. von Willebrand’s 
disease type 3) no propeptide is detectable whereas in milder cases of this disor-
der, such as von Willebrand’s disease type 1, propeptide levels are reduced, though 
to an unpredictable extent [2,37]. Of interest is the observation that, unlike VWF, 
propeptide concentrations are not, or to a much lesser extent, dependent on ABO 
blood type [21,37,39]. Most likely, the propeptide does not carry the ABO blood 
group antigens that have been described for VWF [40-42]. Consequently, differenc-
es in blood group specificity will not complicate the evaluation of propeptide levels 
and may also explain why the correlation between peripheral VWF and propeptide 
levels is rather poor, at least in healthy individuals (Fig. 4, [2,14,37]). 
Another point of interest is that the molar ratio of the propeptide and mature 
VWF is about 0.1 under resting conditions. This value is clearly lower than the 
equimolar ratio observed in cultured endothelial cells ([22], Fig. 3). Because the 
Figure 4. Concentration of propeptide and mature VWF in 
normal plasma. The concentration of VWF (mean concentration ± 
2SD of 47 healthy individuals) is expressed as the half-homodimer 
concentration, assuming that normal pooled plasma contains 10 µg 
VWF/ml (50 nM). The insert shows the concentration of VWF and 
propeptide in the individual plasma samples. (From Borchiellini et al. 
[21], with permission).
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propeptide disappears four to five times faster from the circulation than mature 
VWF, it seems reasonable to assume that the observed differences in steady 
state concentration are due to differences in half-life. Pertinent to this point is the 
observation that upon perturbation of the endothelium, for instance elicited by 
experimental disseminated intravascular coagulation (DIC), or administration of 
1-deamino-8-D-arginine (desmopressin, DDAVP), propeptide levels return much 
faster to their baseline values after termination of the vascular challenge than VWF 
levels ([7,14]; Fig. 5). 
VWF PROPEPTIDE SECRETION IN VASCULAR DISEASE
A number of studies have shown that propeptide levels are not, or only slightly 
elevated in patients with a long history of vascular disease, such as peripheral oc-
clusive vascular disease or chronic diabetes mellitus (Table 2, Fig. 6). Propeptide 
levels do, however, correlate with those of VWF. These studies show that in chronic 
vascular disease the propeptide is not a more sensitive marker of endothelial cell 
dysfunction than VWF levels. On the other hand, in cases of frank, acute vascular 
disease as may occur in thrombotic thrombocytopenic purpura (TTP) or septice-
mia, both propeptide and VWF levels are clearly elevated. This pattern can readily 
be explained in terms of acute perturbation of the endothelium. These data sug-
gests that propeptide analysis adds an extra dimension to the diagnostic evaluation 
of vascular diseases. Measurement of both propeptide and VWF levels allows to 
discriminate between chronic and acute phases of endothelial cell activation and 
Figure 5. Effect of experimental endotoxemia and administration of DDAVP on VWF 
and propeptide levels in healthy individuals. Endotoxin or DDAVP were administered at 
time 0 and at the time points indicated propeptide and VWF levels were measured. [From 
van Mourik et al. [7], with permission].
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provides a basis for a more differentiated analysis of endothelial cell activation that 
may occur in response to vascular pathology. 
The interpretation of propeptide data might be complicated by the contribution 
of platelet propeptide to elevated propeptide levels, particularly in clinical situa-
tions associated with massive platelet activation such as TTP and overt septicemia. 
Probably this is not, or only to a limited extent, the case. First, there is no clear 
relationship between platelet number and propeptide level, neither in healthy indi-
viduals, nor in patients with thrombocytemia or thrombocytopenia [7]. Finally, there 
is no clear correlation (J.A. van Mourik, R. Fijnheer, unpublished observations) be-
tween propeptide concentrations and plasma levels of soluble P-selectin, a specific 
marker of platelet activation [44,45]. Second, the amount of propeptide stored in 
the α-granules of platelets is probably not sufficient to account for the increased 
propeptide concentrations [14,21,37]. 
ORIGIN OF VWF PROPEPTIDE AND VWF IN VASCULAR 
DISEASE
As noted above, cultured endothelial cells release the majority of de novo synthe-
sised VWF, either partly or completely processed, through the constitutive pathway 
Figure 6. Relation between 
plasma pro-peptide and 
VWF levels in patients with 
acute (TTP, septicemia) 
and documented chro-
nic vascular disease 
(diabetes). Dotted lines 
represent the upper limit of 
the 95% confidence interval 
of respectively VWF and 
propeptide levels of the 
control group. The latter 
group consisted of patients 
without vascular disease 
admitted to the hospital. 
(From van Mourik et al. [7], 
with permission).
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[29]. Under these conditions, only part of the stored propeptide and functionally 
mature VWF is secreted through the regulated pathway. Whether secretion of VWF 
and propeptide occurs in a similar way in vivo, remains to be established. To what 
extent the plasma VWF and propeptide pool stems from either the constitutive or 
the regulated pathway is unknown. Only trace amounts of pro-VWF, a candidate 
marker of the constitutive secretion pathway, are detectable in plasma [21]. This 
suggests that under normal physiological conditions the constitutive pathway does 
not substantially contribute to the release of VWF. On the other hand, it is possible 
that upon release, pro-VWF is rapidly cleared from the circulation, or, alternatively 
converted into mature VWF and propeptide outside the cell. Indeed, experimental 
studies in animals have shown that upon infusion of (unprocessed) pro-VWF, its 
propeptide is rapidly cleaved from the precursor protein [46]. 
It should be noted that the storage capacity of endothelial cells is limited. Par-
ticularly in cases where the endothelium is exposed to repeated challenges, such 
as in chronic vascular disease, the propeptide and VWF pool might be exhausted. 
In cultured endothelial cells it takes about one to two days after a single exposure 
to endothelial cell agonists to restore this pool [47]. Taking into account that only a 
fraction of newly synthesised pro-VWF is directed to Weibel-Palade bodies [29], it 
is to be expected that in situations of severe and widespread endothelial cell per-
φ) Data are collected from 5 different studies. Mean values are listed as % 
of normalised control values (100%), unless otherwise indicated.
*) p < 0.05, **) p < 0.001; n, number of patients studied.
ND, not reported; NS, not significant; §) median value; #) significance not 
reported.
Table 2. Propeptide and VWF levels in vascular diseaseφ)
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turbation, such as may occur in TTP or septicemia, released propeptide and VWF 
primarily originate from the Weibel-Palade bodies. Pertinent to this point is also the 
observation that in the acute phase of myocardial infarction the plasma concentra-
tion of high molecular weight VWF multimers increased [48]. As these large VWF 
polymers primarily stem from endothelial cell Weibel-Palade bodies [29], the raised 
VWF levels observed in these clinical situations most likely originate from the regu-
lated pathway, at least in part. 
Persistent rises of plasma VWF and propeptide most likely reflect enhanced 
constitutive release. The latter condition would require upregulation of de novo 
pro-VWF synthesis. Indeed, under various conditions endothelial cell-specific VWF 
synthesis can be subject to enhanced transcriptional activity [49,50]. It seems rea-
sonable to assume, therefore, that elevated propeptide and VWF levels in patients 
with sustained endothelial cell injury not only reflect regulated secretion but also 
increased transcriptional activity and subsequent enhanced constitutive release. 
In any case, only mature VWF and its propeptide are detectable in plasma in sig-
nificant amounts but not their precursor pro-VWF. Knowledge of the contribution of 
either pathway in supplying functionally mature VWF multimers, its precursor pro-
VWF and its propeptide to the blood stream, could be of help to get insight into the 
complex functional alterations of the endothelium either as a cause or a result of 
vascular disease.
BIOLOGICAL SIGNIFICANCE OF PROPEPTIDE RELEASE
Evidence is accumulating that the VWF propeptide not only plays an important 
role in controlling intra-cellular targeting and polymerisation of VWF, but may also 
serve a variety of biological functions after its release from the cell, notably in in-
flammatory and cell adhesion processes. In this respect, enhanced secretion of 
the propeptide in various clinical situations is not merely of diagnostic significance. 
Recent studies indicate that the propeptide, apart from its putative inherent protein 
disulphide isomerase (PDI) activity [51], could serve a role in controlling cell adhe-
sion processes by various mechanisms. For instance, it has been shown that the 
VWF propeptide is a substrate for coagulation factor XIIIa. This transglutaminase is 
able to catalyse the cross-linking of the propeptide to laminin, a constituent of the 
extra-cellular matrix [52,53]. As laminin has a variety of cellular functions, including 
its role as cell attachment or cell migration mediator, it is tempting to speculate that 
the propeptide could play a role in modulating these processes. 
Of particular interest is also the observation that the propeptide harbours a 
recognition site for α4β1 (VLA4) and α9β1 (VLA9) and is able to promote specific 
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adhesion and spreading of certain leukemia and melanoma cell lines mediated 
by these cell surface receptors [54-56]. Interestingly, these integrins also bind 
factor XIIIa. Both integrins are highly expressed on leukocytes; VLA-4 is primarily 
expressed by lymphocytes, monocytes and eosinophils, whereas VLA-9 is mostly 
found on neutrophils [57]. As these integrins play a prominent role in transendo-
thelial migration of these cells, the propeptide could modulate these processes. It 
has also been shown that the propeptide may bind to collagen (type I) and inhibits 
collagen-induced platelet aggregation [58,59]. 
Taken together, it seems clear that the propeptide may serve a number of 
extra-cellular functions and is not just a waste product after it is secreted. This is 
reminiscent of proinsulin C-peptide, the propeptide of insulin which, like the VWF 
propeptide, participates in inter-chain disulphide bond formation necessary for gen-
erating mature insulin. After its secretion, along with insulin, C-peptide appears to 
produce significant biological effects, including restoration of diabetes- and hyper-
glycemia-induced vascular and neural dysfunction [60]. 
CONCLUSION AND FUTURE PERSPECTIVES
This review has served to illustrate the potential role and significance of the VWF 
propeptide as a novel marker of endothelial cell perturbation. This is a rather young 
field of investigation and clearly more studies are required to reveal the significance 
of the propeptide in vascular biology. From a clinical perspective, prospective, serial 
studies should reveal whether indeed measurements of both propeptide and VWF 
levels have a predictive value in terms of disease activity and are useful in monitor-
ing the degree of vascular involvement as well as the response to therapy. It would 
also be of great interest to get insight into the biological and pathophysiological sig-
nificance of the regulated and constitutive VWF secretion pathway. Through each 
pathway different VWF species are secreted. These VWF molecules differ in degree 
of polymerisation and adhesive properties and knowledge of the contribution of 
each pathway in providing VWF (and its propeptide) to the extra-cellular milieu, 
could lead to a better understanding of the role of the endothelium in controlling 
VWF-mediated processes in vascular pathology. This is still a rather poorly under-
stood phenomenon. Finally, it also seems clear that the biological function of the 
propeptide is more diverse than previously anticipated. It will be a challenge to de-
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ABSTRACT
It is generally assumed that endothelial cell injury is the primary event in the patho-
genesis of TTP. In this study we have determined the extent of vascular perturbation 
during acute episodes of the disease. We performed a prospective, serial study of 9 
patients with relapsing TTP during hospitalization and treatment and assessed the 
degree of endothelial cell involvement at admission, exacerbation and remission by 
measurement of VWF and VWF-propeptide levels. Measurement of both VWF and 
its propeptide allows discrimination between acute and chronic perturbation of the 
endothelium. Elevated levels of both VWF and propeptide were found at admission. 
These levels decreased immediately upon plasma exchange therapy. However, 
plasma VWF and propeptide concentrations did not change, even at exacerbations. 
These observations indicate that endothelial cell activation is not the primary event 
leading to TTP. Vascular perturbation seems rather a consequence than a cause of 
the disease.
INTRODUCTION
Thrombotic thrombocytopenic purpura (TTP) is a rare hematological disorder that 
appears mostly at young age, of acute presentation and difficult diagnosis. The 
clinical features are thrombocytopenia, microangiopathic hemolytic anemia, renal 
failure, and neurological abnormalities resulting from formation of platelet thrombi 
within the microvasculature [1-4]. However, the etiology of the formation of platelet 
aggregates remains elusive. So far, accumulated data suggest that two important 
risk factors are involved in the events leading to the manifestation of TTP [5]. It 
is generally assumed that endothelial cell injury is one of the initial events in the 
pathogenesis of TTP. This view is primarily based on the observations that, in TTP, 
endothelial cells of the microvasculature are prone to apoptosis [6]. In addition, VWF 
multimers present in plasma of patients with TTP are sometimes larger than VWF 
multimers found in normal plasma. These multimers most likely stem from Weibel-
Palade bodies which release their contents upon endothelial cell perturbation [7-9]. 
These VWF species are more potent in controlling platelet adhesion and aggrega-
tion than normal VWF multimers [10-12] and, as such, may contribute to pathologic 
platelet aggregation and arteriolar thrombi formation. A second risk factor thought 
to be involved in TTP is deficiency of the VWF-cleaving protease ADAMTS13 
[13,14], a proteinase that has recently been identified as a member of the ADAMTS 
family of metalloproteinases [15-17]. Deficiency of this protease is thought to cause 
accumulation of the unusually large and highly reactive multimeric forms of VWF 
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that can adhere disproportionally to platelets and increase their adhesive potential. 
Evidence for constitutive protease deficiency as well as for deficiency associated 
with autoimmune inhibitors of this protease has been provided [14,18]. 
To document in more detail whether endothelial cell perturbation is the primary 
event in TTP, we performed a prospective, serial study of patients with relapsing 
TTP during hospitalization and treatment. To our knowledge, prospective studies on 
the role of endothelial cells in TTP have not been reported. To measure the degree 
of vascular involvement in TTP we examined levels of both plasma VWF and VWF-
propeptide at various stages of the disease. The rationale of this approach is based 
on the observation that measurement of both VWF and propeptide plasma levels 
allows discriminating between chronic and acute phases of endothelial cell activa-
tion [19-21]. In patients with a long history of vascular disease, such as peripheral 
occlusive vascular disease or diabetes mellitus, propeptide levels are not, or only 
slightly, elevated, whereas VWF levels are increased two- to three-fold. On the other 
hand, in cases of acute vascular disease, as may occur in TTP, both propeptide and 
VWF levels are clearly elevated. On the basis of these observations, it was postu-
lated that measurement of both propeptide and VWF levels allows discrimination 
between acute and chronic perturbation of the endothelium in TTP. So far, these 
data concerning the involvement of the endothelium in TTP have been obtained 
in a cross-sectional study [20]. We reasoned that only a prospective study could 
reveal whether indeed measurements of both propeptide and VWF levels have a 
predictive value in terms of disease activity and are useful in monitoring the degree 
of vascular involvement as well as the response to therapy in TTP. Therefore, we 
studied TTP patients during hospitalization and treatment and focussed on patients 
suffering from one or more exacerbations. This allowed assessing the degree of 
endothelial cell perturbation also at this critical phase of the disease. 
MATERIALS AND METHODS
Patients
From 21 patients that were admitted to the hospital with acute symptoms of TTP, 
9 having one or more exacerbations (relapsing TTP following initial complete re-
sponse) were included in this study. Upon admission to the hospital, all patients 
had thrombocytopenia (platelet count <100 x 109/L; normal platelet count: 150-450 
x 109/L) and microangiopathic hemolytic anemia (lactate dehydrogenase (LDH) 
levels > 800 U/L; normal LDH levels: 300-620 U/L). Most of the patients had a 
decreased hemoglobin level and 3 of them had impaired renal function (creatinine 
> 100 µmol/L). No VWF-protease activity was found in any of the patients upon ad-
mission. The clinical data at admission to the hospital are listed in Table 1.
Endothelial cell damage is not the primary event in TTP
109
Treatment
All patients were daily treated with plasma exchange for at least eight days or until 
a complete response (platelet count > 100 x 109/L and serum LDH < 800 U/L, for 
at least two consecutive days) was established. The frequency of plasma exchange 
was then decreased to 3 times a week and finally 2 times a week. Plasma exchange 
was immediately restarted upon exacerbation (thrombocytopenia and hemolytic 
anemia following initial complete response). During plasma exchange, one and a 
half plasma volume of the patient was removed daily and replaced by the same vol-
ume of fresh frozen plasma. Remission is defined as 30 days or more of complete 
response [4]. 
Blood collection and assays
Blood was sampled daily during plasmapheresis and at exacerbation. The frequen-
cy of blood sampling was decreased at complete response and remission. Blood 
samples were taken both before and after plasma exchange. All samples used for 
this study were obtained after informed consent. Blood was collected by vacutainer 
system in 3.1% citrate (1:10). To obtain platelet-free plasma, the blood was cen-
trifuged for 15 minutes at 4oC at 2000 g, the supernatant was removed and cen-
trifuged a second time. Samples were stored at -80oC. VWF and VWF-propeptide 
concentrations were measured by enzyme-linked immunosorbent assay (ELISA) 
as described previously [22]. Normal plasma from a pool of 30 donors served as 
standard. This plasma pool contains 6.3 nmol/L VWF-propeptide as assessed by 
calibration against purified recombinant propeptide [22] and 50 nmol/L of VWF.
VWF cleaving protease 
VWF-cleaving protease (CP) activity was quantified by using an assay based on 
the preferential binding of high-molecular-weight forms of VWF to collagen [23]. 
Recombinant VWF with a substitution of glutamine for arginine at amino acid posi-
tion 834 (VWF R834Q), which has an enhanced sensitivity to proteolysis by the 
protease, was used as substrate. The construction, expression, and purification of 
recombinant human VWF R834Q was described previously [24,25]. 
Statistical analysis
Statistics were performed using SPSS software version 10.0 (SPSS, Chicago, IL, 
U.S.A.). Data are presented as mean ± SD. Differences between groups were ana-
lyzed by ANOVA, followed by Tukey post hoc tests. Correlations between VWF and 
propeptide levels were determined by bivariate correlation analysis (Pearson). P 





Nine patients with acute symptoms of TTP and one or more exacerbations were 
followed in time during hospitalization. All patients suffered from thrombocytopenia 
(mean platelet count, 10 x 109 platelets/L; range, 2 – 21 x 109 platelets/L, Table 
1) and severe hemolysis (mean LDH level, 5030 U/L; range, 2275 - 10780 U/L). 
Three of the nine patients had impaired renal function (creatinine > 100 µmol/L). At 
admission, mean levels of VWF (100.9 ± 26.2 nM) were twice as high as the VWF 
values of healthy individuals (50 ± 25 nM). VWF-propeptide concentrations were 
also significantly increased (21.0 ± 11.6 nM). All patients at hospitalization had no 
detectable VWF cleaving protease activity in their plasma. In four of them an inhibi-
tor of the protease was detected. This indicates that some patients may suffer from 
congenital TTP, whereas others had developed inhibitory antibodies against the 
VWF-CP. 
LDH and platelets levels during exacerbation and remission
All patients were treated with plasma exchange. The initiation of plasma exchange 
was associated with an immediate drop of LDH levels in all patients. LDH levels 
reached normal values within 8 days, provided that no exacerbation occurred. Upon 
treatment, platelets levels increased gradually, reaching values greater than 100 x 
109 /L within one week after treatment. Despite first recovery, all patients included 
in this study suffered from one or more exacerbations during treatment (Table1), 
defined by recurrent hemolysis and thrombocytopenia. In most of the patients, 
Table 1. Presenting features of patients with TTP
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Figure 1. Time course of platelet 
count, LDH, VWF and VWF-
propeptide levels in a patient 
with relapsing TTP during 
hospitalization.
On admission, the patient suffered 
from thrombocytopenia (21 x 109 
platelets/L) and severe hemolysis 
(LDH > 6000 U/L). Upon plasma 
exchange therapy (indicated by 
filled circles) platelets and LDH 
levels began to recover slowly 
(days 4-6). Thrombocytopenia 
and hemolysis recurred at day 7 
(exacerbation, filled arrow). After 
extensive therapy, platelets and 
LDH recovered and remained 
normal until remission was 
established (day 45). At day 
77, the patient relapsed a 
second time (open arrow) and 
recovered after treatment. Also 
VWF and propeptide levels were 
elevated at admission (85.1 and 
34.8 nM respectively). Upon 
plasmapheresis, propeptide 
levels decreased immediately 
reaching normal values (day 2). 
VWF levels decreased as well, 
though slower. Propeptide and 
VWF levels remained stable 
during further hospitalization, even 
at exacerbation (day 7 and 77). 




exacerbation occurred when the intensity of plasma exchange was diminished. 
Because of exacerbation, daily plasma exchange was reinitiated until LDH and 
platelets returned to normal levels. Remission was established when these two pa-
rameters stabilized at normal values for 2 or more days. Figure 1 depicts the follow 
up of one patient during treatment.
Figure 2 shows the mean levels of LDH and platelets at hospitalization, at 
exacerbation and during remission. During remission, patients had normal concen-
trations of LDH (418 ± 87 U/L) and platelets (278 ± 73 x109/L). These data were 
significantly different from values measured at admission (p<0.01 and p<0.001 re-
spectively). At exacerbation, the levels of LDH were elevated (1298 ± 822 U/L) but 
not significantly different from remission values. LDH levels at exacerbation were, 
however, significantly lower than at hospitalization (p<0.01). Similarly, the number 
Figure 2. Mean levels of LDH, platelets, VWF and propeptide at admission, 
exacerbation and remission. 
Admission (all parameters, n=9), exacerbation (LDH, n=13; platelets, n=14; VWF and 
propeptide, n=12), remission (LDH, n=3; platelets, VWF and propeptide, n=5). NS, 
Not Significant.
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of platelets at exacerbation was low (56 ± 37 x109/L) compared to remission levels 
(p<0.001). However platelet number was significantly higher than at admission 
(p<0.05). The differences in LDH and platelets levels at exacerbation compared 
to those at hospitalization were probably due differences in clinical management. 
As soon as platelets dropped and LDH increased, patients were submitted to daily 
plasmapheresis, resulting in less extreme values of these two parameters. These 
observations confirm that upon treatment, LDH and platelets levels recover.
VWF and propeptide levels during exacerbation and remission
Upon plasma exchange VWF levels either decreased slightly (7 patients) or re-
mained elevated (2 patients) (cf. Fig.1). On the other hand, propeptide levels 
dropped immediately in all patients upon plasmapheresis, reaching normal values 
in 8 of the 9 cases. During exacerbation, which was associated with an increase of 
LDH and a decrease of platelet number, both VWF and propeptide levels remained 
stable (cf. Fig. 1). Also at remission VWF and propeptide concentrations did not 
change. 
Figure 2 shows that VWF levels at exacerbation (71.8 ± 29.2 nM) were lower 
than VWF levels at admission (100.9 ± 26.2 nM). However, the difference was not 
significant. During remission, VWF levels remained elevated (74.1 ± 36.7 nM) and 
did not significantly differ from admission and exacerbation values. Thus, TTP pa-
tients have, also outside the acute phase of the disease, significantly elevated VWF 
levels. The propeptide pattern during various phases of the disease was distinct 
from the VWF pattern (Fig. 2). Unlike at admission, propeptide concentrations were 
not elevated at exacerbation (9.1 ± 2.8 nM, p<0.01). Propeptide levels during remis-
sion remained normal (8.0 ± 1.6 nM). 
In Figure 3, propeptide and VWF levels during various stages of the disease 
are depicted on an individual basis. This figure shows that at admission both VWF 
Figure 3. Relation between plasma VWF and propeptide levels in individual patients with TTP 




and propeptide levels are elevated. In contrast, at exacerbation and remission most 
of the patients had normal propeptide concentrations but elevated VWF levels.  
DISCUSSION
It is generally believed that damage or activation of endothelial cells is a promi-
nent event in the pathogenesis of TTP. The present study provides evidence that 
acute perturbation of the endothelium is less evident in overt, relapsing TTP than 
previously anticipated. Endothelial activation seems rather a secondary event. This 
conclusion is primarily based on the observation that during hospitalization and 
excessive treatment of patients with chronic relapsing TTP, exacerbations that oc-
curred during the follow up period did not result in elevation of plasma levels of the 
propeptide of VWF. Similarly, VWF levels did not significantly change during this 
acute phase of the disease. As elevated VWF-polypeptide levels reflect fulminant, 
acute vascular disease [19,20,22], one would expect that exacerbation of the dis-
ease activity would be associated with increased propeptide levels (and concurrent 
increase of plasma VWF). This appeared not to be the case. In only 2 of the patients 
that experienced an exacerbation, propeptide levels increased (Fig. 3). On the 
other hand, at hospitalization, both propeptide and VWF levels were significantly 
elevated, a finding which, as also shown previously [20,21], is indicative of vas-
cular involvement in the pathogenesis of the disease. This is further corroborated 
by the observation that successful response to plasma exchange treatment, as 
demonstrated by normalization of platelet count, LDH level and clinical signs of the 
disease, was also associated with normalization of propeptide levels and reduction 
of VWF levels (though not significantly) in 8 out of the 9 patients studied. We can 
only speculate about the discrepancy observed between VWF and VWF-propep-
tide levels at admission and further hospitalization. It seems reasonable to assume 
that propeptide and VWF levels of plasma collected immediately upon admission 
to the hospital reflect vascular stimulation for a prolonged, though unknown period 
of time. In contrast, exacerbations were treated immediately by plasma exchange. 
We suppose that rapid and adequate therapeutical intervention has prevented the 
occurrence of new vascular events, such as secretion of propeptide and VWF. Vas-
cular perturbation observed at hospitalization seems rather a consequence than a 
cause of TTP.
The immediate drop of plasma levels of propeptide upon plasmapheresis 
at admission and the long-term normalization of propeptide levels suggest that 
plasma exchange therapy suppresses regulated release of the propeptide, and as 
VWF and propeptide are stored together in Weibel-Palade bodies, also of VWF. 
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Apparently, circulating agonists that trigger release of VWF and its propeptide from 
the endothelium are neutralized during plasma exchange therapy. However, the ef-
fect of plasma exchange on VWF levels is less prominent than on the propeptide 
levels. It seems likely that this is due to the differences in half-life between VWF and 
propeptide (respectively 12 and 3 hours) [20]. These observations further support 
the view that the VWF-propeptide is a better marker for endothelial cell perturbation 
than VWF [19,20]. This study also indicates that measurement of the propeptide 
may provide an adequate index for the effect of therapy on the excitation state of 
the endothelium.
If endothelium perturbation is not the primary event causing TTP, or exacerba-
tions of the disease, which other etiologic factors contribute to the onset of acute 
episodes of TTP? We can only speculate about this point. One of the possibilities 
is that aberrant proteolytic processing of VWF multimers released by endothelial 
cells through the constitutive pathway, rather than the regulated route, is a factor 
that contributes to the occurrence of relapses. It is generally thought that acute, 
regulated release of a Weibel-Palade body-derived storage pool of hyperreactive 
VWF species, together with impaired proteolytic degradation of these multimers, 
predisposes to microvascular thrombosis [5,26]. However, this study revealed that 
regulated secretion of VWF during single episodes or relapses of TTP is not always 
apparent (as demonstrated by the absence of increase of VWF-propeptide levels 
during these episodes of the disease). This observation raises the possibility that 
also impaired proteolytic processing of VWF released through the constitutive 
pathway, and subsequent accumulation of hyperreactive VWF multimers, contrib-
ute to enhanced platelet aggregation in the microvasculature. This view favors the 
hypothesis that hyperreactive VWF multimers may accumulate slowly in the blood 
stream, exceeding a threshold level that is required to initiate microvascular platelet 
aggregation and subsequent exacerbation of the disease [26]. 
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ABSTRACT
In this report we assessed the potential role of the von Willebrand factor (VWF) 
propeptide as an inflammatory mediator. In a chemotaxis assay, neutrophils were 
allowed to migrate toward the propeptide, IL-8, or a combination of both. The pro-
peptide alone was not able to induce a chemotactic effect on neutrophils. However, 
neutrophil adhesion induced by IL-8 increased about 30 % upon co-stimulation with 
VWF-propeptide (p < 0.05). Migration of neutrophils was not significantly affected. 
Thus, the VWF-propeptide potentiates the chemotactic response of neutrophils 
toward IL-8. This observation suggests that this VWF-derived protein serves a bio-
logical function after its release from the endothelium.
INTRODUCTION
Von Willebrand factor (VWF) is a multimeric plasma glycoprotein that is required for 
normal haemostasis. VWF is synthesized by endothelial cells and megakaryocytes 
and originates from its precursor pro-VWF. Endoproteolytic processing of pro-
VWF results in mature VWF and the VWF propeptide (also known as VWAg II). In 
endothelial cells, the propeptide controls polymerization and subsequent targeting 
of VWF to storage vesicles, the so-called Weibel-Palade bodies. Upon stimulation 
of endothelial cells, the Weibel-Palade bodies are translocated to the plasma 
membrane of the cell and mature VWF and its propeptide are co-secreted. After 
release, mature VWF both controls platelet adhesion and aggregation at sites of 
vascular injury and acts as a chaperone protein for coagulation factor VIII. In the last 
few years, increasing evidence has been obtained that the VWF-propeptide might 
also be involved in a variety of biological processes after it is secreted (reviewed 
by [1]). It has been suggested that the VWF propeptide may act as an inflamma-
tory mediator. This view stems from the observation that the propeptide is able to 
promote specific adhesion and spreading of certain leukemia and melanoma cell 
lines through the integrins α4β1 (VLA4) and α9β1 (VLA9) [2-4]. As both integrins 
are highly expressed on leukocytes and play a prominent role in transendothelial 
migration of these cells, it is possible that the propeptide could modulate these pro-
cesses. To assess the potential role of VWF propeptide as an inflammatory media-






Serum-free conditioned medium of CHO cells expressing human VWF-propeptide 
was kindly provided by dr. U. Schlokat, Baxter Hyland Immuno, Vienna, Austria. The 
VWF-propeptide was purified from the medium by immuno-affinity chromatography 
with an immobilized monoclonal antibody (CLB-Pro 35), directed against the pro-
peptide [5]. The purity of VWF-propeptide was established by SDS-PAGE analysis.
 
Materials
Recombinant human IL-8 was from PreproTech (London, UK), human serum albu-
min and fibronectin were obtained from our own institute (Sanquin Plasma Prod-
ucts, Amsterdam, The Netherlands).
Isolation of neutrophils
Granulocytes were isolated from blood obtained from healthy volunteers as previ-
ously described [6]. Prior to each assay, neutrophils were labeled with 4 mg/ml 
calcein-AM in Hepes medium for 30 minutes at 37oC. After labeling, the cells were 
washed twice with and resuspended in Hepes medium [6].
Neutrophil chemotaxis assay
The neutrophil transmigration assay was performed according to [6] except that 
filters coated, prior to the experiments, for 30 minutes with fibronectin were used 
instead of endothelial cell monolayers. Migration of neutrophils towards various 
concentrations of chemoattractants (propeptide, IL-8) was allowed for 5, 15 and 30 
minutes. Data are presented as mean ± SEM of 10 experiments and were statisti-
cally analyzed with the Student’s t-test. 
RESULTS AND DISCUSSION
Neutrophils were allowed to migrate through a fibronectin-coated filter toward either 
IL-8 (1-10 nM), propeptide (0.05-0.2 nM) or a combination of both which were ap-
plied in the lower compartment of the microchamber. The percentage of neutrophils 
that bound to the filter and the percentage transmigrated neutrophils was deter-
mined at different time points. 
Fig. 1 shows the effect of IL-8 (10 nM) and propeptide (0.1 nM) on neutrophil 
chemotaxis. As expected, IL-8 clearly induced neutrophil chemokinesis in a typical 
bell-shape manner. Neutrophils first adhered to the filter after which they migrated 
VWF-propeptide enhances IL-8 induced neutrophil adhesion
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Figure 1. VWF-propeptide enhances the adhesive response of 
neutrophils toward IL-8. Neutrophils were allowed to migrate through a 
fibronectin-coated filter toward either IL-8 (10 nM), propeptide (propeptide, 
0.1 nM) or a combination of both which were applied in the lower 
compartment of the microchamber. The percentage of neutrophils that 
bound to the filter (A) and the percentage transmigrated neutrophils (B) 
was determined after 5, 15 and 30 minutes of incubation. Data are from 
10 experiments and are expressed as mean ± SEM. Significant difference 




to the lower compartment. Most neutrophils (26 %) were bound after 15 minutes 
of incubation with IL-8. After 30 minutes, 41 % of the cells had migrated toward 
the chemoattractant. Neutrophils did not respond to the propeptide under these 
conditions. On the other hand, when applied to the lower compartment together 
with IL-8, the adhesive response of neutrophils toward IL-8 was further enhanced 
by the propeptide. Neutrophil adhesion induced by IL-8 increased about 35 % upon 
co-stimulation with VWF-propeptide (p < 0.05) after 15 min of incubation. Propep-
tide decreased IL-8-induced migration. However, as compared to the effect of IL-8 
alone, this difference was not significant. Thus, although VWF-propeptide seems 
unable to induce neutrophil chemotaxis, it potentiates the chemotactic response 
of neutrophils toward IL-8. This cooperative effect is most prominent at the level of 
adhesion. 
Synergistic interactions between weak and potent chemokines have been pre-
viously described. For instance, the weak chemotactic activities of PF-4 and Rega-
kine-1 on leukocytes are enhanced by TNF-α and IL-8, respectively [7,8]. Given its 
high plasma concentration (5-10 nM, [5])), a feature shared with chemokines such 
as HCC-1 [9] and also Regakine-1 [8], it seems unlikely that the propeptide serves 
a role as a primary chemoattractant. The co-targeting of IL-8 and propeptide into 
a storage compartment of endothelial cells, the Weibel-Palade bodies, and their 
regulated co-secretion [10,11] rather raises the possibility that the propeptide acts 
synergistically with IL-8 upon appropriate stimulation of the endothelium, thereby 
enhancing local adherence of neutrophils.
We can only speculate about the mechanism of this apparent synergistic 
effect. As the propeptide harbours a recognition site for α9β1 (VLA9, [4]), an 
integrin involved in neutrophil migration, it is tempting to speculate that interaction of 
propeptide with this receptor enhances IL-8-mediated adhesion. Similarly, the RGD 
motif of the propeptide could be involved. It is also possible that VWF-propeptide 
exerts its synergistic effect through a peptide motif that is structurally closely related 
to the receptor recognition site of CXC chemokines and the biologically active locus 
of EMAP II, another potent pro-inflammatory [12]. Further studies are required to 
get insight into the mechanism of the apparent chemokine-like activity op the 
propeptide at the molecular basis.
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The aim of the studies described in this thesis was to further unravel the life cycle 
and fate of Weibel-Palade bodies, the specialized storage vesicles in endothelial 
cells that contain proteins such as von Willebrand factor (VWF), P-selecting and 
IL-8. As schematically depicted in Fig. 1, this life cycle can arbitrarily be divided in 
different phases: a. sorting of proteins into Weibel-Palade bodies, b. intracellular 
trafficking comprising maturation, transport along microtubules and tethering in 
the actin network, c. docking, d. exocytosis and, finally, e. endocytosis of released 
membrane-associated Weibel-Palade body constituents.
Sorting of proteins into Weibel-Palade bodies.
The current, widely accepted model for the biogenesis of secretory granules 
comprises a number of distinct steps occurring at different levels in the secretory 
pathway (see Fig. 1) [1-4]. These steps include: 1, sorting of granule constituents 
(e.g. VWF) within the trans-Golgi network (TGN), the so-called “sorting for entry”, 2, 
budding of constitutive secretory vesicles and immature secretory granules (short-
lived vesicular intermediates) from the TGN, and, 3, maturation of the immature 
secretory granules into mature secretory granules where further refinement of 
granular constituents occurs, either by “sorting for exit” or “sorting by retention” [1]. 
In this chapter, protein sorting and maturation processes that are thought to occur 
in endothelial cell Weibel-Palade bodies will be discussed. 
Despite the limited knowledge about the mechanism of protein sorting to 
Weibel-Palade bodies, evidence is accumulating that VWF not only plays a role in 
directing the formation of Weibel-Palade bodies, but may also have a helper func-
tion in the sorting of other proteins to these secretory vesicles. For instance, trans-
Figure 1. Life cycle of Weibel-Palade bodies. TGN, trans-Golgi Network; iWPb, immature Weibel-




fection of an epithelial cell line which synthesizes P-selectin, but does not retain 
this receptor in storage vesicles, with VWF-cDNA resulted in the formation of Wei-
bel-Palade body-like organelles, containing both VWF and P-selectin [5]. Similarly, 
IL-8 is also co-targeted with VWF into Weibel-Palade bodies (Chapter 2). Cells that 
synthesize IL-8 in substantial amounts, do not store this cytokine in Weibel-Palade 
bodies, unless VWF and IL-8 are co-expressed. These findings support the view 
that VWF may trigger sequestration of structurally unrelated proteins into Weibel-
Palade bodies. This may also be the case with other Weibel-Palade body constitu-
ents, such as CD63, endothelin and α1,3-fucosyltransferase. It is possible that IL-8 
and other Weibel-Palade body constituents interact or co-aggregate with VWF in 
the TGN, a process that may facilitate their retention and condensation within the 
Weibel-Palade bodies [1]. As VWF is able to bind a variety of proteins and biologi-
cal compounds [6], it is tempting to speculate that Weibel-Palade body constituents 
may specifically interact with VWF preceding maturation of secretory vesicles. This 
view is supported by our finding that IL-8 specifically binds with VWF in vitro under 
conditions that may mimic the TGN milieu (Romani de Wit, unpublished data). Simi-
larly, coexpression studies of VWF and factor VIII (a coagulation factor that readily 
binds to VWF) in AtT-20 cells and vascular endothelial cells, showed co-localization 
of factor VIII and VWF in storage vesicles [7]. Apparently, VWF-mediated sorting of 
factor VIII was due to interaction of these proteins in the TGN. 
 So far, no distinction has been made between the role of mature VWF in 
protein sorting and that of its propeptide. However, the propeptide moiety of VWF 
may also play an important role in the targeting process (see below). Two models of 
protein sorting that are not mutually exclusive have been reported: the multimeriza-
tion hypothesis and the propeptide targeting model. The multimerization hypothesis 
advocates that storage of VWF is directed by selective aggregation (i.e. multimer-
ization) and condensation [5,8,9], a process that underlies the sorting and targeting 
of many other proteins and hormones destined for regulated secretion (reviewed 
in [1,10,11]). The propeptide hypothesis considers that the VWF-propeptide con-
tains a targeting signal that interacts with a carrier protein or receptor in the Golgi 
membrane to mediate targeting of VWF (and the propeptide itself) to storage [12]. 
According to the latter view, VWF would traffic to storage vesicles only through its 
noncovalent interaction with its propeptide. A recent report showed that the VWF-
propeptide is also capable of targeting a protein structurally unrelated to VWF, the 
complement protein C3, into storage vesicles, provided that VWF-propeptide is 
covalently linked to this foreign protein [13]. It is very well possible that either VWF 
or its propeptide interact noncovalently with other Weibel-Palade body residents to 




Intracellular trafficking of Weibel-Palade bodies
Once (premature) Weibel-Palade bodies are formed and are packed with a variety 
of bioactive molecules, what is the fate of these vesicles preceding exocytosis?
Based on the data presented in this thesis (chapters 3 and 4) and on the findings 
reported elsewhere, intracellular trafficking of Weibel-Palade bodies is likely to 
comprise a succession of distinct processes. 
1. Maturation of Weibel-Palade bodies
Little is known about the maturation of Weibel-Palade bodies; not even whether 
these vesicles undergo maturation at all. In general, organelles involved in the regu-
lated secretory pathway of a variety of cell types are initially formed in the TGN as 
immature secretory granules. They undergo maturation and become mature secre-
tory granules. This maturation involves selective removal of molecules that are not 
destined for secretion. For example, membrane proteins such as mannose 6-phos-
phate receptor, TGN endoprotease furin and carboxypeptidase D, are removed 
from immature vesicles in a clathrin-dependent process and end up in endosomes 
[14] [15] [16]. Furin and carboxypeptidase D not only exert their enzymatic activities 
in the TGN, but are also active in immature secretory granules [17]. Interestingly, 
furin has also been shown to cleave pro-VWF into mature VWF and VWF-propep-
tide. This process is thought to take place in the TGN [18-21]. Although the process 
of maturation of Weibel-Palade bodies has not yet been documented, it is possible 
that proteolytic cleavage of pro-VWF occurs in immature Weibel-Palade bodies. 
Co-localization studies of furin with VWF containing vesicles could provide more 
insight in the maturation process of these vesicles.
In this thesis, indirect evidence was provided that Weibel-Palade bodies in-
deed undergo maturation. In chapter 3 we describe the existence of different pools 
of Weibel-Palade bodies. Some VWF containing vesicles barely move as if they 
were tethered, others seem to travel in a stochastic manner and frequently reverse 
their direction. Furthermore, all Weibel-Palade bodies moved with remarkably low 
speed, not exceeding 10 nm/s. Previous studies on other cell types have shown that 
secretory vesicles travel in different motion. Fast, microtubule-associated vesicles, 
travelling from the Golgi to the plasma membrane, move at an average speed of 
about 1 µm/s, and are thought to represent a subset of immature vesicles [22-25]. 
Upon arrival at the plasma membrane, vesicles are tethered which decreases 
considerably their motility to about 50 nm/s [25,26]. Mature vesicles are trapped in 
the dense meshwork of the actin cortex that prevents movement and are awaiting 
release [25,27]. The real time data from chapter 3 indicate that tethered Weibel-Pal-
ade bodies are trapped in the actin cortex of endothelial cells. On the other hand, 
those Weibel-Palade bodies that move in all directions are reminiscent of microtu-
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bule-associated granules [22]. Based on their behavior and dynamics, it is tempting 
to speculate that tethered, slowly moving WPbs represent mature vesicles, where-
as the other pool consists of immature microtubule-associated vesicles. Whether 
this is indeed the case remains to be established.
2. Weibel-Palade body transport along microtubules
It is now well established that vesicle trafficking proceeds both on microtubules 
and on microfilaments and involves cytoskeletal-associated motor proteins [28-30]. 
Microtubules are thought to provide tracks for movement over long distances while 
actin filaments preferentially control movement to local sites [31]. Vesicles have motor 
proteins for both actin- and microtubule-mediated transport. Also a direct interaction 
between actin- and microtubule-dependent motors themselves has been found, 
suggesting the existence of an extensive cross-talk between the two cytoskeletal 
systems. Similarly, a role of microtubules in Weibel-Palade body trafficking has 
been demonstrated. In fact, intact microtubules are essential for correct processing 
and regulated secretion of VWF by endothelial cells [32]. Disruption of microtubules 
inhibited thrombin- and histamine-induced VWF secretion [32,33]. In this thesis 
(chapter 3), additional evidence was provided that microtubules play an important 
role in the intracellular transport of Weibel-Palade body. The stochastic movement 
of Weibel-Palade bodies observed in resting endothelial cells is reminiscent of 
microtubule-associated trafficking. When endothelial cells were stimulated with 
cAMP-raising agonists, Weibel-Palade bodies migrated perinuclearly (chapter 
3). They were specifically recruited to the microtubule organizing centre as 
schematically illustrated in Figure 1. Based on their location and dynamics, this 
process most likely involves active transport of Weibel-Palade bodies along 
microtubules. Intracellular vesicles are transported along microtubules by utilising 
microtubule-associated motor proteins such as kinesin and dynein [34-36]. Kinesin 
moves towards the fast growing (or plus end), away from the microtubule organizing 
centre, and cytoplasmic dynein moves towards the minus end [30,37]. The 
movement of Weibel-Palade bodies in a zigzag fashion, in both plus- as minus-end 
direction, suggests that both types of motor proteins are involved in Weibel-Palade 
body trafficking in resting cells. The mechanisms underlying Weibel-Palade body 
trafficking along the cytoskeletal tracks have not been identified so far. A growing 
number of interactions between small GTPases and kinesin-like proteins has been 
described in literature. For instance, rab6 directly binds rabkinesin6 [38], Rho, Rac 
and Cdc42 have been found to interact with the kinesin-associated protein kinectin 
[39]. Since such molecules have also been identified in endothelial cells [40-42], 
it is tempting to speculate that GTPases-kinesin interactions may contribute to 
Weibel-Palade body-trafficking. Future studies could reveal whether these proteins 
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commonly involved in intracellular trafficking are also associated with Weibel-
Palade bodies in endothelial cells.
3. Tethering of Weibel-Palade bodies in the actin cortex
Upon arrival at the plasma membrane, secretory vesicles are tethered which de-
creases considerably their motility [25,26]. These vesicles are sequestered in the 
dense meshwork of the actin cortex that forms a physical barrier to exocytosis for 
the majority of secretory granules in resting cells [43-45]. Thus, tethering is an im-
portant step in the trafficking of vesicles and is essential for exocytosis. Although 
the co-localization of Weibel-Palade bodies and the actin cortex was not studied, 
a number of Weibel-Palade bodies seemed indeed to be trapped near the plasma 
membrane (chapter 3). Apparently, Weibel-Palade bodies are recruited at the cell 
periphery awaiting the trigger for release. The process of tethering is regulated by 
a complex series of protein interactions, most of which remain to be identified in 
endothelial cells. 
Recent data showed co-localization of Weibel-Palade bodies with another 
small GTP-binding protein, Rab27 [46]. This GTPase regulates a variety of pro-
cesses involving melanosome motility in melanocytes [47], lytic granule release 
in cytotoxic lymphocytes [48], and exocytosis of dense core granules in platelets 
[49,50] and pancreatic β-cells [51]. The tethering mechanism of melanosomes has 
been investigated in more detail. It seems that Rab27 recruits myosin Va to the 
melanosome and that myosin Va then tethers the melanosomes to subcortical actin 
filaments at the periphery of the cell [52]. Weibel-Palade bodies may be recruited to 
the plasma membrane by a similar trapping mechanism. It would be very interest-
ing to elucidate the involvement of these different GTPases in Weibel-Palade body.
Docking of Weibel-Palade bodies with the plasma membrane
Activation of cells induce rearrangements in the actin cytoskeleton occur, which 
enable docking of vesicles at exocytic sites. Docking of exocytic vesicles with the 
plasma membrane has been shown to involve a protein complex known as the 
“exocyst”. The exocyst localizes specifically to regions of active secretion. Recent 
data have demonstrated that many small GTPases regulate the exocyst, includ-
ing members of the Rab [53], Rho [54-56] and Ral families [57-60]. Interaction of 
Rab, Rho and Cdc42 with different exocyst components has only been identified in 
yeast. The mammalian exocyst (or Sec6/8 complex) associates with activated RalA 
through the binding to the exocyst subunit Sec5, leading to the targeting of synaptic 
vesicles to the plasma membrane. Furthermore, RalA has been implicated in the 
regulation of processes such as endocytosis and actin cytoskeleton dynamics. It is 
likely that the functional role of the majority of small GTP-binding proteins in endo-
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thelial cells is similar, if not identical, to that defined in other cell types. In endothelial 
cells, RalA associates with Weibel-Palade bodies [61] and in chapter 4, evidence 
is provided that RalA is involved in the exocytosis of these vesicles. Therefore, it is 
tempting to speculate that docking of Weibel-Palade bodies occurs through interac-
tion of Weibel-palade body-associated RalA and a putative exocyst at the plasma 
membrane. Studies on the presence of components of the exocyst complex in 
endothelial cells and their functional involvement in exocytosis of Weibel-Palade 
bodies are certainly worth further investigations. 
Exocytosis 
Exocytosis of Weibel-Palade bodies occurs upon stimulation of endothelial cells, ei-
ther with Ca2+- or cAMP-raising agents. Contrary to previous suggestions, our data 
indicate that Weibel-Palade bodies do not fuse with each other during exocytosis. 
Chapter 3 demonstrates that exocytosis of Weibel-Palade bodies comprises fusion 
of individual vesicles with the plasma membrane, gradual release and diffusion of 
Weibel-Palade body contents into the extracellular compartment. The mechanism 
underlying fusion between Weibel-Palade bodies and the plasma membrane re-
mains to be established. 
 During exocytosis, the different residents of Weibel-Palade bodies are ei-
ther secreted (e.g. VWF, propeptide, IL-8) or exposed at the cell surface (P-selectin 
and CD63). Striking is the relative long life span of Weibel-Palade body exocytosis 
(minutes, chapter 3) compared to that of other secretory vesicles (seconds) [24,26]. 
The apparent slow exocytosis of Weibel-Palade bodies could be due to the com-
pact, crystalloid structure of VWF, which may hamper its release and dissolution. 
The possible interaction of VWF with other Weibel-Palade body constituents or with 
proteins localized at the plasma membrane may also affect the rate of exocytosis. 
 Slow exocytosis may be of important physiological significance. As a result 
of slow exocytosis, stimulated endothelial cells may present at their surface focal 
sites with a high concentration of VWF, which, together with other Weibel-Palade 
body constituents, could serve a role in adequately recruiting distinct plasma 
proteins, blood cells or matrix components at sites of vascular injury. Pertinent to 
this point is the observation of André and co-workers [62] who showed that plate-
lets adhered rapidly, though transiently, to VWF secreted at the luminal face of 
endothelial cells upon triggering of the cell with Ca2+-agonists. The observation that 
adherence of platelets to the endothelium was transient (minutes) corresponds with 
the time course of exocytosis. In addition, focal sites expressing high levels of P-se-
lectin and IL-8 may contribute to the rapid recruitment of leukocytes by endothelial 
cells after simulation. Pertinent to this view is the observation that in VWF-deficient 
mice, [63] Weibel-Palade body formation is defective resulting in reduced P-selectin 
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expression at the cell surface. This, in turn, hampers neutrophil recruitment in early 
phases of inflammation. Interestingly, the time frame of P-selectin-mediated rolling 
of leukocytes on the endothelium [64] is in the same order of magnitude as the 
exocytosis process and concomitant patch formation described in chapter 3. Based 
on our model of focal site formation, also a defect in IL-8 secretion could impair 
leukocyte recruitment found in VWF-deficient mice. Interestingly, the results de-
scribed in chapter 7 show that the VWF-propeptide acts synergistically with IL-8 by 
enhancing the adhesion of neutrophils. The co-localization of IL-8 and propeptide 
in Weibel-Palade bodies and their co-secretion may favor cooperative effects. Thus, 
focal sites expressing these two proteins at high levels could also contribute to the 
rapid recruitment of neutrophils to endothelial cells after stimulation. Although not 
studied in this thesis, the propeptide may also be involved in monocyte adhesion 
to the endothelium. Actually, monocytes can adhere to the endothelium by various 
integrins, such as α4β1, on their surfaces. Since the VWF-propeptide is a ligand 
for α4β1, it is possible that the propeptide may also participate in the recruitment 
of monocytes by the endothelium. Pertinent to this point are the observations of 
Methia et al [65] that in VWF-deficient mice, atherosclerotic lesion formation was 
reduced. Localized reduction of artherosclerosis correlated with a reduced recruit-
ment of monocytes. 
Taken together, ample evidence is provided that emphasizes the importance 
of Weibel-Palade body exocytosis at the interface between inflammatory and the 
hemostatic response. Furthermore, the biological functions of the different Weibel-
Palade body constituents seem more intertwined than previously anticipated. It 
would be fascinating to determine in real-time studies whether blood components 
interact indeed with Weibel-Palade body constituents at these specific focal sites 
during vascular perturbation.
Endocytosis
Although not studied in this thesis, endocytosis can also be considered as a step 
in the life cycle of Weibel-Palade bodies (see figure 1). Endocytosis does not lead 
to the formation of new Weibel-Palade bodies, but produces small vesicles that end 
up in for example endosomes. Endocytosis enables the recycling of membrane-
bound Weibel-Palade body constituents from the plasma membrane back to the 
TGN, lysosomal compartment or even to new Weibel-Palade bodies. Indeed, after 
translocation on the plasma membrane following exocytosis, the trans-membrane 
proteins P-selectin and CD63 are rapidly internalized [66-68]. P-selectin recycles 
to the Weibel-Palade bodies via the TGN. Unlike P-selectin, endocytosed CD63 ac-
cumulates in endosomes and either recycles directly to Weibel-Palade bodies or is 
targeted to lysosomes. Besides the different routes used by P-selectin and CD63 
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to re-enter Weibel-Palade bodies, also the kinetics and extent of recycling are very 
different. Recycling of proteins and the fusion of endosomes with Weibel-Palade 
bodies may provide a new supply of elements required to support the life cycle of 
Weibel-Palade bodies. This new supply may, for example, be useful for tethering of 
Weibel-Palade bodies to the plasma membrane. We hypothesize that recycling of 
proteins to Weibel-Palade bodies could be involved in the maturation process of 
these vesicles. Future research should reveal whether this is indeed the case.
We can only speculate about the mechanisms involved in endocytosis. Evi-
dence has been provided of the implication of the small GTPase RalA in endocy-
tosis of EGF and insulin receptors [69]. GTP hydrolysis was shown to be critical for 
RalA endocytosis. Similarly, RalA, which is associated with Weibel-Palade bodies, 
may not only play a role in the exocytosis of Weibel-Palade bodies (chapter 4) but 
may also be involved in the endocytotic process. No data are currently available 
with respect to the involvement of RalA in endocytosis of Weibel-Palade body com-
ponents. It is tempting to speculate that RalA modulates re-entry of endocytosed 
CD63 and P-selectin into newly formed, immature Weibel-Palade bodies.
Life span of a Weibel-Palade body?
The life cycle of Weibel-Palade bodies is affected by distinct physiological condi-
tions. During steady-state conditions, the basal turnover of Weibel-Palade bodies 
is estimated to be about 24 h [68]. Indeed, Weibel-Palade bodies undergo low-level 
spontaneous exocytosis even in the absence of stimulation [70]. Upon stimulation, 
endothelial cells undergo different secretory processes depending on the agonists 
to which they are exposed. These processes are of importance for the release of 
Weibel-Palade bodies and consequently for their life span. Based on our knowledge 
and observations described in this thesis, we propose a model that describes the 
processes occurring during stimulation with either Ca2+- or cAMP raising agents 
(Figure 2). These two stimulation processes could be considered to represent 
physiological (cAMP-raising agonists) and pathophysiological (Ca2+-raising ago-
nists) mechanisms (also reviewed in [71]).
As illustrated in Figure 2, Ca2+-raising agonists, such as thrombin or histamine, 
induce cell retraction very rapidly (within 5 minutes) producing gaps between cells. 
This is accompanied by redistribution of actin and myosin into stress fibers [33]. 
Exocytosis of Weibel-Palade bodies is observed also within a few minutes after 
stimulation (chapter 3). In vivo, Ca2+-raising agonists are mediators of inflamma-
tion or thrombosis, usually acting locally. Cell retraction possibly results in edema 
formation or exposure of the subendothelium (and subsequent thrombotic events). 
Fast release of inflammatory and pro-thrombotic agents, such as those present in 
Weibel-Palade bodies, may amplify these pathophysiological processes. Ca2+-me-
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diated secretion, e.g. in response to vascular damage, most likely reflects mobili-
zation of the entire WPb population to accomplish adequate release of bioactive 
molecules at sites of vascular injury. Consequently the life span of Weibel-Palade 
bodies under pathophysiological conditions is reduced.
cAMP-raising agonists, e.g. epinephrin and forskolin, induce disruption of 
stress fibers, strengthening of the cortical actin rim, and tightening of cell-cell 
contacts [33]. Following such stimulus, Weibel-Palade bodies are recruited peri-
nuclearly, and more specifically move toward the microtubular organizing center. 
Perinuclear recruitment most likely involves trafficking along microtubules and 
association of microtubule-associated motor proteins. cAMP-induced exocytosis 
starts about 20 minutes after stimulation, a process that is delayed compared to 
that induced by Ca2+-raising agonists. Interestingly, after addition of cAMP-raising 
agonists less Weibel-Palade bodies seem to undergo exocytosis compared to Ca2+-
raising agents. Apparently, the cAMP-dependent perinuclear recruitment of Weibel-
Palade bodies may be a mechanism to retrieve the storage pool of pro-thrombotic 
and pro-inflammatory mediators from the plasma membrane and prevents exces-
sive release of their contents. As such, it may provide a means to limit excessive 
release in Weibel-Palade bodies under physiological conditions, such as physical 
exercise or other stress situations [71]. Under physiological conditions, two pools 
Figure 2. Dynamics of Weibel-Palade bodies upon stimulation with Ca2+- and cAMP-raising 
agonists. Note the different effects of these agonists on the cell-shape, Weibel-Palade recruitment and 
the start of Weibel-Palade body exocytosis. See text for details.
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of Weibel-Palade bodies may exist: One pool, that is probably already tethered 
near the plasma membrane, undergoes exocytosis and has a short life span. The 
second (probably immature) pool of Weibel-Palade bodies escapes exocytosis, 
perhaps because it is not tethered, resulting in a longer life span. 
The existence of “physiological” or “pathophysiological” secretion of Weibel-
Palade bodies is not always obvious in pathophysiological conditions such as 
thrombotic thrombocytopenic purpura (TTP, chapter 6). It is generally thought that 
acute, regulated release of a Weibel-Palade body-derived storage pool of hyper-
reactive VWF species, together with impaired proteolytic degradation of these mul-
timers, predisposes to microvascular thrombosis [72]. We can’t exclude, however, 
that slow accumulation of hyperreactive VWF multimers in the bloodstream is a 
result of “physiological”, cAMP-mediated exocytosis exceeding threshold levels re-
quired to initiate microvascular platelet aggregation and subsequent exacerbation 
of the disease. 
 
In conclusion, this thesis has brought forward different issues concerning the 
life cycle of Weibel-Palade bodies. This life cycle comprises multiple processes 
and mechanisms of remarkable complexity. We and other studies have provided 
evidence that the different steps in this life cycle most likely are of important physi-
ological significance in the processes underlying hemostatic, thrombotic and 
inflammatory responses. However, the different phases and stages of the life cycle 
of Weibel-Palade bodies are far of being unraveled and merit further investigation.
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Vascular endothelial cells are equipped with a machinery that, upon perturbation, 
allows prompt delivery of a number of bioactive substances, including hormones, 
receptors and adhesive molecules, to the surface of the cell. A distinct subset of 
proteins destined to be released upon stimulation of the endothelium stems from 
Weibel-Palade bodies, typical and morphologically organized storage vesicles that 
release their contents by regulated exocytosis. Weibel-Palade bodies are able to 
store a variety of proteins with different biological functions such as the multimeric 
glycoprotein  von Willebrand factor (VWF) that is required for normal haemostasis, 
the leukocyte adhesion receptor P-selectin, and the chemokine interleukin-8 (IL-8). 
Correct delivery of these proteins to the cell membrane or to the circulation is es-
sential for the biological role of these proteins. Indeed, regulated secretion of VWF 
provides an adequate means for endothelial cells in controlling the arrest of bleed-
ing upon vascular damage. In addition, effective translocation of P-selectin from 
Weibel-Palade bodies to the cell surface is critical for the binding and rolling of leu-
kocytes on the endothelium at sites of inflammation. Similarly, regulated exocytosis 
of IL-8 provides an effective means of controlling local leukocyte extravasation. 
Taken together, regulated exocytosis of Weibel-Palade bodies serves several physi-
ological functions including inflammatory and haemostatic responses. However, the 
mechanisms such as sorting of proteins to Weibel-Palade bodies, Weibel-Palade 
body trafficking in the cell and secretion of their content into the circulation, are far 
of being understood. In this thesis, I tried to get more insight into the life cycle of 
Weibel-Palade bodies and the extracellular function of one of their constituents.
Chapter 1 provides background information about this subject and describes 
the biosynthesis, processing and secretion of VWF, the major constituent of Wei-
bel-Palade bodies, known so far. It introduces the importance of protein storage in 
Weibel-Palade bodies which forms the basis of research on the life cycle of these 
vesicles described in the following three chapters.
The first step of the life cycle of Weibel-Palade bodies is the sorting process 
of proteins into these storage organelles. Despite the limited knowledge about the 
mechanism of protein sorting to Weibel-Palade bodies, evidence is accumulating 
that VWF has a helper function in the sorting of other proteins (e.g. P-selectin) to 
these secretory vesicles. In Chapter 2, the role of VWF in the sorting of IL-8 into 
Weibel-Palade bodies was investigated. For this purpose, an endothelial cell line 
that had retained the typical phenotypic characteristics of primary endothelial cells, 
but that has lost the ability to produce VWF in appreciable amounts was used. 
Strikingly, this cell line is no longer able to store IL-8 in Weibel-Palade bodies. By 
transducing this cell line with a vector encoding a VWF-green fluorescent protein 
chimera (VWF-GFP), we restored the expression of VWF and the generation of 
Weibel-Palade body-like organelles. VWF-GFP-expressing cells also showed 
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significant co-localization of VWF-GFP and IL-8 in these storage vesicles. These 
observations indicated that VWF plays an active role in sequestering IL-8 into Wei-
bel-Palade bodies.
After sorting into Weibel-Palade bodies, proteins such as VWF are transported 
throughout the cell and are secreted upon stimulation of endothelial cells. Chapter 
3 describes possible mechanisms involved in the intracellular trafficking of Weibel-
Palade bodies and their exocytosis. For that purpose, the above-mentioned VWF-
GFP chimera to infect wild-type endothelial cells was used. This approach allowed 
direct visualization of the routing and fate of Weibel-Palade bodies upon stimulation 
in live cells.  Different pools of Weibel-Palade bodies were observed: some vesicles 
barely moved as if they were tethered, others seemed to travel in a stochastic man-
ner and frequently reverse their direction. It was hypothesized that Weibel-Palade 
bodies undergo maturation during transport along microtubules. Upon arrival at the 
plasma membrane, tethered (mature?) Weibel-Palade bodies are trapped in the 
actin cortex of endothelial cells that forms a physical barrier to exocytosis. Appar-
ently, Weibel-Palade bodies are recruited at the cell periphery awaiting a trigger for 
release. Exocytosis of Weibel-Palade bodies occurs upon stimulation of endothe-
lial cells, either with Ca2+- or cAMP-raising agonists. These results suggested that 
exocytosis of Weibel-Palade bodies comprises fusion of individual vesicles with the 
plasma membrane, gradual release and diffusion of Weibel-Palade body content 
into the extracellular compartment. As a result of slow exocytosis, endothelial cells 
may present at their surface focal sites with high concentrations VWF, IL-8 and 
P-selectin which, in turn, may play a role in focal adhesion of blood constituents 
to the endothelium upon vascular injury. In addition to exocytosis, cAMP-raising 
agonists induce clustering of a subset of Weibel-Palade bodies in the perinuclear 
region of the cell. The cAMP-dependent recruitment of Weibel-Palade bodies may 
be a mechanism to retrieve the storage pool of pro-thrombotic and pro-inflamma-
tory mediators from the plasma membrane and to prevent excessive exocytosis of 
Weibel-Palade bodies.
Chapter 4 focuses on the role of RalA, a small GTP-binding protein shown 
to be associated with Weibel-Palade bodies, in the regulated exocytosis of these 
vesicles. Activation of endothelial cells by thrombin resulted in transient cycling of 
RalA from its inactive GDP- to its active GTP-bound state, a process which coin-
cided with release of VWF. Furthermore, expression of constitutively active Ral in 
endothelial cells resulted in exocytosis of Weibel-Palade bodies whereas expres-
sion of a dominant negative Ral variant did not show this effect. Taken together, 
RalA seems to be involved in regulated exocytosis of Weibel-Palade bodies from 
endothelial cells. RalA associates with the exocyst of different cell types to target 
vesicles to the plasma membrane. It is tempting to speculate that also in endothelial 
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cells, Weibel-Palade body-associated RalA interacts with a putative exocyst leading 
to docking of Weibel-Palade bodies at the plasma membrane. RalA may also be 
involved in the endocytosis of integral membrane proteins like P-selectin and CD63 
that are contained within Weibel-Palade bodies.
As mentioned above, Weibel-Palade bodies store a variety of proteins with 
different biological functions and secrete them into the circulation upon stimula-
tion of endothelial cells. There is no doubt that regulated exocytosis of Weibel-
Palade bodies serves several physiological functions including inflammatory and 
haemostatic responses. The second part of this thesis focuses on the biological 
significance of the VWF-propeptide, one of the Weibel-Palade body constituents. 
Chapter 5 serves as introduction of this part and illustrates the potential role of the 
propeptide as a marker of endothelial cell perturbation. Measurement of both VWF 
and VWF-propeptide levels allows discrimination between acute and chronic endo-
thelial perturbation. Further, this chapter shows that the biological function of the 
VWF-propeptide is more diverse than previously anticipated. This is starting point 
for the following chapters.
VWF-propeptide was used as a marker for endothelial cell perturbation in 
Chapter 6 to determine whether endothelial cell activation is the primary event in 
the pathogenesis of thrombotic thrombocytopenic purpura (TTP). The degree of 
endothelial cell involvement was assessed in TTP patients at admission, exacerba-
tion and remission by measurement of VWF and VWF-propeptide levels. Elevated 
levels of both VWF and its propeptide were found at admission. These levels de-
creased immediately upon plasma exchange therapy. However, plasma VWF and 
propeptide concentrations did not change, even at exacerbations. We conclude that 
endothelial cell activation is not the primary event leading to TTP. Vascular pertur-
bation seems a consequence rather than a cause of the disease.
The VWF-propeptide is able to promote specific adhesion and spreading of 
certain leukemia and melanoma cells through the integrins α4ß1 (VLA4) and α9ß1 
(VLA9). As both integrins are highly expressed on leukocytes and play a prominent 
role in transendothelial migration of these cells, we hypothesized that the VWF-pro-
peptide could modulate this process. In Chapter 7 the potential role of the VWF-
propeptide as an inflammatory mediator was investigated. In a chemotaxis assay, 
neutrophils were allowed to migrate toward the propeptide, IL-8, or mixtures of both. 
The propeptide alone had no chemotactic effect on neutrophils. However, neutro-
phil adhesion induced by IL-8 increased significantly upon co-stimulation with 
VWF-propeptide. The co-storage of IL-8 and propeptide in Weibel-Palade bodies 
and their co-secretion raises the possibility that the propeptide acts synergistically 
with IL-8 upon appropriate stimulation of the endothelium, thereby enhancing local 
adherence of neutrophils. 
148
In conclusion, this thesis has brought forward different issues concerning the life 
cycle of Weibel-Palade bodies. This life cycle comprises multiple processes and 
mechanisms of remarkable complexity, many of which remain to be unraveled. Evi-
dence has been provided that, besides its important role inside the cell,  the Weibel-
Palade body resident VWF-propeptide may also have a biologically significant role 
after its release into the circulation. Taken together, biogenesis and exocytosis of 
Weibel-Palade bodies are essential in the processes underlying hemostatic, throm-




















Wanneer een persoon zich verwondt en een bloeding optreedt zal normaal gespro-
ken snel de bloedstolling beginnen en zich een korstje vormen dat de wond afdekt 
en het begin is van genezing. Een van de belangrijkste factoren die betrokken is bij 
dit bloedstollingsproces is een eiwit, genaamd ‘von Willebrand factor’, dat gemaakt 
en opgeslagen wordt in de zogenaamde endotheel cellen die de wand van bloe-
dvaten bekleden. Als deze endotheel cellen worden geprikkeld, dan pas wordt de 
von Willebrand factor uitgescheiden in de bloedbaan om zijn werk te doen. Endo-
theel cellen kunnen op twee manieren geprikkeld worden: 1) door het ontstaan van 
een beschadiging in het bloedvat, bijvoorbeeld door een snee, een operatie of een 
ziekte, of 2) door een verhoging van het stresshormoon adrenaline, bijvoorbeeld 
simpelweg als gevolg van hard lopen of fietsen. 
Het stollingsproces moet natuurlijk niet spontaan in de bloedvaten optreden, 
dat zou namelijk tot trombose leiden. Daarom wordt het uitscheiden van de von 
Willebrand factor strikt gereguleerd: von Willebrand factor wordt eerst opgeslagen 
in de endotheel cellen in speciale blaasjes, genaamd Weibel-Palade lichaampjes. 
Pas na prikkeling van of schade aan het endotheel zullen deze Weibel-Palade 
lichaampjes naar het cel-oppervlak gaan, daarmee fuseren en zodoende hun in-
houd in de bloedbaan uitscheiden. 
Een normaal functionerend bloedstollingsproces is van vanzelfsprekend van 
levensbelang. Wanneer de von Willebrand factor niet goed functioneert of wanneer 
er te weinig von Willebrand factor aangemaakt of uitgescheiden wordt, kan het 
bloed niet goed stollen. Patiënten die lijden aan de zogenaamde ‘ziekte van von 
Willebrand’ kunnen vaak ernstige bloedingen krijgen en daaraan zelfs overlijden. 
Er zijn verschillende defecten van de von Willebrand factor aangetoond die leiden 
tot het slecht functioneren van dit eiwit. Wat echter zelden is beschreven, is de 
manier waarop Weibel-Palade lichaampjes de von Willebrand factor door de cel 
transporteren en in de bloedbaan uitscheiden. In dit proefschrift heb ik getracht de 
hele “levenscyclus” van de Weibel-Palade lichaampjes in kaart te brengen, vanaf 
het ontstaan in de cellen, via het transport door de cel tot het vrijlaten van hun in-
houd na prikkeling van de cel. 
Hoofdstuk 1 geeft  achtergrond informatie over de aanmaak, ontwikkeling en 
uitscheiding van het tot dusver belangrijkste eiwit in de Weibel-Palade lichaampjes: 
de von Willebrand factor. Het belang van eiwit opslag in Weibel-Palade lichaampjes 
wordt hierin geintroduceerd en daarmee vormt dit hoofdstuk de basis voor de vol-
gende hoofdstukken, waarin de verschillende aspecten van de levenscyslus van de 
Weibel-Palade lichaampjes verder worden bestudeerd.
De eerste stap in de levenscyclus van de Weibel-Palade lichaampjes is de 
selectie van de eiwitten die samen met de von Willebrand factor in de Weibel-
Palade lichaampjes opgeslagen worden. Het is bekend dat de von Willebrand 
162
factor belangrijk is om bijvoorbeeld het eiwit P-selectine mee de Weibel-Palade 
lichaampjes in te ‘lokken’. In hoofdstuk 2 van dit proefschrift wordt de rol van de 
von Willebrand factor in de selectie procedure bestudeerd van een ander belangrijk 
eiwit: het signalerings-eiwit interleukine-8 (IL-8). Het blijkt dat in normale endotheel 
cellen interleukine-8 samen met de von Willebrand factor opgeslagen in Weibel-
Palade lichaampjes wordt. In bepaalde endotheel cellen die geen von Willebrand 
factor kunnen maken, wordt interleukine-8 wel gemaakt maar niet in Weibel-Palade 
lichaampjes opgeslagen. Als deze cellen door middel van gentherapie weer von 
Willebrand factor gaan produceren, verschijnt interleukine-8 ook weer in de Weibel-
Palade lichaampjes.
Na deze eerste stap, waarin eiwitten zoals de von Willebrand factor selectief 
worden opgeslagen in de Weibel-Palade lichaampjes, worden de gevulde Weibel-
Palade lichaampjes door de endotheel cellen getransporteerd. Door de von Wil-
lebrand factor met een groen fluorescerend eiwit te markeren was het mogelijk om 
het transport van de Weibel-Palade lichaampjes door de cel te volgen met behulp 
van een fluorescentie microscoop [hoofdstuk 3]. Deze aanpaak bracht aan het 
licht dat rustende endotheel cellen twee soorten Weibel-Palade lichaampjes bevat-
ten. Sommige liggen bijna onbeweeglijk stil in de cel terwijl andere Weibel-Palade 
lichaampjes als het ware willekeurig door de endotheel cel heen bewegen en regel-
matig van richting veranderen. Het lijkt erop dat de Weibel-Palade lichaampjes ‘vol-
wassen’ worden tijdens dit transport en dat de gerijpte Weibel-Palade lichaampjes 
klaar liggen vlak onder het celoppervlak om zodra er een signaal komt, hun inhoud 
in de bloedbaan uit te storten. Wanneer een signaal gegeven wordt dat besch-
adiging van het bloedvat naabootst, fuseren alle Weibel-Palade lichaampjes met 
het celoppervlak en komt de inhoud vrij. Met behulp van de groene fluorescente 
markering is aangetoond dat het vrijkomen van de von Willebrand factor (en de 
rest van de inhoud van de Weibel Palade lichaampjes) inhoud erg langzaam gaat. 
Het gevolg hiervan is dat er op die plekken tijdelijk een hoge concentratie von Wil-
lebrand factor, IL-8 en P-selectine aanwezig is: de ‘hot spots’. Dit zou belangrijk 
kunnen zijn voor het aantrekken van de bloedcellen die bij de stolling betrokken 
zijn en de schade komen herstellen. Wanneer echter een signaal gegeven wordt 
dat stress nabootst, dan fuseert maar een deel van de Weibel-Palade lichaampjes 
met cel celoppervlak. De rest beweegt weg van het celoppervlak en gaat naar het 
centrum van de cel. Hierdoor zou er voorkomen kunnen worden dat er bloedcellen 
worden opgeroepen die stolling gaan geven terwijl er geen beschadiging is.
In hoofdstuk 4 wordt dieper ingegaan op de rol van een klein eiwitje, RalA 
genaamd, bij het vrijkomen van Weibel-Palade lichaampjes aan het celoppervlak. 
RalA zit vast aan de Weibel-Palade lichaampjes en er wordt vermoed dat RalA 
betrokken is bij de koppeling van de Weibel Palade lichaampjes met de cel mem-
Samenvatting voor niet-ingewijden
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braan tijdens de fusie. Het activeren van endotheel cellen zorgt ervoor dat RalA 
tijdelijk actief wordt. Deze actieve fase gaat gepaard met het vrijkomen van von 
Willebrand factor. Daarnaast blijken endotheel cellen die door middel van genthera-
pie actief RalA bevatten, continu Weibel-Palade lichaampjes uit te storten alsof ze 
een signaal hebben gekregen. Deze resultaten ondersteunen het vermoeden dat 
RalA waarschijnlijk betrokken is bij het gereguleerd vrijkomen van Weibel-Palade 
lichaampjes.
Zoals reeds eerder is gezegd bevatten Weibel-Palade lichaampjes een meng-
sel van eiwitten die een groot aantal functies in het lichaam hebben. In het tweede 
deel van dit proefschrift is de biologische functie van een van deze eiwitten, de von 
Willebrand factor propeptide, bestudeerd. Hoofdstuk 5 is een introductie voor dit 
deel van het werk en illustreerd de mogelijke toepassing van dit propeptide als maat 
voor schade aan de endotheel cellen. Het meten van bloedspiegels van zowel de 
von Willebrand factor als van de propeptide maakt het mogellijk om acute en chro-
nische beschadiging aan endotheel cellen te onderscheiden. Daarnaast blijkt de 
biologische rol van de propetide veel diverser dan voorheen werd aangenomen.
Het gebruik van de von Willebrand factor propeptide als maat voor schade aan 
de endotheel cellen wordt in hoofdstuk 6 geillustreerd aan de hand van de ernstige 
bloedziekte thrombotic thrombocytopenic purpura (TTP), waarvan nog grotendeels 
onbekend is hoe de ziekte ontstaat. De bloedspiegels van dit eiwit werden gemeten 
in patienten bij opname in het ziekenhuis, op moment van (tijdelijk) herstel en bij het 
opvlammen van de ziekte. De resultaten suggereren dat endotheel activatie niet de 
primaire oorzaak van deze ziekte is, maar dat het eerder een consequentie is van 
het ziekteproces. Deze gegevens illustreren hoe het meten van bloedspiegels van 
eiwitten afkomstig uit Weibel-Palade lichaampjes kan helpen in het ontrafelen van 
onbekende ziekteprocessen.
Een andere aspect van de von Willebrand factor propeptide is de mogelijke 
rol die het speelt in het aantrekken van cellen tijdens ontstekingsprocessen. In 
hoofdstuk 7 is beschreven dat de propeptide een bijdrage levert aan het aantrek-
ken van bepaalde cellen uit het bloed (neutrophielen) door het signalerings-eiwit 
interleukine-8. Dit interleukine-8 wordt samen met de von Willebrand factor propep-
tide opgeslagen in Weibel-Palade lichaampjes (zie hoofdstuk 2) en ook tezamen 
uitgescheiden. De propeptide heeft zelf niet of nauwlijks aantrekkingskracht voor 
bloedcellen maar de gegevens uit dit hoofdstuk laten zien dat het de aantrekking-
skracht van interleukine-8 versterkt. Op deze manier werkt de von Willebrand prop-
etide samen met interleukine-8 om na activatie van de endotheel cellen, de juiste 
bloedcellen naar de beschadigde plek te loodsen. 
Samengevat worden er in dit proefschrift verschillende aspecten van de lev-
enscyclus van Weibel-Palade lichaampjes beschreven. Deze levencyclus bestaat 
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uit verschillende fasen met een opmerkelijke complexiteit, die nog maar ten dele 
ontrafelt is. De von Willebrand factor propeptide, die opgeslagen wordt in de Wei-
bel-Palade lichaampjes, blijkt naast een rol in de endotheel cellen ook een belan-
grijke biologische rol te vervullen na uitscheiding in de bloedbaan. De gegevens 
in dit proefschrift helpen de levenscyclus van de Weibel-Palade lichaampjes beter 
te begrijpen en onderstrepen eens te meer de cruciale rol van Weibel-Palade li-
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ches m’ont énormement fait plaisir et soutenu a travers de cette période de travaux 
forcés. Maintenant que tout est fini j’espère avoir plus de temps pour vous visiter.
Al mijn vrienden hebben met mij meegeleefd. Bedankt voor de gezellige etentjes bij 
Stefan en Eline, de afspraakjes met Annemarie en Mourad, de leuke middagjes 
bij Theo, Marion en de kinderen, de spelletjes-avonden bij Ingrid en Michel. 
Enrico and Giovanna, I am very gratefull for your hospitality, your friendship and 
your interest, which have helped me during these four years of thesis work. I re-
ally miss our dinners together. OK, Canada was also splendid, but there is nothing 
better than to be able to knock at the door whenever you feel like it. Delphine et 
Laurent, merci pour votre hospitalité et pour le contact qui a survécu incroyable-
ment le long de toutes ces années. Avril, thank you for your patience, you could 
wait very long for my e-mails. Now that I’m finished I will make it up. Edith, Johan, 
Cathelijn en Jurriaan, ik ben jullie zo dankbaar voor jullie dierbare vriendschap. 
Ik heb heel veel steun aan onze -tot diep in de nacht durende- discussies gehad. 
Edith, hartstikke leuk dat je me straks als paranimf wilt bijstaan! Ik zou niet zonder 
de gezellige Catan afspraakjes, de avonden shooters, het weekeindje Edinburgh, 
de squash dates of gewoon lekker kleppen met Mirjam en Martin, Marielle en 
Sjoerd, Ingrid en Bjorn. Bedankt voor deze ontspannende afspraakjes en gewoon 
voor jullie vriendschap. Een speciaal dank aan Bjorn, die de laatste maand als per-
soonlijlke helpdesk “Photoshop/InDesign” heeft gefungeerd. Ik had dit proefschrift 
niet zonder jouw hulp kunnen afmaken! 
De aller, aller, aller belangrijkste persoon, zonder wie dit allemaal onmogelijk zou 
zijn geweest, is Jeroen. Zonder jou, was ik ermee gestopt,  was ik helemaal gek 
geworden, of zou het allemaal niet op tijd klaar zijn geweest. Jouw onvoorwaarde-
lijke liefde, jouw geduld, jouw nuchtere kijk op het leven en jouw vertrouwen in mij 
hebben mij gered. Bedankt voor ALLES!!!!! Nu kunnen we pas van onze quality 
time genieten.
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